CINXE.COM

<!DOCTYPE html> <html dir="ltr" lang="en-US" prefix="og: https://ogp.me/ns#" id="html"> <head> <meta charset="UTF-8" /> <meta http-equiv="X-UA-Compatible" content="IE=edge"> <link rel="pingback" href="https://vaccinenation.org/xmlrpc.php" /> <script type="text/javascript"> document.documentElement.className = 'js'; </script> <title>Charlotte Kilpatrick - VaccineNation</title> <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin /><style id="et-divi-open-sans-inline-css">/* Original: https://fonts.googleapis.com/css?family=Open+Sans:300italic,400italic,600italic,700italic,800italic,400,300,600,700,800&subset=cyrillic,cyrillic-ext,greek,greek-ext,hebrew,latin,latin-ext,vietnamese&display=swap *//* User Agent: Mozilla/5.0 (Unknown; Linux x86_64) AppleWebKit/538.1 (KHTML, like Gecko) Safari/538.1 Daum/4.1 */@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 300;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk5hkaVc.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 400;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkaVc.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 600;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0RkxhjaVc.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 700;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0RkyFjaVc.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 800;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk0ZjaVc.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 300;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsiH0C4n.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 400;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0C4n.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 600;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsgH1y4n.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 700;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1y4n.ttf) format('truetype');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 800;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgshZ1y4n.ttf) format('truetype');}/* User Agent: Mozilla/5.0 (Windows NT 6.1; WOW64; rv:27.0) Gecko/20100101 Firefox/27.0 */@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 300;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk5hkaVQ.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 400;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkaVQ.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 600;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0RkxhjaVQ.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 700;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0RkyFjaVQ.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 800;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk0ZjaVQ.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 300;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsiH0C4k.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 400;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0C4k.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 600;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsgH1y4k.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 700;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1y4k.woff) format('woff');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 800;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgshZ1y4k.woff) format('woff');}/* User Agent: Mozilla/5.0 (Windows NT 6.3; rv:39.0) Gecko/20100101 Firefox/39.0 */@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 300;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk5hkaVI.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 400;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk8ZkaVI.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 600;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0RkxhjaVI.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 700;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0RkyFjaVI.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: italic;font-weight: 800;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memQYaGs126MiZpBA-UFUIcVXSCEkx2cmqvXlWq8tWZ0Pw86hd0Rk0ZjaVI.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 300;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsiH0C4i.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 400;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsjZ0C4i.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 600;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsgH1y4i.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 700;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgsg-1y4i.woff2) format('woff2');}@font-face {font-family: 'Open Sans';font-style: normal;font-weight: 800;font-stretch: normal;font-display: swap;src: url(https://fonts.gstatic.com/s/opensans/v40/memSYaGs126MiZpBA-UvWbX2vVnXBbObj2OVZyOOSr4dVJWUgshZ1y4i.woff2) format('woff2');}</style> <style>img:is([sizes="auto" i], [sizes^="auto," i]) { contain-intrinsic-size: 3000px 1500px }</style>  <meta name="robots" content="max-image-preview:large" /> <link rel="canonical" href="https://vaccinenation.org/author/charlotte-kilpatrick/" /> <link rel="next" href="https://vaccinenation.org/author/charlotte-kilpatrick/page/2/" /> <meta name="generator" content="All in One SEO (AIOSEO) 4.7.5.1" /> <script type="application/ld+json" class="aioseo-schema"> {"@context":"https:\/\/schema.org","@graph":[{"@type":"BreadcrumbList","@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#breadcrumblist","itemListElement":[{"@type":"ListItem","@id":"https:\/\/vaccinenation.org\/#listItem","position":1,"name":"Home","item":"https:\/\/vaccinenation.org\/","nextItem":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#listItem"},{"@type":"ListItem","@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#listItem","position":2,"name":"Charlotte Kilpatrick","previousItem":"https:\/\/vaccinenation.org\/#listItem"}]},{"@type":"Organization","@id":"https:\/\/vaccinenation.org\/#organization","name":"Vaccine Nation","description":"Strategy & Innovation in\u00a0Vaccines","url":"https:\/\/vaccinenation.org\/","sameAs":["https:\/\/twitter.com\/vaccinenation","https:\/\/www.linkedin.com\/groups\/1351197\/"]},{"@type":"Person","@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#author","url":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/","name":"Charlotte Kilpatrick","image":{"@type":"ImageObject","@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#authorImage","url":"https:\/\/secure.gravatar.com\/avatar\/6e339d30a2b74cf1835b1bb3e011c9ed?s=96&d=mm&r=g","width":96,"height":96,"caption":"Charlotte Kilpatrick"},"mainEntityOfPage":{"@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#profilepage"}},{"@type":"ProfilePage","@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#profilepage","url":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/","name":"Charlotte Kilpatrick - VaccineNation","inLanguage":"en-US","isPartOf":{"@id":"https:\/\/vaccinenation.org\/#website"},"breadcrumb":{"@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#breadcrumblist"},"dateCreated":"2022-07-22T08:15:14+01:00","mainEntity":{"@id":"https:\/\/vaccinenation.org\/author\/charlotte-kilpatrick\/#author"}},{"@type":"WebSite","@id":"https:\/\/vaccinenation.org\/#website","url":"https:\/\/vaccinenation.org\/","name":"VaccineNation","description":"Strategy & Innovation in\u00a0Vaccines","inLanguage":"en-US","publisher":{"@id":"https:\/\/vaccinenation.org\/#organization"}}]} </script>  <script type="text/javascript"> let jqueryParams=[],jQuery=function(r){return jqueryParams=[...jqueryParams,r],jQuery},$=function(r){return jqueryParams=[...jqueryParams,r],$};window.jQuery=jQuery,window.$=jQuery;let customHeadScripts=!1;jQuery.fn=jQuery.prototype={},$.fn=jQuery.prototype={},jQuery.noConflict=function(r){if(window.jQuery)return jQuery=window.jQuery,$=window.jQuery,customHeadScripts=!0,jQuery.noConflict},jQuery.ready=function(r){jqueryParams=[...jqueryParams,r]},$.ready=function(r){jqueryParams=[...jqueryParams,r]},jQuery.load=function(r){jqueryParams=[...jqueryParams,r]},$.load=function(r){jqueryParams=[...jqueryParams,r]},jQuery.fn.ready=function(r){jqueryParams=[...jqueryParams,r]},$.fn.ready=function(r){jqueryParams=[...jqueryParams,r]};</script><link rel='dns-prefetch' href='//www.googletagmanager.com' /> <link rel='dns-prefetch' href='//stats.wp.com' /> <link rel='dns-prefetch' href='//jetpack.wordpress.com' /> <link rel='dns-prefetch' href='//s0.wp.com' /> <link rel='dns-prefetch' href='//public-api.wordpress.com' /> <link rel='dns-prefetch' href='//0.gravatar.com' /> <link rel='dns-prefetch' href='//1.gravatar.com' /> <link rel='dns-prefetch' href='//2.gravatar.com' /> <link rel='dns-prefetch' href='//widgets.wp.com' /> <link rel='preconnect' href='//c0.wp.com' /> <link rel="alternate" type="application/rss+xml" title="VaccineNation » Feed" href="https://vaccinenation.org/feed/" /> <link rel="alternate" type="application/rss+xml" title="VaccineNation » Comments Feed" href="https://vaccinenation.org/comments/feed/" /> <link rel="alternate" type="application/rss+xml" title="VaccineNation » Posts by Charlotte Kilpatrick Feed" href="https://vaccinenation.org/author/charlotte-kilpatrick/feed/" /> <meta content="Divi Child v.1.0.0" name="generator"/><link rel='stylesheet' id='all-css-33415e2015fb3b2a1b5469b514133ad8' href='https://vaccinenation.org/_static/??-eJyVkt1uwjAMhV9oIQIu2M20m73H5MZeMeRPsdPSt18KBVWTQNpV5Piczzlyxmw4Ol+RxDoRiyxqO5/c2XjuCpTJik6eNoHjpgnexmxcikpRbfa15yjWw5Sqmr4wLuJF+CCfxAZCBvIUZue6yM1OxXjqwU3rMU/drbeuXz2NQkdoIE4Gk6tX95zydp1r59m9suuRTE6yZAMRUrEDRUzF/jStgZEkBbpC1xf/hs4Azb2RYyrqEr4kAA4QXUtQSHKKwgOZgZGSuQZDKrar7NEGeA45kWZw5/v5vcSCqimAKrt754bObZYsWOSBTduANj1HpMvfGS1iaIv7mnXuOFse/+IzfGwP+91uu9sf3n8BTmzysw==' type='text/css' media='all' /> <style id='wp-block-library-inline-css'> .has-text-align-justify{text-align:justify;} </style> <style id='wp-block-library-theme-inline-css'> .wp-block-audio :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-audio :where(figcaption){color:#ffffffa6}.wp-block-audio{margin:0 0 1em}.wp-block-code{border:1px solid #ccc;border-radius:4px;font-family:Menlo,Consolas,monaco,monospace;padding:.8em 1em}.wp-block-embed :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-embed :where(figcaption){color:#ffffffa6}.wp-block-embed{margin:0 0 1em}.blocks-gallery-caption{color:#555;font-size:13px;text-align:center}.is-dark-theme .blocks-gallery-caption{color:#ffffffa6}:root :where(.wp-block-image figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme :root :where(.wp-block-image figcaption){color:#ffffffa6}.wp-block-image{margin:0 0 1em}.wp-block-pullquote{border-bottom:4px solid;border-top:4px solid;color:currentColor;margin-bottom:1.75em}.wp-block-pullquote cite,.wp-block-pullquote footer,.wp-block-pullquote__citation{color:currentColor;font-size:.8125em;font-style:normal;text-transform:uppercase}.wp-block-quote{border-left:.25em solid;margin:0 0 1.75em;padding-left:1em}.wp-block-quote cite,.wp-block-quote footer{color:currentColor;font-size:.8125em;font-style:normal;position:relative}.wp-block-quote:where(.has-text-align-right){border-left:none;border-right:.25em solid;padding-left:0;padding-right:1em}.wp-block-quote:where(.has-text-align-center){border:none;padding-left:0}.wp-block-quote.is-large,.wp-block-quote.is-style-large,.wp-block-quote:where(.is-style-plain){border:none}.wp-block-search .wp-block-search__label{font-weight:700}.wp-block-search__button{border:1px solid #ccc;padding:.375em .625em}:where(.wp-block-group.has-background){padding:1.25em 2.375em}.wp-block-separator.has-css-opacity{opacity:.4}.wp-block-separator{border:none;border-bottom:2px solid;margin-left:auto;margin-right:auto}.wp-block-separator.has-alpha-channel-opacity{opacity:1}.wp-block-separator:not(.is-style-wide):not(.is-style-dots){width:100px}.wp-block-separator.has-background:not(.is-style-dots){border-bottom:none;height:1px}.wp-block-separator.has-background:not(.is-style-wide):not(.is-style-dots){height:2px}.wp-block-table{margin:0 0 1em}.wp-block-table td,.wp-block-table th{word-break:normal}.wp-block-table :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-table :where(figcaption){color:#ffffffa6}.wp-block-video :where(figcaption){color:#555;font-size:13px;text-align:center}.is-dark-theme .wp-block-video :where(figcaption){color:#ffffffa6}.wp-block-video{margin:0 0 1em}:root :where(.wp-block-template-part.has-background){margin-bottom:0;margin-top:0;padding:1.25em 2.375em} </style> <style id='jetpack-sharing-buttons-style-inline-css'> .jetpack-sharing-buttons__services-list{display:flex;flex-direction:row;flex-wrap:wrap;gap:0;list-style-type:none;margin:5px;padding:0}.jetpack-sharing-buttons__services-list.has-small-icon-size{font-size:12px}.jetpack-sharing-buttons__services-list.has-normal-icon-size{font-size:16px}.jetpack-sharing-buttons__services-list.has-large-icon-size{font-size:24px}.jetpack-sharing-buttons__services-list.has-huge-icon-size{font-size:36px}@media print{.jetpack-sharing-buttons__services-list{display:none!important}}.editor-styles-wrapper .wp-block-jetpack-sharing-buttons{gap:0;padding-inline-start:0}ul.jetpack-sharing-buttons__services-list.has-background{padding:1.25em 2.375em} </style> <style id='global-styles-inline-css'> :root{--wp--preset--aspect-ratio--square: 1;--wp--preset--aspect-ratio--4-3: 4/3;--wp--preset--aspect-ratio--3-4: 3/4;--wp--preset--aspect-ratio--3-2: 3/2;--wp--preset--aspect-ratio--2-3: 2/3;--wp--preset--aspect-ratio--16-9: 16/9;--wp--preset--aspect-ratio--9-16: 9/16;--wp--preset--color--black: #000000;--wp--preset--color--cyan-bluish-gray: #abb8c3;--wp--preset--color--white: #ffffff;--wp--preset--color--pale-pink: #f78da7;--wp--preset--color--vivid-red: #cf2e2e;--wp--preset--color--luminous-vivid-orange: #ff6900;--wp--preset--color--luminous-vivid-amber: #fcb900;--wp--preset--color--light-green-cyan: #7bdcb5;--wp--preset--color--vivid-green-cyan: #00d084;--wp--preset--color--pale-cyan-blue: #8ed1fc;--wp--preset--color--vivid-cyan-blue: #0693e3;--wp--preset--color--vivid-purple: #9b51e0;--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple: linear-gradient(135deg,rgba(6,147,227,1) 0%,rgb(155,81,224) 100%);--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan: linear-gradient(135deg,rgb(122,220,180) 0%,rgb(0,208,130) 100%);--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange: linear-gradient(135deg,rgba(252,185,0,1) 0%,rgba(255,105,0,1) 100%);--wp--preset--gradient--luminous-vivid-orange-to-vivid-red: linear-gradient(135deg,rgba(255,105,0,1) 0%,rgb(207,46,46) 100%);--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray: linear-gradient(135deg,rgb(238,238,238) 0%,rgb(169,184,195) 100%);--wp--preset--gradient--cool-to-warm-spectrum: linear-gradient(135deg,rgb(74,234,220) 0%,rgb(151,120,209) 20%,rgb(207,42,186) 40%,rgb(238,44,130) 60%,rgb(251,105,98) 80%,rgb(254,248,76) 100%);--wp--preset--gradient--blush-light-purple: linear-gradient(135deg,rgb(255,206,236) 0%,rgb(152,150,240) 100%);--wp--preset--gradient--blush-bordeaux: linear-gradient(135deg,rgb(254,205,165) 0%,rgb(254,45,45) 50%,rgb(107,0,62) 100%);--wp--preset--gradient--luminous-dusk: linear-gradient(135deg,rgb(255,203,112) 0%,rgb(199,81,192) 50%,rgb(65,88,208) 100%);--wp--preset--gradient--pale-ocean: linear-gradient(135deg,rgb(255,245,203) 0%,rgb(182,227,212) 50%,rgb(51,167,181) 100%);--wp--preset--gradient--electric-grass: linear-gradient(135deg,rgb(202,248,128) 0%,rgb(113,206,126) 100%);--wp--preset--gradient--midnight: linear-gradient(135deg,rgb(2,3,129) 0%,rgb(40,116,252) 100%);--wp--preset--font-size--small: 13px;--wp--preset--font-size--medium: 20px;--wp--preset--font-size--large: 36px;--wp--preset--font-size--x-large: 42px;--wp--preset--font-family--albert-sans: 'Albert Sans', sans-serif;--wp--preset--font-family--alegreya: Alegreya, serif;--wp--preset--font-family--arvo: Arvo, serif;--wp--preset--font-family--bodoni-moda: 'Bodoni Moda', serif;--wp--preset--font-family--bricolage-grotesque: 'Bricolage Grotesque', sans-serif;--wp--preset--font-family--cabin: Cabin, sans-serif;--wp--preset--font-family--chivo: Chivo, sans-serif;--wp--preset--font-family--commissioner: Commissioner, sans-serif;--wp--preset--font-family--cormorant: Cormorant, serif;--wp--preset--font-family--courier-prime: 'Courier Prime', monospace;--wp--preset--font-family--crimson-pro: 'Crimson Pro', serif;--wp--preset--font-family--dm-mono: 'DM Mono', monospace;--wp--preset--font-family--dm-sans: 'DM Sans', sans-serif;--wp--preset--font-family--dm-serif-display: 'DM Serif Display', serif;--wp--preset--font-family--domine: Domine, serif;--wp--preset--font-family--eb-garamond: 'EB Garamond', serif;--wp--preset--font-family--epilogue: Epilogue, sans-serif;--wp--preset--font-family--fahkwang: Fahkwang, sans-serif;--wp--preset--font-family--figtree: Figtree, sans-serif;--wp--preset--font-family--fira-sans: 'Fira Sans', sans-serif;--wp--preset--font-family--fjalla-one: 'Fjalla One', sans-serif;--wp--preset--font-family--fraunces: Fraunces, serif;--wp--preset--font-family--gabarito: Gabarito, system-ui;--wp--preset--font-family--ibm-plex-mono: 'IBM Plex Mono', monospace;--wp--preset--font-family--ibm-plex-sans: 'IBM Plex Sans', sans-serif;--wp--preset--font-family--ibarra-real-nova: 'Ibarra Real Nova', serif;--wp--preset--font-family--instrument-serif: 'Instrument Serif', serif;--wp--preset--font-family--inter: Inter, sans-serif;--wp--preset--font-family--josefin-sans: 'Josefin Sans', sans-serif;--wp--preset--font-family--jost: Jost, sans-serif;--wp--preset--font-family--libre-baskerville: 'Libre Baskerville', serif;--wp--preset--font-family--libre-franklin: 'Libre Franklin', sans-serif;--wp--preset--font-family--literata: Literata, serif;--wp--preset--font-family--lora: Lora, serif;--wp--preset--font-family--merriweather: Merriweather, serif;--wp--preset--font-family--montserrat: Montserrat, sans-serif;--wp--preset--font-family--newsreader: Newsreader, serif;--wp--preset--font-family--noto-sans-mono: 'Noto Sans Mono', sans-serif;--wp--preset--font-family--nunito: Nunito, sans-serif;--wp--preset--font-family--open-sans: 'Open Sans', sans-serif;--wp--preset--font-family--overpass: Overpass, sans-serif;--wp--preset--font-family--pt-serif: 'PT Serif', serif;--wp--preset--font-family--petrona: Petrona, serif;--wp--preset--font-family--piazzolla: Piazzolla, serif;--wp--preset--font-family--playfair-display: 'Playfair Display', serif;--wp--preset--font-family--plus-jakarta-sans: 'Plus Jakarta Sans', sans-serif;--wp--preset--font-family--poppins: Poppins, sans-serif;--wp--preset--font-family--raleway: Raleway, sans-serif;--wp--preset--font-family--roboto: Roboto, sans-serif;--wp--preset--font-family--roboto-slab: 'Roboto Slab', serif;--wp--preset--font-family--rubik: Rubik, sans-serif;--wp--preset--font-family--rufina: Rufina, serif;--wp--preset--font-family--sora: Sora, sans-serif;--wp--preset--font-family--source-sans-3: 'Source Sans 3', sans-serif;--wp--preset--font-family--source-serif-4: 'Source Serif 4', serif;--wp--preset--font-family--space-mono: 'Space Mono', monospace;--wp--preset--font-family--syne: Syne, sans-serif;--wp--preset--font-family--texturina: Texturina, serif;--wp--preset--font-family--urbanist: Urbanist, sans-serif;--wp--preset--font-family--work-sans: 'Work Sans', sans-serif;--wp--preset--spacing--20: 0.44rem;--wp--preset--spacing--30: 0.67rem;--wp--preset--spacing--40: 1rem;--wp--preset--spacing--50: 1.5rem;--wp--preset--spacing--60: 2.25rem;--wp--preset--spacing--70: 3.38rem;--wp--preset--spacing--80: 5.06rem;--wp--preset--shadow--natural: 6px 6px 9px rgba(0, 0, 0, 0.2);--wp--preset--shadow--deep: 12px 12px 50px rgba(0, 0, 0, 0.4);--wp--preset--shadow--sharp: 6px 6px 0px rgba(0, 0, 0, 0.2);--wp--preset--shadow--outlined: 6px 6px 0px -3px rgba(255, 255, 255, 1), 6px 6px rgba(0, 0, 0, 1);--wp--preset--shadow--crisp: 6px 6px 0px rgba(0, 0, 0, 1);}:root { --wp--style--global--content-size: 823px;--wp--style--global--wide-size: 1080px; }:where(body) { margin: 0; }.wp-site-blocks > .alignleft { float: left; margin-right: 2em; }.wp-site-blocks > .alignright { float: right; margin-left: 2em; }.wp-site-blocks > .aligncenter { justify-content: center; margin-left: auto; margin-right: auto; }:where(.is-layout-flex){gap: 0.5em;}:where(.is-layout-grid){gap: 0.5em;}.is-layout-flow > .alignleft{float: left;margin-inline-start: 0;margin-inline-end: 2em;}.is-layout-flow > .alignright{float: right;margin-inline-start: 2em;margin-inline-end: 0;}.is-layout-flow > .aligncenter{margin-left: auto !important;margin-right: auto !important;}.is-layout-constrained > .alignleft{float: left;margin-inline-start: 0;margin-inline-end: 2em;}.is-layout-constrained > .alignright{float: right;margin-inline-start: 2em;margin-inline-end: 0;}.is-layout-constrained > .aligncenter{margin-left: auto !important;margin-right: auto !important;}.is-layout-constrained > :where(:not(.alignleft):not(.alignright):not(.alignfull)){max-width: var(--wp--style--global--content-size);margin-left: auto !important;margin-right: auto !important;}.is-layout-constrained > .alignwide{max-width: var(--wp--style--global--wide-size);}body .is-layout-flex{display: flex;}.is-layout-flex{flex-wrap: wrap;align-items: center;}.is-layout-flex > :is(*, div){margin: 0;}body .is-layout-grid{display: grid;}.is-layout-grid > :is(*, div){margin: 0;}body{padding-top: 0px;padding-right: 0px;padding-bottom: 0px;padding-left: 0px;}:root :where(.wp-element-button, .wp-block-button__link){background-color: #32373c;border-width: 0;color: #fff;font-family: inherit;font-size: inherit;line-height: inherit;padding: calc(0.667em + 2px) calc(1.333em + 2px);text-decoration: none;}.has-black-color{color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-color{color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-color{color: var(--wp--preset--color--white) !important;}.has-pale-pink-color{color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-color{color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-color{color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-color{color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-color{color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-color{color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-color{color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-color{color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-color{color: var(--wp--preset--color--vivid-purple) !important;}.has-black-background-color{background-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-background-color{background-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-background-color{background-color: var(--wp--preset--color--white) !important;}.has-pale-pink-background-color{background-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-background-color{background-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-background-color{background-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-background-color{background-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-background-color{background-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-background-color{background-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-background-color{background-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-background-color{background-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-background-color{background-color: var(--wp--preset--color--vivid-purple) !important;}.has-black-border-color{border-color: var(--wp--preset--color--black) !important;}.has-cyan-bluish-gray-border-color{border-color: var(--wp--preset--color--cyan-bluish-gray) !important;}.has-white-border-color{border-color: var(--wp--preset--color--white) !important;}.has-pale-pink-border-color{border-color: var(--wp--preset--color--pale-pink) !important;}.has-vivid-red-border-color{border-color: var(--wp--preset--color--vivid-red) !important;}.has-luminous-vivid-orange-border-color{border-color: var(--wp--preset--color--luminous-vivid-orange) !important;}.has-luminous-vivid-amber-border-color{border-color: var(--wp--preset--color--luminous-vivid-amber) !important;}.has-light-green-cyan-border-color{border-color: var(--wp--preset--color--light-green-cyan) !important;}.has-vivid-green-cyan-border-color{border-color: var(--wp--preset--color--vivid-green-cyan) !important;}.has-pale-cyan-blue-border-color{border-color: var(--wp--preset--color--pale-cyan-blue) !important;}.has-vivid-cyan-blue-border-color{border-color: var(--wp--preset--color--vivid-cyan-blue) !important;}.has-vivid-purple-border-color{border-color: var(--wp--preset--color--vivid-purple) !important;}.has-vivid-cyan-blue-to-vivid-purple-gradient-background{background: var(--wp--preset--gradient--vivid-cyan-blue-to-vivid-purple) !important;}.has-light-green-cyan-to-vivid-green-cyan-gradient-background{background: var(--wp--preset--gradient--light-green-cyan-to-vivid-green-cyan) !important;}.has-luminous-vivid-amber-to-luminous-vivid-orange-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-amber-to-luminous-vivid-orange) !important;}.has-luminous-vivid-orange-to-vivid-red-gradient-background{background: var(--wp--preset--gradient--luminous-vivid-orange-to-vivid-red) !important;}.has-very-light-gray-to-cyan-bluish-gray-gradient-background{background: var(--wp--preset--gradient--very-light-gray-to-cyan-bluish-gray) !important;}.has-cool-to-warm-spectrum-gradient-background{background: var(--wp--preset--gradient--cool-to-warm-spectrum) !important;}.has-blush-light-purple-gradient-background{background: var(--wp--preset--gradient--blush-light-purple) !important;}.has-blush-bordeaux-gradient-background{background: var(--wp--preset--gradient--blush-bordeaux) !important;}.has-luminous-dusk-gradient-background{background: var(--wp--preset--gradient--luminous-dusk) !important;}.has-pale-ocean-gradient-background{background: var(--wp--preset--gradient--pale-ocean) !important;}.has-electric-grass-gradient-background{background: var(--wp--preset--gradient--electric-grass) !important;}.has-midnight-gradient-background{background: var(--wp--preset--gradient--midnight) !important;}.has-small-font-size{font-size: var(--wp--preset--font-size--small) !important;}.has-medium-font-size{font-size: var(--wp--preset--font-size--medium) !important;}.has-large-font-size{font-size: var(--wp--preset--font-size--large) !important;}.has-x-large-font-size{font-size: var(--wp--preset--font-size--x-large) !important;}.has-albert-sans-font-family{font-family: var(--wp--preset--font-family--albert-sans) !important;}.has-alegreya-font-family{font-family: var(--wp--preset--font-family--alegreya) !important;}.has-arvo-font-family{font-family: var(--wp--preset--font-family--arvo) !important;}.has-bodoni-moda-font-family{font-family: var(--wp--preset--font-family--bodoni-moda) !important;}.has-bricolage-grotesque-font-family{font-family: var(--wp--preset--font-family--bricolage-grotesque) !important;}.has-cabin-font-family{font-family: var(--wp--preset--font-family--cabin) !important;}.has-chivo-font-family{font-family: var(--wp--preset--font-family--chivo) !important;}.has-commissioner-font-family{font-family: var(--wp--preset--font-family--commissioner) !important;}.has-cormorant-font-family{font-family: var(--wp--preset--font-family--cormorant) !important;}.has-courier-prime-font-family{font-family: var(--wp--preset--font-family--courier-prime) !important;}.has-crimson-pro-font-family{font-family: var(--wp--preset--font-family--crimson-pro) !important;}.has-dm-mono-font-family{font-family: var(--wp--preset--font-family--dm-mono) !important;}.has-dm-sans-font-family{font-family: var(--wp--preset--font-family--dm-sans) !important;}.has-dm-serif-display-font-family{font-family: var(--wp--preset--font-family--dm-serif-display) !important;}.has-domine-font-family{font-family: var(--wp--preset--font-family--domine) !important;}.has-eb-garamond-font-family{font-family: var(--wp--preset--font-family--eb-garamond) !important;}.has-epilogue-font-family{font-family: var(--wp--preset--font-family--epilogue) !important;}.has-fahkwang-font-family{font-family: var(--wp--preset--font-family--fahkwang) !important;}.has-figtree-font-family{font-family: var(--wp--preset--font-family--figtree) !important;}.has-fira-sans-font-family{font-family: var(--wp--preset--font-family--fira-sans) !important;}.has-fjalla-one-font-family{font-family: var(--wp--preset--font-family--fjalla-one) !important;}.has-fraunces-font-family{font-family: var(--wp--preset--font-family--fraunces) !important;}.has-gabarito-font-family{font-family: var(--wp--preset--font-family--gabarito) !important;}.has-ibm-plex-mono-font-family{font-family: var(--wp--preset--font-family--ibm-plex-mono) !important;}.has-ibm-plex-sans-font-family{font-family: var(--wp--preset--font-family--ibm-plex-sans) !important;}.has-ibarra-real-nova-font-family{font-family: var(--wp--preset--font-family--ibarra-real-nova) !important;}.has-instrument-serif-font-family{font-family: var(--wp--preset--font-family--instrument-serif) !important;}.has-inter-font-family{font-family: var(--wp--preset--font-family--inter) !important;}.has-josefin-sans-font-family{font-family: var(--wp--preset--font-family--josefin-sans) !important;}.has-jost-font-family{font-family: var(--wp--preset--font-family--jost) !important;}.has-libre-baskerville-font-family{font-family: var(--wp--preset--font-family--libre-baskerville) !important;}.has-libre-franklin-font-family{font-family: var(--wp--preset--font-family--libre-franklin) !important;}.has-literata-font-family{font-family: var(--wp--preset--font-family--literata) !important;}.has-lora-font-family{font-family: var(--wp--preset--font-family--lora) !important;}.has-merriweather-font-family{font-family: var(--wp--preset--font-family--merriweather) !important;}.has-montserrat-font-family{font-family: var(--wp--preset--font-family--montserrat) !important;}.has-newsreader-font-family{font-family: var(--wp--preset--font-family--newsreader) !important;}.has-noto-sans-mono-font-family{font-family: var(--wp--preset--font-family--noto-sans-mono) !important;}.has-nunito-font-family{font-family: var(--wp--preset--font-family--nunito) !important;}.has-open-sans-font-family{font-family: var(--wp--preset--font-family--open-sans) !important;}.has-overpass-font-family{font-family: var(--wp--preset--font-family--overpass) !important;}.has-pt-serif-font-family{font-family: var(--wp--preset--font-family--pt-serif) !important;}.has-petrona-font-family{font-family: var(--wp--preset--font-family--petrona) !important;}.has-piazzolla-font-family{font-family: var(--wp--preset--font-family--piazzolla) !important;}.has-playfair-display-font-family{font-family: var(--wp--preset--font-family--playfair-display) !important;}.has-plus-jakarta-sans-font-family{font-family: var(--wp--preset--font-family--plus-jakarta-sans) !important;}.has-poppins-font-family{font-family: var(--wp--preset--font-family--poppins) !important;}.has-raleway-font-family{font-family: var(--wp--preset--font-family--raleway) !important;}.has-roboto-font-family{font-family: var(--wp--preset--font-family--roboto) !important;}.has-roboto-slab-font-family{font-family: var(--wp--preset--font-family--roboto-slab) !important;}.has-rubik-font-family{font-family: var(--wp--preset--font-family--rubik) !important;}.has-rufina-font-family{font-family: var(--wp--preset--font-family--rufina) !important;}.has-sora-font-family{font-family: var(--wp--preset--font-family--sora) !important;}.has-source-sans-3-font-family{font-family: var(--wp--preset--font-family--source-sans-3) !important;}.has-source-serif-4-font-family{font-family: var(--wp--preset--font-family--source-serif-4) !important;}.has-space-mono-font-family{font-family: var(--wp--preset--font-family--space-mono) !important;}.has-syne-font-family{font-family: var(--wp--preset--font-family--syne) !important;}.has-texturina-font-family{font-family: var(--wp--preset--font-family--texturina) !important;}.has-urbanist-font-family{font-family: var(--wp--preset--font-family--urbanist) !important;}.has-work-sans-font-family{font-family: var(--wp--preset--font-family--work-sans) !important;} :where(.wp-block-post-template.is-layout-flex){gap: 1.25em;}:where(.wp-block-post-template.is-layout-grid){gap: 1.25em;} :where(.wp-block-columns.is-layout-flex){gap: 2em;}:where(.wp-block-columns.is-layout-grid){gap: 2em;} :root :where(.wp-block-pullquote){font-size: 1.5em;line-height: 1.6;} </style> <style id='divi-style-parent-inline-inline-css'> /*! Theme Name: Divi Theme URI: http://www.elegantthemes.com/gallery/divi/ Version: 4.27.3 Description: Smart. Flexible. Beautiful. Divi is the most powerful theme in our collection. Author: Elegant Themes Author URI: http://www.elegantthemes.com License: GNU General Public License v2 License URI: http://www.gnu.org/licenses/gpl-2.0.html */ a,abbr,acronym,address,applet,b,big,blockquote,body,center,cite,code,dd,del,dfn,div,dl,dt,em,fieldset,font,form,h1,h2,h3,h4,h5,h6,html,i,iframe,img,ins,kbd,label,legend,li,object,ol,p,pre,q,s,samp,small,span,strike,strong,sub,sup,tt,u,ul,var{margin:0;padding:0;border:0;outline:0;font-size:100%;-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;vertical-align:baseline;background:transparent}body{line-height:1}ol,ul{list-style:none}blockquote,q{quotes:none}blockquote:after,blockquote:before,q:after,q:before{content:"";content:none}blockquote{margin:20px 0 30px;border-left:5px solid;padding-left:20px}:focus{outline:0}del{text-decoration:line-through}pre{overflow:auto;padding:10px}figure{margin:0}table{border-collapse:collapse;border-spacing:0}article,aside,footer,header,hgroup,nav,section{display:block}body{font-family:Open Sans,Arial,sans-serif;font-size:14px;color:#666;background-color:#fff;line-height:1.7em;font-weight:500;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}body.page-template-page-template-blank-php #page-container{padding-top:0!important}body.et_cover_background{background-size:cover!important;background-position:top!important;background-repeat:no-repeat!important;background-attachment:fixed}a{color:#2ea3f2}a,a:hover{text-decoration:none}p{padding-bottom:1em}p:not(.has-background):last-of-type{padding-bottom:0}p.et_normal_padding{padding-bottom:1em}strong{font-weight:700}cite,em,i{font-style:italic}code,pre{font-family:Courier New,monospace;margin-bottom:10px}ins{text-decoration:none}sub,sup{height:0;line-height:1;position:relative;vertical-align:baseline}sup{bottom:.8em}sub{top:.3em}dl{margin:0 0 1.5em}dl dt{font-weight:700}dd{margin-left:1.5em}blockquote p{padding-bottom:0}embed,iframe,object,video{max-width:100%}h1,h2,h3,h4,h5,h6{color:#333;padding-bottom:10px;line-height:1em;font-weight:500}h1 a,h2 a,h3 a,h4 a,h5 a,h6 a{color:inherit}h1{font-size:30px}h2{font-size:26px}h3{font-size:22px}h4{font-size:18px}h5{font-size:16px}h6{font-size:14px}input{-webkit-appearance:none}input[type=checkbox]{-webkit-appearance:checkbox}input[type=radio]{-webkit-appearance:radio}input.text,input.title,input[type=email],input[type=password],input[type=tel],input[type=text],select,textarea{background-color:#fff;border:1px solid #bbb;padding:2px;color:#4e4e4e}input.text:focus,input.title:focus,input[type=text]:focus,select:focus,textarea:focus{border-color:#2d3940;color:#3e3e3e}input.text,input.title,input[type=text],select,textarea{margin:0}textarea{padding:4px}button,input,select,textarea{font-family:inherit}img{max-width:100%;height:auto}.clear{clear:both}br.clear{margin:0;padding:0}.pagination{clear:both}#et_search_icon:hover,.et-social-icon a:hover,.et_password_protected_form .et_submit_button,.form-submit .et_pb_buttontton.alt.disabled,.nav-single a,.posted_in a{color:#2ea3f2}.et-search-form,blockquote{border-color:#2ea3f2}#main-content{background-color:#fff}.container{width:80%;max-width:1080px;margin:auto;position:relative}body:not(.et-tb) #main-content .container,body:not(.et-tb-has-header) #main-content .container{padding-top:58px}.et_full_width_page #main-content .container:before{display:none}.main_title{margin-bottom:20px}.et_password_protected_form .et_submit_button:hover,.form-submit .et_pb_button:hover{background:rgba(0,0,0,.05)}.et_button_icon_visible .et_pb_button{padding-right:2em;padding-left:.7em}.et_button_icon_visible .et_pb_button:after{opacity:1;margin-left:0}.et_button_left .et_pb_button:hover:after{left:.15em}.et_button_left .et_pb_button:after{margin-left:0;left:1em}.et_button_icon_visible.et_button_left .et_pb_button,.et_button_left .et_pb_button:hover,.et_button_left .et_pb_module .et_pb_button:hover{padding-left:2em;padding-right:.7em}.et_button_icon_visible.et_button_left .et_pb_button:after,.et_button_left .et_pb_button:hover:after{left:.15em}.et_password_protected_form .et_submit_button:hover,.form-submit .et_pb_button:hover{padding:.3em 1em}.et_button_no_icon .et_pb_button:after{display:none}.et_button_no_icon.et_button_icon_visible.et_button_left .et_pb_button,.et_button_no_icon.et_button_left .et_pb_button:hover,.et_button_no_icon .et_pb_button,.et_button_no_icon .et_pb_button:hover{padding:.3em 1em!important}.et_button_custom_icon .et_pb_button:after{line-height:1.7em}.et_button_custom_icon.et_button_icon_visible .et_pb_button:after,.et_button_custom_icon .et_pb_button:hover:after{margin-left:.3em}#left-area .post_format-post-format-gallery .wp-block-gallery:first-of-type{padding:0;margin-bottom:-16px}.entry-content table:not(.variations){border:1px solid #eee;margin:0 0 15px;text-align:left;width:100%}.entry-content thead th,.entry-content tr th{color:#555;font-weight:700;padding:9px 24px}.entry-content tr td{border-top:1px solid #eee;padding:6px 24px}#left-area ul,.entry-content ul,.et-l--body ul,.et-l--footer ul,.et-l--header ul{list-style-type:disc;padding:0 0 23px 1em;line-height:26px}#left-area ol,.entry-content ol,.et-l--body ol,.et-l--footer ol,.et-l--header ol{list-style-type:decimal;list-style-position:inside;padding:0 0 23px;line-height:26px}#left-area ul li ul,.entry-content ul li ol{padding:2px 0 2px 20px}#left-area ol li ul,.entry-content ol li ol,.et-l--body ol li ol,.et-l--footer ol li ol,.et-l--header ol li ol{padding:2px 0 2px 35px}#left-area ul.wp-block-gallery{display:-webkit-box;display:-ms-flexbox;display:flex;-ms-flex-wrap:wrap;flex-wrap:wrap;list-style-type:none;padding:0}#left-area ul.products{padding:0!important;line-height:1.7!important;list-style:none!important}.gallery-item a{display:block}.gallery-caption,.gallery-item a{width:90%}#wpadminbar{z-index:100001}#left-area .post-meta{font-size:14px;padding-bottom:15px}#left-area .post-meta a{text-decoration:none;color:#666}#left-area .et_featured_image{padding-bottom:7px}.single .post{padding-bottom:25px}body.single .et_audio_content{margin-bottom:-6px}.nav-single a{text-decoration:none;color:#2ea3f2;font-size:14px;font-weight:400}.nav-previous{float:left}.nav-next{float:right}.et_password_protected_form p input{background-color:#eee;border:none!important;width:100%!important;border-radius:0!important;font-size:14px;color:#999!important;padding:16px!important;-webkit-box-sizing:border-box;box-sizing:border-box}.et_password_protected_form label{display:none}.et_password_protected_form .et_submit_button{font-family:inherit;display:block;float:right;margin:8px auto 0;cursor:pointer}.post-password-required p.nocomments.container{max-width:100%}.post-password-required p.nocomments.container:before{display:none}.aligncenter,div.post .new-post .aligncenter{display:block;margin-left:auto;margin-right:auto}.wp-caption{border:1px solid #ddd;text-align:center;background-color:#f3f3f3;margin-bottom:10px;max-width:96%;padding:8px}.wp-caption.alignleft{margin:0 30px 20px 0}.wp-caption.alignright{margin:0 0 20px 30px}.wp-caption img{margin:0;padding:0;border:0}.wp-caption p.wp-caption-text{font-size:12px;padding:0 4px 5px;margin:0}.alignright{float:right}.alignleft{float:left}img.alignleft{display:inline;float:left;margin-right:15px}img.alignright{display:inline;float:right;margin-left:15px}.page.et_pb_pagebuilder_layout #main-content{background-color:transparent}body #main-content .et_builder_inner_content>h1,body #main-content .et_builder_inner_content>h2,body #main-content .et_builder_inner_content>h3,body #main-content .et_builder_inner_content>h4,body #main-content .et_builder_inner_content>h5,body #main-content .et_builder_inner_content>h6{line-height:1.4em}body #main-content .et_builder_inner_content>p{line-height:1.7em}.wp-block-pullquote{margin:20px 0 30px}.wp-block-pullquote.has-background blockquote{border-left:none}.wp-block-group.has-background{padding:1.5em 1.5em .5em}@media (min-width:981px){#left-area{width:79.125%;padding-bottom:23px}#main-content .container:before{content:"";position:absolute;top:0;height:100%;width:1px;background-color:#e2e2e2}.et_full_width_page #left-area,.et_no_sidebar #left-area{float:none;width:100%!important}.et_full_width_page #left-area{padding-bottom:0}.et_no_sidebar #main-content .container:before{display:none}}@media (max-width:980px){#page-container{padding-top:80px}.et-tb #page-container,.et-tb-has-header #page-container{padding-top:0!important}#left-area,#sidebar{width:100%!important}#main-content .container:before{display:none!important}.et_full_width_page .et_gallery_item:nth-child(4n+1){clear:none}}@media print{#page-container{padding-top:0!important}}#wp-admin-bar-et-use-visual-builder a:before{font-family:ETmodules!important;content:"\e625";font-size:30px!important;width:28px;margin-top:-3px;color:#974df3!important}#wp-admin-bar-et-use-visual-builder:hover a:before{color:#fff!important}#wp-admin-bar-et-use-visual-builder:hover a,#wp-admin-bar-et-use-visual-builder a:hover{transition:background-color .5s ease;-webkit-transition:background-color .5s ease;-moz-transition:background-color .5s ease;background-color:#7e3bd0!important;color:#fff!important}* html .clearfix,:first-child+html .clearfix{zoom:1}.iphone .et_pb_section_video_bg video::-webkit-media-controls-start-playback-button{display:none!important;-webkit-appearance:none}.et_mobile_device .et_pb_section_parallax .et_pb_parallax_css{background-attachment:scroll}.et-social-facebook a.icon:before{content:"\e093"}.et-social-twitter a.icon:before{content:"\e094"}.et-social-google-plus a.icon:before{content:"\e096"}.et-social-instagram a.icon:before{content:"\e09a"}.et-social-rss a.icon:before{content:"\e09e"}.ai1ec-single-event:after{content:" ";display:table;clear:both}.evcal_event_details .evcal_evdata_cell .eventon_details_shading_bot.eventon_details_shading_bot{z-index:3}.wp-block-divi-layout{margin-bottom:1em}*{-webkit-box-sizing:border-box;box-sizing:border-box}#et-info-email:before,#et-info-phone:before,#et_search_icon:before,.comment-reply-link:after,.et-cart-info span:before,.et-pb-arrow-next:before,.et-pb-arrow-prev:before,.et-social-icon a:before,.et_audio_container .mejs-playpause-button button:before,.et_audio_container .mejs-volume-button button:before,.et_overlay:before,.et_password_protected_form .et_submit_button:after,.et_pb_button:after,.et_pb_contact_reset:after,.et_pb_contact_submit:after,.et_pb_font_icon:before,.et_pb_newsletter_button:after,.et_pb_pricing_table_button:after,.et_pb_promo_button:after,.et_pb_testimonial:before,.et_pb_toggle_title:before,.form-submit .et_pb_button:after,.mobile_menu_bar:before,a.et_pb_more_button:after{font-family:ETmodules!important;speak:none;font-style:normal;font-weight:400;-webkit-font-feature-settings:normal;font-feature-settings:normal;font-variant:normal;text-transform:none;line-height:1;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;text-shadow:0 0;direction:ltr}.et-pb-icon,.et_pb_custom_button_icon.et_pb_button:after,.et_pb_login .et_pb_custom_button_icon.et_pb_button:after,.et_pb_woo_custom_button_icon .button.et_pb_custom_button_icon.et_pb_button:after,.et_pb_woo_custom_button_icon .button.et_pb_custom_button_icon.et_pb_button:hover:after{content:attr(data-icon)}.et-pb-icon{font-family:ETmodules;speak:none;font-weight:400;-webkit-font-feature-settings:normal;font-feature-settings:normal;font-variant:normal;text-transform:none;line-height:1;-webkit-font-smoothing:antialiased;font-size:96px;font-style:normal;display:inline-block;-webkit-box-sizing:border-box;box-sizing:border-box;direction:ltr}#et-ajax-saving{display:none;-webkit-transition:background .3s,-webkit-box-shadow .3s;transition:background .3s,-webkit-box-shadow .3s;transition:background .3s,box-shadow .3s;transition:background .3s,box-shadow .3s,-webkit-box-shadow .3s;-webkit-box-shadow:rgba(0,139,219,.247059) 0 0 60px;box-shadow:0 0 60px rgba(0,139,219,.247059);position:fixed;top:50%;left:50%;width:50px;height:50px;background:#fff;border-radius:50px;margin:-25px 0 0 -25px;z-index:999999;text-align:center}#et-ajax-saving img{margin:9px}.et-safe-mode-indicator,.et-safe-mode-indicator:focus,.et-safe-mode-indicator:hover{-webkit-box-shadow:0 5px 10px rgba(41,196,169,.15);box-shadow:0 5px 10px rgba(41,196,169,.15);background:#29c4a9;color:#fff;font-size:14px;font-weight:600;padding:12px;line-height:16px;border-radius:3px;position:fixed;bottom:30px;right:30px;z-index:999999;text-decoration:none;font-family:Open Sans,sans-serif;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale}.et_pb_button{font-size:20px;font-weight:500;padding:.3em 1em;line-height:1.7em!important;background-color:transparent;background-size:cover;background-position:50%;background-repeat:no-repeat;border:2px solid;border-radius:3px;-webkit-transition-duration:.2s;transition-duration:.2s;-webkit-transition-property:all!important;transition-property:all!important}.et_pb_button,.et_pb_button_inner{position:relative}.et_pb_button:hover,.et_pb_module .et_pb_button:hover{border:2px solid transparent;padding:.3em 2em .3em .7em}.et_pb_button:hover{background-color:hsla(0,0%,100%,.2)}.et_pb_bg_layout_light.et_pb_button:hover,.et_pb_bg_layout_light .et_pb_button:hover{background-color:rgba(0,0,0,.05)}.et_pb_button:after,.et_pb_button:before{font-size:32px;line-height:1em;content:"\35";opacity:0;position:absolute;margin-left:-1em;-webkit-transition:all .2s;transition:all .2s;text-transform:none;-webkit-font-feature-settings:"kern" off;font-feature-settings:"kern" off;font-variant:none;font-style:normal;font-weight:400;text-shadow:none}.et_pb_button.et_hover_enabled:hover:after,.et_pb_button.et_pb_hovered:hover:after{-webkit-transition:none!important;transition:none!important}.et_pb_button:before{display:none}.et_pb_button:hover:after{opacity:1;margin-left:0}.et_pb_column_1_3 h1,.et_pb_column_1_4 h1,.et_pb_column_1_5 h1,.et_pb_column_1_6 h1,.et_pb_column_2_5 h1{font-size:26px}.et_pb_column_1_3 h2,.et_pb_column_1_4 h2,.et_pb_column_1_5 h2,.et_pb_column_1_6 h2,.et_pb_column_2_5 h2{font-size:23px}.et_pb_column_1_3 h3,.et_pb_column_1_4 h3,.et_pb_column_1_5 h3,.et_pb_column_1_6 h3,.et_pb_column_2_5 h3{font-size:20px}.et_pb_column_1_3 h4,.et_pb_column_1_4 h4,.et_pb_column_1_5 h4,.et_pb_column_1_6 h4,.et_pb_column_2_5 h4{font-size:18px}.et_pb_column_1_3 h5,.et_pb_column_1_4 h5,.et_pb_column_1_5 h5,.et_pb_column_1_6 h5,.et_pb_column_2_5 h5{font-size:16px}.et_pb_column_1_3 h6,.et_pb_column_1_4 h6,.et_pb_column_1_5 h6,.et_pb_column_1_6 h6,.et_pb_column_2_5 h6{font-size:15px}.et_pb_bg_layout_dark,.et_pb_bg_layout_dark h1,.et_pb_bg_layout_dark h2,.et_pb_bg_layout_dark h3,.et_pb_bg_layout_dark h4,.et_pb_bg_layout_dark h5,.et_pb_bg_layout_dark h6{color:#fff!important}.et_pb_module.et_pb_text_align_left{text-align:left}.et_pb_module.et_pb_text_align_center{text-align:center}.et_pb_module.et_pb_text_align_right{text-align:right}.et_pb_module.et_pb_text_align_justified{text-align:justify}.clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.et_pb_bg_layout_light .et_pb_more_button{color:#2ea3f2}.et_builder_inner_content{position:relative;z-index:1}header .et_builder_inner_content{z-index:2}.et_pb_css_mix_blend_mode_passthrough{mix-blend-mode:unset!important}.et_pb_image_container{margin:-20px -20px 29px}.et_pb_module_inner{position:relative}.et_hover_enabled_preview{z-index:2}.et_hover_enabled:hover{position:relative;z-index:2}.et_pb_all_tabs,.et_pb_module,.et_pb_posts_nav a,.et_pb_tab,.et_pb_with_background{position:relative;background-size:cover;background-position:50%;background-repeat:no-repeat}.et_pb_background_mask,.et_pb_background_pattern{bottom:0;left:0;position:absolute;right:0;top:0}.et_pb_background_mask{background-size:calc(100% + 2px) calc(100% + 2px);background-repeat:no-repeat;background-position:50%;overflow:hidden}.et_pb_background_pattern{background-position:0 0;background-repeat:repeat}.et_pb_with_border{position:relative;border:0 solid #333}.post-password-required .et_pb_row{padding:0;width:100%}.post-password-required .et_password_protected_form{min-height:0}body.et_pb_pagebuilder_layout.et_pb_show_title .post-password-required .et_password_protected_form h1,body:not(.et_pb_pagebuilder_layout) .post-password-required .et_password_protected_form h1{display:none}.et_pb_no_bg{padding:0!important}.et_overlay.et_pb_inline_icon:before,.et_pb_inline_icon:before{content:attr(data-icon)}.et_pb_more_button{color:inherit;text-shadow:none;text-decoration:none;display:inline-block;margin-top:20px}.et_parallax_bg_wrap{overflow:hidden;position:absolute;top:0;right:0;bottom:0;left:0}.et_parallax_bg{background-repeat:no-repeat;background-position:top;background-size:cover;position:absolute;bottom:0;left:0;width:100%;height:100%;display:block}.et_parallax_bg.et_parallax_bg__hover,.et_parallax_bg.et_parallax_bg_phone,.et_parallax_bg.et_parallax_bg_tablet,.et_parallax_gradient.et_parallax_gradient__hover,.et_parallax_gradient.et_parallax_gradient_phone,.et_parallax_gradient.et_parallax_gradient_tablet,.et_pb_section_parallax_hover:hover .et_parallax_bg:not(.et_parallax_bg__hover),.et_pb_section_parallax_hover:hover .et_parallax_gradient:not(.et_parallax_gradient__hover){display:none}.et_pb_section_parallax_hover:hover .et_parallax_bg.et_parallax_bg__hover,.et_pb_section_parallax_hover:hover .et_parallax_gradient.et_parallax_gradient__hover{display:block}.et_parallax_gradient{bottom:0;display:block;left:0;position:absolute;right:0;top:0}.et_pb_module.et_pb_section_parallax,.et_pb_posts_nav a.et_pb_section_parallax,.et_pb_tab.et_pb_section_parallax{position:relative}.et_pb_section_parallax .et_pb_parallax_css,.et_pb_slides .et_parallax_bg.et_pb_parallax_css{background-attachment:fixed}body.et-bfb .et_pb_section_parallax .et_pb_parallax_css,body.et-bfb .et_pb_slides .et_parallax_bg.et_pb_parallax_css{background-attachment:scroll;bottom:auto}.et_pb_section_parallax.et_pb_column .et_pb_module,.et_pb_section_parallax.et_pb_row .et_pb_column,.et_pb_section_parallax.et_pb_row .et_pb_module{z-index:9;position:relative}.et_pb_more_button:hover:after{opacity:1;margin-left:0}.et_pb_preload .et_pb_section_video_bg,.et_pb_preload>div{visibility:hidden}.et_pb_preload,.et_pb_section.et_pb_section_video.et_pb_preload{position:relative;background:#464646!important}.et_pb_preload:before{content:"";position:absolute;top:50%;left:50%;background:url(https://vaccinenation.org/wp-content/themes/Divi/includes/builder/styles/images/preloader.gif) no-repeat;border-radius:32px;width:32px;height:32px;margin:-16px 0 0 -16px}.box-shadow-overlay{position:absolute;top:0;left:0;width:100%;height:100%;z-index:10;pointer-events:none}.et_pb_section>.box-shadow-overlay~.et_pb_row{z-index:11}body.safari .section_has_divider{will-change:transform}.et_pb_row>.box-shadow-overlay{z-index:8}.has-box-shadow-overlay{position:relative}.et_clickable{cursor:pointer}.screen-reader-text{border:0;clip:rect(1px,1px,1px,1px);-webkit-clip-path:inset(50%);clip-path:inset(50%);height:1px;margin:-1px;overflow:hidden;padding:0;position:absolute!important;width:1px;word-wrap:normal!important}.et_multi_view_hidden,.et_multi_view_hidden_image{display:none!important}@keyframes multi-view-image-fade{0%{opacity:0}10%{opacity:.1}20%{opacity:.2}30%{opacity:.3}40%{opacity:.4}50%{opacity:.5}60%{opacity:.6}70%{opacity:.7}80%{opacity:.8}90%{opacity:.9}to{opacity:1}}.et_multi_view_image__loading{visibility:hidden}.et_multi_view_image__loaded{-webkit-animation:multi-view-image-fade .5s;animation:multi-view-image-fade .5s}#et-pb-motion-effects-offset-tracker{visibility:hidden!important;opacity:0;position:absolute;top:0;left:0}.et-pb-before-scroll-animation{opacity:0}header.et-l.et-l--header:after{clear:both;display:block;content:""}.et_pb_module{-webkit-animation-timing-function:linear;animation-timing-function:linear;-webkit-animation-duration:.2s;animation-duration:.2s}@-webkit-keyframes fadeBottom{0%{opacity:0;-webkit-transform:translateY(10%);transform:translateY(10%)}to{opacity:1;-webkit-transform:translateY(0);transform:translateY(0)}}@keyframes fadeBottom{0%{opacity:0;-webkit-transform:translateY(10%);transform:translateY(10%)}to{opacity:1;-webkit-transform:translateY(0);transform:translateY(0)}}@-webkit-keyframes fadeLeft{0%{opacity:0;-webkit-transform:translateX(-10%);transform:translateX(-10%)}to{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@keyframes fadeLeft{0%{opacity:0;-webkit-transform:translateX(-10%);transform:translateX(-10%)}to{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@-webkit-keyframes fadeRight{0%{opacity:0;-webkit-transform:translateX(10%);transform:translateX(10%)}to{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@keyframes fadeRight{0%{opacity:0;-webkit-transform:translateX(10%);transform:translateX(10%)}to{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@-webkit-keyframes fadeTop{0%{opacity:0;-webkit-transform:translateY(-10%);transform:translateY(-10%)}to{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@keyframes fadeTop{0%{opacity:0;-webkit-transform:translateY(-10%);transform:translateY(-10%)}to{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@-webkit-keyframes fadeIn{0%{opacity:0}to{opacity:1}}@keyframes fadeIn{0%{opacity:0}to{opacity:1}}.et-waypoint:not(.et_pb_counters){opacity:0}@media (min-width:981px){.et_pb_section.et_section_specialty div.et_pb_row .et_pb_column .et_pb_column .et_pb_module.et-last-child,.et_pb_section.et_section_specialty div.et_pb_row .et_pb_column .et_pb_column .et_pb_module:last-child,.et_pb_section.et_section_specialty div.et_pb_row .et_pb_column .et_pb_row_inner .et_pb_column .et_pb_module.et-last-child,.et_pb_section.et_section_specialty div.et_pb_row .et_pb_column .et_pb_row_inner .et_pb_column .et_pb_module:last-child,.et_pb_section div.et_pb_row .et_pb_column .et_pb_module.et-last-child,.et_pb_section div.et_pb_row .et_pb_column .et_pb_module:last-child{margin-bottom:0}}@media (max-width:980px){.et_overlay.et_pb_inline_icon_tablet:before,.et_pb_inline_icon_tablet:before{content:attr(data-icon-tablet)}.et_parallax_bg.et_parallax_bg_tablet_exist,.et_parallax_gradient.et_parallax_gradient_tablet_exist{display:none}.et_parallax_bg.et_parallax_bg_tablet,.et_parallax_gradient.et_parallax_gradient_tablet{display:block}.et_pb_column .et_pb_module{margin-bottom:30px}.et_pb_row .et_pb_column .et_pb_module.et-last-child,.et_pb_row .et_pb_column .et_pb_module:last-child,.et_section_specialty .et_pb_row .et_pb_column .et_pb_module.et-last-child,.et_section_specialty .et_pb_row .et_pb_column .et_pb_module:last-child{margin-bottom:0}.et_pb_more_button{display:inline-block!important}.et_pb_bg_layout_light_tablet.et_pb_button,.et_pb_bg_layout_light_tablet.et_pb_module.et_pb_button,.et_pb_bg_layout_light_tablet .et_pb_more_button{color:#2ea3f2}.et_pb_bg_layout_light_tablet .et_pb_forgot_password a{color:#666}.et_pb_bg_layout_light_tablet h1,.et_pb_bg_layout_light_tablet h2,.et_pb_bg_layout_light_tablet h3,.et_pb_bg_layout_light_tablet h4,.et_pb_bg_layout_light_tablet h5,.et_pb_bg_layout_light_tablet h6{color:#333!important}.et_pb_module .et_pb_bg_layout_light_tablet.et_pb_button{color:#2ea3f2!important}.et_pb_bg_layout_light_tablet{color:#666!important}.et_pb_bg_layout_dark_tablet,.et_pb_bg_layout_dark_tablet h1,.et_pb_bg_layout_dark_tablet h2,.et_pb_bg_layout_dark_tablet h3,.et_pb_bg_layout_dark_tablet h4,.et_pb_bg_layout_dark_tablet h5,.et_pb_bg_layout_dark_tablet h6{color:#fff!important}.et_pb_bg_layout_dark_tablet.et_pb_button,.et_pb_bg_layout_dark_tablet.et_pb_module.et_pb_button,.et_pb_bg_layout_dark_tablet .et_pb_more_button{color:inherit}.et_pb_bg_layout_dark_tablet .et_pb_forgot_password a{color:#fff}.et_pb_module.et_pb_text_align_left-tablet{text-align:left}.et_pb_module.et_pb_text_align_center-tablet{text-align:center}.et_pb_module.et_pb_text_align_right-tablet{text-align:right}.et_pb_module.et_pb_text_align_justified-tablet{text-align:justify}}@media (max-width:767px){.et_pb_more_button{display:inline-block!important}.et_overlay.et_pb_inline_icon_phone:before,.et_pb_inline_icon_phone:before{content:attr(data-icon-phone)}.et_parallax_bg.et_parallax_bg_phone_exist,.et_parallax_gradient.et_parallax_gradient_phone_exist{display:none}.et_parallax_bg.et_parallax_bg_phone,.et_parallax_gradient.et_parallax_gradient_phone{display:block}.et-hide-mobile{display:none!important}.et_pb_bg_layout_light_phone.et_pb_button,.et_pb_bg_layout_light_phone.et_pb_module.et_pb_button,.et_pb_bg_layout_light_phone .et_pb_more_button{color:#2ea3f2}.et_pb_bg_layout_light_phone .et_pb_forgot_password a{color:#666}.et_pb_bg_layout_light_phone h1,.et_pb_bg_layout_light_phone h2,.et_pb_bg_layout_light_phone h3,.et_pb_bg_layout_light_phone h4,.et_pb_bg_layout_light_phone h5,.et_pb_bg_layout_light_phone h6{color:#333!important}.et_pb_module .et_pb_bg_layout_light_phone.et_pb_button{color:#2ea3f2!important}.et_pb_bg_layout_light_phone{color:#666!important}.et_pb_bg_layout_dark_phone,.et_pb_bg_layout_dark_phone h1,.et_pb_bg_layout_dark_phone h2,.et_pb_bg_layout_dark_phone h3,.et_pb_bg_layout_dark_phone h4,.et_pb_bg_layout_dark_phone h5,.et_pb_bg_layout_dark_phone h6{color:#fff!important}.et_pb_bg_layout_dark_phone.et_pb_button,.et_pb_bg_layout_dark_phone.et_pb_module.et_pb_button,.et_pb_bg_layout_dark_phone .et_pb_more_button{color:inherit}.et_pb_module .et_pb_bg_layout_dark_phone.et_pb_button{color:#fff!important}.et_pb_bg_layout_dark_phone .et_pb_forgot_password a{color:#fff}.et_pb_module.et_pb_text_align_left-phone{text-align:left}.et_pb_module.et_pb_text_align_center-phone{text-align:center}.et_pb_module.et_pb_text_align_right-phone{text-align:right}.et_pb_module.et_pb_text_align_justified-phone{text-align:justify}}@media (max-width:479px){a.et_pb_more_button{display:block}}@media (min-width:768px) and (max-width:980px){[data-et-multi-view-load-tablet-hidden=true]:not(.et_multi_view_swapped){display:none!important}}@media (max-width:767px){[data-et-multi-view-load-phone-hidden=true]:not(.et_multi_view_swapped){display:none!important}}.et_pb_menu.et_pb_menu--style-inline_centered_logo .et_pb_menu__menu nav ul{-webkit-box-pack:center;-ms-flex-pack:center;justify-content:center}@-webkit-keyframes multi-view-image-fade{0%{-webkit-transform:scale(1);transform:scale(1);opacity:1}50%{-webkit-transform:scale(1.01);transform:scale(1.01);opacity:1}to{-webkit-transform:scale(1);transform:scale(1);opacity:1}} </style> <style id='divi-dynamic-critical-inline-css'> @font-face{font-family:ETmodules;font-display:block;src:url(//vaccinenation.org/wp-content/themes/Divi/core/admin/fonts/modules/all/modules.eot);src:url(//vaccinenation.org/wp-content/themes/Divi/core/admin/fonts/modules/all/modules.eot?#iefix) format("embedded-opentype"),url(//vaccinenation.org/wp-content/themes/Divi/core/admin/fonts/modules/all/modules.woff) format("woff"),url(//vaccinenation.org/wp-content/themes/Divi/core/admin/fonts/modules/all/modules.ttf) format("truetype"),url(//vaccinenation.org/wp-content/themes/Divi/core/admin/fonts/modules/all/modules.svg#ETmodules) format("svg");font-weight:400;font-style:normal} .et_audio_content,.et_link_content,.et_quote_content{background-color:#2ea3f2}.et_pb_post .et-pb-controllers a{margin-bottom:10px}.format-gallery .et-pb-controllers{bottom:0}.et_pb_blog_grid .et_audio_content{margin-bottom:19px}.et_pb_row .et_pb_blog_grid .et_pb_post .et_pb_slide{min-height:180px}.et_audio_content .wp-block-audio{margin:0;padding:0}.et_audio_content h2{line-height:44px}.et_pb_column_1_2 .et_audio_content h2,.et_pb_column_1_3 .et_audio_content h2,.et_pb_column_1_4 .et_audio_content h2,.et_pb_column_1_5 .et_audio_content h2,.et_pb_column_1_6 .et_audio_content h2,.et_pb_column_2_5 .et_audio_content h2,.et_pb_column_3_5 .et_audio_content h2,.et_pb_column_3_8 .et_audio_content h2{margin-bottom:9px;margin-top:0}.et_pb_column_1_2 .et_audio_content,.et_pb_column_3_5 .et_audio_content{padding:35px 40px}.et_pb_column_1_2 .et_audio_content h2,.et_pb_column_3_5 .et_audio_content h2{line-height:32px}.et_pb_column_1_3 .et_audio_content,.et_pb_column_1_4 .et_audio_content,.et_pb_column_1_5 .et_audio_content,.et_pb_column_1_6 .et_audio_content,.et_pb_column_2_5 .et_audio_content,.et_pb_column_3_8 .et_audio_content{padding:35px 20px}.et_pb_column_1_3 .et_audio_content h2,.et_pb_column_1_4 .et_audio_content h2,.et_pb_column_1_5 .et_audio_content h2,.et_pb_column_1_6 .et_audio_content h2,.et_pb_column_2_5 .et_audio_content h2,.et_pb_column_3_8 .et_audio_content h2{font-size:18px;line-height:26px}article.et_pb_has_overlay .et_pb_blog_image_container{position:relative}.et_pb_post>.et_main_video_container{position:relative;margin-bottom:30px}.et_pb_post .et_pb_video_overlay .et_pb_video_play{color:#fff}.et_pb_post .et_pb_video_overlay_hover:hover{background:rgba(0,0,0,.6)}.et_audio_content,.et_link_content,.et_quote_content{text-align:center;word-wrap:break-word;position:relative;padding:50px 60px}.et_audio_content h2,.et_link_content a.et_link_main_url,.et_link_content h2,.et_quote_content blockquote cite,.et_quote_content blockquote p{color:#fff!important}.et_quote_main_link{position:absolute;text-indent:-9999px;width:100%;height:100%;display:block;top:0;left:0}.et_quote_content blockquote{padding:0;margin:0;border:none}.et_audio_content h2,.et_link_content h2,.et_quote_content blockquote p{margin-top:0}.et_audio_content h2{margin-bottom:20px}.et_audio_content h2,.et_link_content h2,.et_quote_content blockquote p{line-height:44px}.et_link_content a.et_link_main_url,.et_quote_content blockquote cite{font-size:18px;font-weight:200}.et_quote_content blockquote cite{font-style:normal}.et_pb_column_2_3 .et_quote_content{padding:50px 42px 45px}.et_pb_column_2_3 .et_audio_content,.et_pb_column_2_3 .et_link_content{padding:40px 40px 45px}.et_pb_column_1_2 .et_audio_content,.et_pb_column_1_2 .et_link_content,.et_pb_column_1_2 .et_quote_content,.et_pb_column_3_5 .et_audio_content,.et_pb_column_3_5 .et_link_content,.et_pb_column_3_5 .et_quote_content{padding:35px 40px}.et_pb_column_1_2 .et_quote_content blockquote p,.et_pb_column_3_5 .et_quote_content blockquote p{font-size:26px;line-height:32px}.et_pb_column_1_2 .et_audio_content h2,.et_pb_column_1_2 .et_link_content h2,.et_pb_column_3_5 .et_audio_content h2,.et_pb_column_3_5 .et_link_content h2{line-height:32px}.et_pb_column_1_2 .et_link_content a.et_link_main_url,.et_pb_column_1_2 .et_quote_content blockquote cite,.et_pb_column_3_5 .et_link_content a.et_link_main_url,.et_pb_column_3_5 .et_quote_content blockquote cite{font-size:14px}.et_pb_column_1_3 .et_quote_content,.et_pb_column_1_4 .et_quote_content,.et_pb_column_1_5 .et_quote_content,.et_pb_column_1_6 .et_quote_content,.et_pb_column_2_5 .et_quote_content,.et_pb_column_3_8 .et_quote_content{padding:35px 30px 32px}.et_pb_column_1_3 .et_audio_content,.et_pb_column_1_3 .et_link_content,.et_pb_column_1_4 .et_audio_content,.et_pb_column_1_4 .et_link_content,.et_pb_column_1_5 .et_audio_content,.et_pb_column_1_5 .et_link_content,.et_pb_column_1_6 .et_audio_content,.et_pb_column_1_6 .et_link_content,.et_pb_column_2_5 .et_audio_content,.et_pb_column_2_5 .et_link_content,.et_pb_column_3_8 .et_audio_content,.et_pb_column_3_8 .et_link_content{padding:35px 20px}.et_pb_column_1_3 .et_audio_content h2,.et_pb_column_1_3 .et_link_content h2,.et_pb_column_1_3 .et_quote_content blockquote p,.et_pb_column_1_4 .et_audio_content h2,.et_pb_column_1_4 .et_link_content h2,.et_pb_column_1_4 .et_quote_content blockquote p,.et_pb_column_1_5 .et_audio_content h2,.et_pb_column_1_5 .et_link_content h2,.et_pb_column_1_5 .et_quote_content blockquote p,.et_pb_column_1_6 .et_audio_content h2,.et_pb_column_1_6 .et_link_content h2,.et_pb_column_1_6 .et_quote_content blockquote p,.et_pb_column_2_5 .et_audio_content h2,.et_pb_column_2_5 .et_link_content h2,.et_pb_column_2_5 .et_quote_content blockquote p,.et_pb_column_3_8 .et_audio_content h2,.et_pb_column_3_8 .et_link_content h2,.et_pb_column_3_8 .et_quote_content blockquote p{font-size:18px;line-height:26px}.et_pb_column_1_3 .et_link_content a.et_link_main_url,.et_pb_column_1_3 .et_quote_content blockquote cite,.et_pb_column_1_4 .et_link_content a.et_link_main_url,.et_pb_column_1_4 .et_quote_content blockquote cite,.et_pb_column_1_5 .et_link_content a.et_link_main_url,.et_pb_column_1_5 .et_quote_content blockquote cite,.et_pb_column_1_6 .et_link_content a.et_link_main_url,.et_pb_column_1_6 .et_quote_content blockquote cite,.et_pb_column_2_5 .et_link_content a.et_link_main_url,.et_pb_column_2_5 .et_quote_content blockquote cite,.et_pb_column_3_8 .et_link_content a.et_link_main_url,.et_pb_column_3_8 .et_quote_content blockquote cite{font-size:14px}.et_pb_post .et_pb_gallery_post_type .et_pb_slide{min-height:500px;background-size:cover!important;background-position:top}.format-gallery .et_pb_slider.gallery-not-found .et_pb_slide{-webkit-box-shadow:inset 0 0 10px rgba(0,0,0,.1);box-shadow:inset 0 0 10px rgba(0,0,0,.1)}.format-gallery .et_pb_slider:hover .et-pb-arrow-prev{left:0}.format-gallery .et_pb_slider:hover .et-pb-arrow-next{right:0}.et_pb_post>.et_pb_slider{margin-bottom:30px}.et_pb_column_3_4 .et_pb_post .et_pb_slide{min-height:442px}.et_pb_column_2_3 .et_pb_post .et_pb_slide{min-height:390px}.et_pb_column_1_2 .et_pb_post .et_pb_slide,.et_pb_column_3_5 .et_pb_post .et_pb_slide{min-height:284px}.et_pb_column_1_3 .et_pb_post .et_pb_slide,.et_pb_column_2_5 .et_pb_post .et_pb_slide,.et_pb_column_3_8 .et_pb_post .et_pb_slide{min-height:180px}.et_pb_column_1_4 .et_pb_post .et_pb_slide,.et_pb_column_1_5 .et_pb_post .et_pb_slide,.et_pb_column_1_6 .et_pb_post .et_pb_slide{min-height:125px}.et_pb_portfolio.et_pb_section_parallax .pagination,.et_pb_portfolio.et_pb_section_video .pagination,.et_pb_portfolio_grid.et_pb_section_parallax .pagination,.et_pb_portfolio_grid.et_pb_section_video .pagination{position:relative}.et_pb_bg_layout_light .et_pb_post .post-meta,.et_pb_bg_layout_light .et_pb_post .post-meta a,.et_pb_bg_layout_light .et_pb_post p{color:#666}.et_pb_bg_layout_dark .et_pb_post .post-meta,.et_pb_bg_layout_dark .et_pb_post .post-meta a,.et_pb_bg_layout_dark .et_pb_post p{color:inherit}.et_pb_text_color_dark .et_audio_content h2,.et_pb_text_color_dark .et_link_content a.et_link_main_url,.et_pb_text_color_dark .et_link_content h2,.et_pb_text_color_dark .et_quote_content blockquote cite,.et_pb_text_color_dark .et_quote_content blockquote p{color:#666!important}.et_pb_text_color_dark.et_audio_content h2,.et_pb_text_color_dark.et_link_content a.et_link_main_url,.et_pb_text_color_dark.et_link_content h2,.et_pb_text_color_dark.et_quote_content blockquote cite,.et_pb_text_color_dark.et_quote_content blockquote p{color:#bbb!important}.et_pb_text_color_dark.et_audio_content,.et_pb_text_color_dark.et_link_content,.et_pb_text_color_dark.et_quote_content{background-color:#e8e8e8}@media (min-width:981px) and (max-width:1100px){.et_quote_content{padding:50px 70px 45px}.et_pb_column_2_3 .et_quote_content{padding:50px 50px 45px}.et_pb_column_1_2 .et_quote_content,.et_pb_column_3_5 .et_quote_content{padding:35px 47px 30px}.et_pb_column_1_3 .et_quote_content,.et_pb_column_1_4 .et_quote_content,.et_pb_column_1_5 .et_quote_content,.et_pb_column_1_6 .et_quote_content,.et_pb_column_2_5 .et_quote_content,.et_pb_column_3_8 .et_quote_content{padding:35px 25px 32px}.et_pb_column_4_4 .et_pb_post .et_pb_slide{min-height:534px}.et_pb_column_3_4 .et_pb_post .et_pb_slide{min-height:392px}.et_pb_column_2_3 .et_pb_post .et_pb_slide{min-height:345px}.et_pb_column_1_2 .et_pb_post .et_pb_slide,.et_pb_column_3_5 .et_pb_post .et_pb_slide{min-height:250px}.et_pb_column_1_3 .et_pb_post .et_pb_slide,.et_pb_column_2_5 .et_pb_post .et_pb_slide,.et_pb_column_3_8 .et_pb_post .et_pb_slide{min-height:155px}.et_pb_column_1_4 .et_pb_post .et_pb_slide,.et_pb_column_1_5 .et_pb_post .et_pb_slide,.et_pb_column_1_6 .et_pb_post .et_pb_slide{min-height:108px}}@media (max-width:980px){.et_pb_bg_layout_dark_tablet .et_audio_content h2{color:#fff!important}.et_pb_text_color_dark_tablet.et_audio_content h2{color:#bbb!important}.et_pb_text_color_dark_tablet.et_audio_content{background-color:#e8e8e8}.et_pb_bg_layout_dark_tablet .et_audio_content h2,.et_pb_bg_layout_dark_tablet .et_link_content a.et_link_main_url,.et_pb_bg_layout_dark_tablet .et_link_content h2,.et_pb_bg_layout_dark_tablet .et_quote_content blockquote cite,.et_pb_bg_layout_dark_tablet .et_quote_content blockquote p{color:#fff!important}.et_pb_text_color_dark_tablet .et_audio_content h2,.et_pb_text_color_dark_tablet .et_link_content a.et_link_main_url,.et_pb_text_color_dark_tablet .et_link_content h2,.et_pb_text_color_dark_tablet .et_quote_content blockquote cite,.et_pb_text_color_dark_tablet .et_quote_content blockquote p{color:#666!important}.et_pb_text_color_dark_tablet.et_audio_content h2,.et_pb_text_color_dark_tablet.et_link_content a.et_link_main_url,.et_pb_text_color_dark_tablet.et_link_content h2,.et_pb_text_color_dark_tablet.et_quote_content blockquote cite,.et_pb_text_color_dark_tablet.et_quote_content blockquote p{color:#bbb!important}.et_pb_text_color_dark_tablet.et_audio_content,.et_pb_text_color_dark_tablet.et_link_content,.et_pb_text_color_dark_tablet.et_quote_content{background-color:#e8e8e8}}@media (min-width:768px) and (max-width:980px){.et_audio_content h2{font-size:26px!important;line-height:44px!important;margin-bottom:24px!important}.et_pb_post>.et_pb_gallery_post_type>.et_pb_slides>.et_pb_slide{min-height:384px!important}.et_quote_content{padding:50px 43px 45px!important}.et_quote_content blockquote p{font-size:26px!important;line-height:44px!important}.et_quote_content blockquote cite{font-size:18px!important}.et_link_content{padding:40px 40px 45px}.et_link_content h2{font-size:26px!important;line-height:44px!important}.et_link_content a.et_link_main_url{font-size:18px!important}}@media (max-width:767px){.et_audio_content h2,.et_link_content h2,.et_quote_content,.et_quote_content blockquote p{font-size:20px!important;line-height:26px!important}.et_audio_content,.et_link_content{padding:35px 20px!important}.et_audio_content h2{margin-bottom:9px!important}.et_pb_bg_layout_dark_phone .et_audio_content h2{color:#fff!important}.et_pb_text_color_dark_phone.et_audio_content{background-color:#e8e8e8}.et_link_content a.et_link_main_url,.et_quote_content blockquote cite{font-size:14px!important}.format-gallery .et-pb-controllers{height:auto}.et_pb_post>.et_pb_gallery_post_type>.et_pb_slides>.et_pb_slide{min-height:222px!important}.et_pb_bg_layout_dark_phone .et_audio_content h2,.et_pb_bg_layout_dark_phone .et_link_content a.et_link_main_url,.et_pb_bg_layout_dark_phone .et_link_content h2,.et_pb_bg_layout_dark_phone .et_quote_content blockquote cite,.et_pb_bg_layout_dark_phone .et_quote_content blockquote p{color:#fff!important}.et_pb_text_color_dark_phone .et_audio_content h2,.et_pb_text_color_dark_phone .et_link_content a.et_link_main_url,.et_pb_text_color_dark_phone .et_link_content h2,.et_pb_text_color_dark_phone .et_quote_content blockquote cite,.et_pb_text_color_dark_phone .et_quote_content blockquote p{color:#666!important}.et_pb_text_color_dark_phone.et_audio_content h2,.et_pb_text_color_dark_phone.et_link_content a.et_link_main_url,.et_pb_text_color_dark_phone.et_link_content h2,.et_pb_text_color_dark_phone.et_quote_content blockquote cite,.et_pb_text_color_dark_phone.et_quote_content blockquote p{color:#bbb!important}.et_pb_text_color_dark_phone.et_audio_content,.et_pb_text_color_dark_phone.et_link_content,.et_pb_text_color_dark_phone.et_quote_content{background-color:#e8e8e8}}@media (max-width:479px){.et_pb_column_1_2 .et_pb_carousel_item .et_pb_video_play,.et_pb_column_1_3 .et_pb_carousel_item .et_pb_video_play,.et_pb_column_2_3 .et_pb_carousel_item .et_pb_video_play,.et_pb_column_2_5 .et_pb_carousel_item .et_pb_video_play,.et_pb_column_3_5 .et_pb_carousel_item .et_pb_video_play,.et_pb_column_3_8 .et_pb_carousel_item .et_pb_video_play{font-size:1.5rem;line-height:1.5rem;margin-left:-.75rem;margin-top:-.75rem}.et_audio_content,.et_quote_content{padding:35px 20px!important}.et_pb_post>.et_pb_gallery_post_type>.et_pb_slides>.et_pb_slide{min-height:156px!important}}.et_full_width_page .et_gallery_item{float:left;width:20.875%;margin:0 5.5% 5.5% 0}.et_full_width_page .et_gallery_item:nth-child(3n){margin-right:5.5%}.et_full_width_page .et_gallery_item:nth-child(3n+1){clear:none}.et_full_width_page .et_gallery_item:nth-child(4n){margin-right:0}.et_full_width_page .et_gallery_item:nth-child(4n+1){clear:both} .et_pb_slider{position:relative;overflow:hidden}.et_pb_slide{padding:0 6%;background-size:cover;background-position:50%;background-repeat:no-repeat}.et_pb_slider .et_pb_slide{display:none;float:left;margin-right:-100%;position:relative;width:100%;text-align:center;list-style:none!important;background-position:50%;background-size:100%;background-size:cover}.et_pb_slider .et_pb_slide:first-child{display:list-item}.et-pb-controllers{position:absolute;bottom:20px;left:0;width:100%;text-align:center;z-index:10}.et-pb-controllers a{display:inline-block;background-color:hsla(0,0%,100%,.5);text-indent:-9999px;border-radius:7px;width:7px;height:7px;margin-right:10px;padding:0;opacity:.5}.et-pb-controllers .et-pb-active-control{opacity:1}.et-pb-controllers a:last-child{margin-right:0}.et-pb-controllers .et-pb-active-control{background-color:#fff}.et_pb_slides .et_pb_temp_slide{display:block}.et_pb_slides:after{content:"";display:block;clear:both;visibility:hidden;line-height:0;height:0;width:0}@media (max-width:980px){.et_pb_bg_layout_light_tablet .et-pb-controllers .et-pb-active-control{background-color:#333}.et_pb_bg_layout_light_tablet .et-pb-controllers a{background-color:rgba(0,0,0,.3)}.et_pb_bg_layout_light_tablet .et_pb_slide_content{color:#333}.et_pb_bg_layout_dark_tablet .et_pb_slide_description{text-shadow:0 1px 3px rgba(0,0,0,.3)}.et_pb_bg_layout_dark_tablet .et_pb_slide_content{color:#fff}.et_pb_bg_layout_dark_tablet .et-pb-controllers .et-pb-active-control{background-color:#fff}.et_pb_bg_layout_dark_tablet .et-pb-controllers a{background-color:hsla(0,0%,100%,.5)}}@media (max-width:767px){.et-pb-controllers{position:absolute;bottom:5%;left:0;width:100%;text-align:center;z-index:10;height:14px}.et_transparent_nav .et_pb_section:first-child .et-pb-controllers{bottom:18px}.et_pb_bg_layout_light_phone.et_pb_slider_with_overlay .et_pb_slide_overlay_container,.et_pb_bg_layout_light_phone.et_pb_slider_with_text_overlay .et_pb_text_overlay_wrapper{background-color:hsla(0,0%,100%,.9)}.et_pb_bg_layout_light_phone .et-pb-controllers .et-pb-active-control{background-color:#333}.et_pb_bg_layout_dark_phone.et_pb_slider_with_overlay .et_pb_slide_overlay_container,.et_pb_bg_layout_dark_phone.et_pb_slider_with_text_overlay .et_pb_text_overlay_wrapper,.et_pb_bg_layout_light_phone .et-pb-controllers a{background-color:rgba(0,0,0,.3)}.et_pb_bg_layout_dark_phone .et-pb-controllers .et-pb-active-control{background-color:#fff}.et_pb_bg_layout_dark_phone .et-pb-controllers a{background-color:hsla(0,0%,100%,.5)}}.et_mobile_device .et_pb_slider_parallax .et_pb_slide,.et_mobile_device .et_pb_slides .et_parallax_bg.et_pb_parallax_css{background-attachment:scroll} .et-pb-arrow-next,.et-pb-arrow-prev{position:absolute;top:50%;z-index:100;font-size:48px;color:#fff;margin-top:-24px;-webkit-transition:all .2s ease-in-out;transition:all .2s ease-in-out;opacity:0}.et_pb_bg_layout_light .et-pb-arrow-next,.et_pb_bg_layout_light .et-pb-arrow-prev{color:#333}.et_pb_slider:hover .et-pb-arrow-prev{left:22px;opacity:1}.et_pb_slider:hover .et-pb-arrow-next{right:22px;opacity:1}.et_pb_bg_layout_light .et-pb-controllers .et-pb-active-control{background-color:#333}.et_pb_bg_layout_light .et-pb-controllers a{background-color:rgba(0,0,0,.3)}.et-pb-arrow-next:hover,.et-pb-arrow-prev:hover{text-decoration:none}.et-pb-arrow-next span,.et-pb-arrow-prev span{display:none}.et-pb-arrow-prev{left:-22px}.et-pb-arrow-next{right:-22px}.et-pb-arrow-prev:before{content:"4"}.et-pb-arrow-next:before{content:"5"}.format-gallery .et-pb-arrow-next,.format-gallery .et-pb-arrow-prev{color:#fff}.et_pb_column_1_3 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_1_4 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_1_5 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_1_6 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_2_5 .et_pb_slider:hover .et-pb-arrow-prev{left:0}.et_pb_column_1_3 .et_pb_slider:hover .et-pb-arrow-next,.et_pb_column_1_4 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_1_5 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_1_6 .et_pb_slider:hover .et-pb-arrow-prev,.et_pb_column_2_5 .et_pb_slider:hover .et-pb-arrow-next{right:0}.et_pb_column_1_4 .et_pb_slider .et_pb_slide,.et_pb_column_1_5 .et_pb_slider .et_pb_slide,.et_pb_column_1_6 .et_pb_slider .et_pb_slide{min-height:170px}.et_pb_column_1_4 .et_pb_slider:hover .et-pb-arrow-next,.et_pb_column_1_5 .et_pb_slider:hover .et-pb-arrow-next,.et_pb_column_1_6 .et_pb_slider:hover .et-pb-arrow-next{right:0}@media (max-width:980px){.et_pb_bg_layout_light_tablet .et-pb-arrow-next,.et_pb_bg_layout_light_tablet .et-pb-arrow-prev{color:#333}.et_pb_bg_layout_dark_tablet .et-pb-arrow-next,.et_pb_bg_layout_dark_tablet .et-pb-arrow-prev{color:#fff}}@media (max-width:767px){.et_pb_slider:hover .et-pb-arrow-prev{left:0;opacity:1}.et_pb_slider:hover .et-pb-arrow-next{right:0;opacity:1}.et_pb_bg_layout_light_phone .et-pb-arrow-next,.et_pb_bg_layout_light_phone .et-pb-arrow-prev{color:#333}.et_pb_bg_layout_dark_phone .et-pb-arrow-next,.et_pb_bg_layout_dark_phone .et-pb-arrow-prev{color:#fff}}.et_mobile_device .et-pb-arrow-prev{left:22px;opacity:1}.et_mobile_device .et-pb-arrow-next{right:22px;opacity:1}@media (max-width:767px){.et_mobile_device .et-pb-arrow-prev{left:0;opacity:1}.et_mobile_device .et-pb-arrow-next{right:0;opacity:1}} .et_overlay{z-index:-1;position:absolute;top:0;left:0;display:block;width:100%;height:100%;background:hsla(0,0%,100%,.9);opacity:0;pointer-events:none;-webkit-transition:all .3s;transition:all .3s;border:1px solid #e5e5e5;-webkit-box-sizing:border-box;box-sizing:border-box;-webkit-backface-visibility:hidden;backface-visibility:hidden;-webkit-font-smoothing:antialiased}.et_overlay:before{color:#2ea3f2;content:"\E050";position:absolute;top:50%;left:50%;-webkit-transform:translate(-50%,-50%);transform:translate(-50%,-50%);font-size:32px;-webkit-transition:all .4s;transition:all .4s}.et_portfolio_image,.et_shop_image{position:relative;display:block}.et_pb_has_overlay:not(.et_pb_image):hover .et_overlay,.et_portfolio_image:hover .et_overlay,.et_shop_image:hover .et_overlay{z-index:3;opacity:1}#ie7 .et_overlay,#ie8 .et_overlay{display:none}.et_pb_module.et_pb_has_overlay{position:relative}.et_pb_module.et_pb_has_overlay .et_overlay,article.et_pb_has_overlay{border:none} .et_pb_blog_grid .et_audio_container .mejs-container .mejs-controls .mejs-time span{font-size:14px}.et_audio_container .mejs-container{width:auto!important;min-width:unset!important;height:auto!important}.et_audio_container .mejs-container,.et_audio_container .mejs-container .mejs-controls,.et_audio_container .mejs-embed,.et_audio_container .mejs-embed body{background:none;height:auto}.et_audio_container .mejs-controls .mejs-time-rail .mejs-time-loaded,.et_audio_container .mejs-time.mejs-currenttime-container{display:none!important}.et_audio_container .mejs-time{display:block!important;padding:0;margin-left:10px;margin-right:90px;line-height:inherit}.et_audio_container .mejs-android .mejs-time,.et_audio_container .mejs-ios .mejs-time,.et_audio_container .mejs-ipad .mejs-time,.et_audio_container .mejs-iphone .mejs-time{margin-right:0}.et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-total,.et_audio_container .mejs-controls .mejs-time-rail .mejs-time-total{background:hsla(0,0%,100%,.5);border-radius:5px;height:4px;margin:8px 0 0;top:0;right:0;left:auto}.et_audio_container .mejs-controls>div{height:20px!important}.et_audio_container .mejs-controls div.mejs-time-rail{padding-top:0;position:relative;display:block!important;margin-left:42px;margin-right:0}.et_audio_container span.mejs-time-total.mejs-time-slider{display:block!important;position:relative!important;max-width:100%;min-width:unset!important}.et_audio_container .mejs-button.mejs-volume-button{width:auto;height:auto;margin-left:auto;position:absolute;right:59px;bottom:-2px}.et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-current,.et_audio_container .mejs-controls .mejs-time-rail .mejs-time-current{background:#fff;height:4px;border-radius:5px}.et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle,.et_audio_container .mejs-controls .mejs-time-rail .mejs-time-handle{display:block;border:none;width:10px}.et_audio_container .mejs-time-rail .mejs-time-handle-content{border-radius:100%;-webkit-transform:scale(1);transform:scale(1)}.et_pb_text_color_dark .et_audio_container .mejs-time-rail .mejs-time-handle-content{border-color:#666}.et_audio_container .mejs-time-rail .mejs-time-hovered{height:4px}.et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle{background:#fff;border-radius:5px;height:10px;position:absolute;top:-3px}.et_audio_container .mejs-container .mejs-controls .mejs-time span{font-size:18px}.et_audio_container .mejs-controls a.mejs-horizontal-volume-slider{display:block!important;height:19px;margin-left:5px;position:absolute;right:0;bottom:0}.et_audio_container .mejs-controls div.mejs-horizontal-volume-slider{height:4px}.et_audio_container .mejs-playpause-button button,.et_audio_container .mejs-volume-button button{background:none!important;margin:0!important;width:auto!important;height:auto!important;position:relative!important;z-index:99}.et_audio_container .mejs-playpause-button button:before{content:"E"!important;font-size:32px;left:0;top:-8px}.et_audio_container .mejs-playpause-button button:before,.et_audio_container .mejs-volume-button button:before{color:#fff}.et_audio_container .mejs-playpause-button{margin-top:-7px!important;width:auto!important;height:auto!important;position:absolute}.et_audio_container .mejs-controls .mejs-button button:focus{outline:none}.et_audio_container .mejs-playpause-button.mejs-pause button:before{content:"`"!important}.et_audio_container .mejs-volume-button button:before{content:"\E068";font-size:18px}.et_pb_text_color_dark .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-total,.et_pb_text_color_dark .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-total{background:hsla(0,0%,60%,.5)}.et_pb_text_color_dark .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-current,.et_pb_text_color_dark .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-current{background:#999}.et_pb_text_color_dark .et_audio_container .mejs-playpause-button button:before,.et_pb_text_color_dark .et_audio_container .mejs-volume-button button:before{color:#666}.et_pb_text_color_dark .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle,.et_pb_text_color_dark .mejs-controls .mejs-time-rail .mejs-time-handle{background:#666}.et_pb_text_color_dark .mejs-container .mejs-controls .mejs-time span{color:#999}.et_pb_column_1_3 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_1_4 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_1_5 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_1_6 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_2_5 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_3_8 .et_audio_container .mejs-container .mejs-controls .mejs-time span{font-size:14px}.et_audio_container .mejs-container .mejs-controls{padding:0;-ms-flex-wrap:wrap;flex-wrap:wrap;min-width:unset!important;position:relative}@media (max-width:980px){.et_pb_column_1_3 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_1_4 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_1_5 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_1_6 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_2_5 .et_audio_container .mejs-container .mejs-controls .mejs-time span,.et_pb_column_3_8 .et_audio_container .mejs-container .mejs-controls .mejs-time span{font-size:18px}.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-total,.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-total{background:hsla(0,0%,100%,.5)}.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-current,.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-current{background:#fff}.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-playpause-button button:before,.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-volume-button button:before{color:#fff}.et_pb_bg_layout_dark_tablet .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle,.et_pb_bg_layout_dark_tablet .mejs-controls .mejs-time-rail .mejs-time-handle{background:#fff}.et_pb_bg_layout_dark_tablet .mejs-container .mejs-controls .mejs-time span{color:#fff}.et_pb_text_color_dark_tablet .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-total,.et_pb_text_color_dark_tablet .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-total{background:hsla(0,0%,60%,.5)}.et_pb_text_color_dark_tablet .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-current,.et_pb_text_color_dark_tablet .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-current{background:#999}.et_pb_text_color_dark_tablet .et_audio_container .mejs-playpause-button button:before,.et_pb_text_color_dark_tablet .et_audio_container .mejs-volume-button button:before{color:#666}.et_pb_text_color_dark_tablet .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle,.et_pb_text_color_dark_tablet .mejs-controls .mejs-time-rail .mejs-time-handle{background:#666}.et_pb_text_color_dark_tablet .mejs-container .mejs-controls .mejs-time span{color:#999}}@media (max-width:767px){.et_audio_container .mejs-container .mejs-controls .mejs-time span{font-size:14px!important}.et_pb_bg_layout_dark_phone .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-total,.et_pb_bg_layout_dark_phone .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-total{background:hsla(0,0%,100%,.5)}.et_pb_bg_layout_dark_phone .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-current,.et_pb_bg_layout_dark_phone .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-current{background:#fff}.et_pb_bg_layout_dark_phone .et_audio_container .mejs-playpause-button button:before,.et_pb_bg_layout_dark_phone .et_audio_container .mejs-volume-button button:before{color:#fff}.et_pb_bg_layout_dark_phone .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle,.et_pb_bg_layout_dark_phone .mejs-controls .mejs-time-rail .mejs-time-handle{background:#fff}.et_pb_bg_layout_dark_phone .mejs-container .mejs-controls .mejs-time span{color:#fff}.et_pb_text_color_dark_phone .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-total,.et_pb_text_color_dark_phone .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-total{background:hsla(0,0%,60%,.5)}.et_pb_text_color_dark_phone .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-current,.et_pb_text_color_dark_phone .et_audio_container .mejs-controls .mejs-time-rail .mejs-time-current{background:#999}.et_pb_text_color_dark_phone .et_audio_container .mejs-playpause-button button:before,.et_pb_text_color_dark_phone .et_audio_container .mejs-volume-button button:before{color:#666}.et_pb_text_color_dark_phone .et_audio_container .mejs-controls .mejs-horizontal-volume-slider .mejs-horizontal-volume-handle,.et_pb_text_color_dark_phone .mejs-controls .mejs-time-rail .mejs-time-handle{background:#666}.et_pb_text_color_dark_phone .mejs-container .mejs-controls .mejs-time span{color:#999}} .et_pb_video_box{display:block;position:relative;z-index:1;line-height:0}.et_pb_video_box video{width:100%!important;height:auto!important}.et_pb_video_overlay{position:absolute;z-index:10;top:0;left:0;height:100%;width:100%;background-size:cover;background-repeat:no-repeat;background-position:50%;cursor:pointer}.et_pb_video_play:before{font-family:ETmodules;content:"I"}.et_pb_video_play{display:block;position:absolute;z-index:100;color:#fff;left:50%;top:50%}.et_pb_column_1_2 .et_pb_video_play,.et_pb_column_2_3 .et_pb_video_play,.et_pb_column_3_4 .et_pb_video_play,.et_pb_column_3_5 .et_pb_video_play,.et_pb_column_4_4 .et_pb_video_play{font-size:6rem;line-height:6rem;margin-left:-3rem;margin-top:-3rem}.et_pb_column_1_3 .et_pb_video_play,.et_pb_column_1_4 .et_pb_video_play,.et_pb_column_1_5 .et_pb_video_play,.et_pb_column_1_6 .et_pb_video_play,.et_pb_column_2_5 .et_pb_video_play,.et_pb_column_3_8 .et_pb_video_play{font-size:3rem;line-height:3rem;margin-left:-1.5rem;margin-top:-1.5rem}.et_pb_bg_layout_light .et_pb_video_play{color:#333}.et_pb_video_overlay_hover{background:transparent;width:100%;height:100%;position:absolute;z-index:100;-webkit-transition:all .5s ease-in-out;transition:all .5s ease-in-out}.et_pb_video .et_pb_video_overlay_hover:hover{background:rgba(0,0,0,.6)}@media (min-width:768px) and (max-width:980px){.et_pb_column_1_3 .et_pb_video_play,.et_pb_column_1_4 .et_pb_video_play,.et_pb_column_1_5 .et_pb_video_play,.et_pb_column_1_6 .et_pb_video_play,.et_pb_column_2_5 .et_pb_video_play,.et_pb_column_3_8 .et_pb_video_play{font-size:6rem;line-height:6rem;margin-left:-3rem;margin-top:-3rem}}@media (max-width:980px){.et_pb_bg_layout_light_tablet .et_pb_video_play{color:#333}}@media (max-width:768px){.et_pb_column_1_2 .et_pb_video_play,.et_pb_column_2_3 .et_pb_video_play,.et_pb_column_3_4 .et_pb_video_play,.et_pb_column_3_5 .et_pb_video_play,.et_pb_column_4_4 .et_pb_video_play{font-size:3rem;line-height:3rem;margin-left:-1.5rem;margin-top:-1.5rem}}@media (max-width:767px){.et_pb_bg_layout_light_phone .et_pb_video_play{color:#333}} .et_post_gallery{padding:0!important;line-height:1.7!important;list-style:none!important}.et_gallery_item{float:left;width:28.353%;margin:0 7.47% 7.47% 0}.blocks-gallery-item,.et_gallery_item{padding-left:0!important}.blocks-gallery-item:before,.et_gallery_item:before{display:none}.et_gallery_item:nth-child(3n){margin-right:0}.et_gallery_item:nth-child(3n+1){clear:both} .et_pb_post{margin-bottom:60px;word-wrap:break-word}.et_pb_fullwidth_post_content.et_pb_with_border img,.et_pb_post_content.et_pb_with_border img,.et_pb_with_border .et_pb_post .et_pb_slides,.et_pb_with_border .et_pb_post img:not(.woocommerce-placeholder),.et_pb_with_border.et_pb_posts .et_pb_post,.et_pb_with_border.et_pb_posts_nav span.nav-next a,.et_pb_with_border.et_pb_posts_nav span.nav-previous a{border:0 solid #333}.et_pb_post .entry-content{padding-top:30px}.et_pb_post .entry-featured-image-url{display:block;position:relative;margin-bottom:30px}.et_pb_post .entry-title a,.et_pb_post h2 a{text-decoration:none}.et_pb_post .post-meta{font-size:14px;margin-bottom:6px}.et_pb_post .more,.et_pb_post .post-meta a{text-decoration:none}.et_pb_post .more{color:#82c0c7}.et_pb_posts a.more-link{clear:both;display:block}.et_pb_posts .et_pb_post{position:relative}.et_pb_has_overlay.et_pb_post .et_pb_image_container a{display:block;position:relative;overflow:hidden}.et_pb_image_container img,.et_pb_post a img{vertical-align:bottom;max-width:100%}@media (min-width:981px) and (max-width:1100px){.et_pb_post{margin-bottom:42px}}@media (max-width:980px){.et_pb_post{margin-bottom:42px}.et_pb_bg_layout_light_tablet .et_pb_post .post-meta,.et_pb_bg_layout_light_tablet .et_pb_post .post-meta a,.et_pb_bg_layout_light_tablet .et_pb_post p{color:#666}.et_pb_bg_layout_dark_tablet .et_pb_post .post-meta,.et_pb_bg_layout_dark_tablet .et_pb_post .post-meta a,.et_pb_bg_layout_dark_tablet .et_pb_post p{color:inherit}.et_pb_bg_layout_dark_tablet .comment_postinfo a,.et_pb_bg_layout_dark_tablet .comment_postinfo span{color:#fff}}@media (max-width:767px){.et_pb_post{margin-bottom:42px}.et_pb_post>h2{font-size:18px}.et_pb_bg_layout_light_phone .et_pb_post .post-meta,.et_pb_bg_layout_light_phone .et_pb_post .post-meta a,.et_pb_bg_layout_light_phone .et_pb_post p{color:#666}.et_pb_bg_layout_dark_phone .et_pb_post .post-meta,.et_pb_bg_layout_dark_phone .et_pb_post .post-meta a,.et_pb_bg_layout_dark_phone .et_pb_post p{color:inherit}.et_pb_bg_layout_dark_phone .comment_postinfo a,.et_pb_bg_layout_dark_phone .comment_postinfo span{color:#fff}}@media (max-width:479px){.et_pb_post{margin-bottom:42px}.et_pb_post h2{font-size:16px;padding-bottom:0}.et_pb_post .post-meta{color:#666;font-size:14px}} @media (min-width:981px){.et_pb_gutters3 .et_pb_column,.et_pb_gutters3.et_pb_row .et_pb_column{margin-right:5.5%}.et_pb_gutters3 .et_pb_column_4_4,.et_pb_gutters3.et_pb_row .et_pb_column_4_4{width:100%}.et_pb_gutters3 .et_pb_column_4_4 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_4_4 .et_pb_module{margin-bottom:2.75%}.et_pb_gutters3 .et_pb_column_3_4,.et_pb_gutters3.et_pb_row .et_pb_column_3_4{width:73.625%}.et_pb_gutters3 .et_pb_column_3_4 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_3_4 .et_pb_module{margin-bottom:3.735%}.et_pb_gutters3 .et_pb_column_2_3,.et_pb_gutters3.et_pb_row .et_pb_column_2_3{width:64.833%}.et_pb_gutters3 .et_pb_column_2_3 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_2_3 .et_pb_module{margin-bottom:4.242%}.et_pb_gutters3 .et_pb_column_3_5,.et_pb_gutters3.et_pb_row .et_pb_column_3_5{width:57.8%}.et_pb_gutters3 .et_pb_column_3_5 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_3_5 .et_pb_module{margin-bottom:4.758%}.et_pb_gutters3 .et_pb_column_1_2,.et_pb_gutters3.et_pb_row .et_pb_column_1_2{width:47.25%}.et_pb_gutters3 .et_pb_column_1_2 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_1_2 .et_pb_module{margin-bottom:5.82%}.et_pb_gutters3 .et_pb_column_2_5,.et_pb_gutters3.et_pb_row .et_pb_column_2_5{width:36.7%}.et_pb_gutters3 .et_pb_column_2_5 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_2_5 .et_pb_module{margin-bottom:7.493%}.et_pb_gutters3 .et_pb_column_1_3,.et_pb_gutters3.et_pb_row .et_pb_column_1_3{width:29.6667%}.et_pb_gutters3 .et_pb_column_1_3 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_1_3 .et_pb_module{margin-bottom:9.27%}.et_pb_gutters3 .et_pb_column_1_4,.et_pb_gutters3.et_pb_row .et_pb_column_1_4{width:20.875%}.et_pb_gutters3 .et_pb_column_1_4 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_1_4 .et_pb_module{margin-bottom:13.174%}.et_pb_gutters3 .et_pb_column_1_5,.et_pb_gutters3.et_pb_row .et_pb_column_1_5{width:15.6%}.et_pb_gutters3 .et_pb_column_1_5 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_1_5 .et_pb_module{margin-bottom:17.628%}.et_pb_gutters3 .et_pb_column_1_6,.et_pb_gutters3.et_pb_row .et_pb_column_1_6{width:12.0833%}.et_pb_gutters3 .et_pb_column_1_6 .et_pb_module,.et_pb_gutters3.et_pb_row .et_pb_column_1_6 .et_pb_module{margin-bottom:22.759%}.et_pb_gutters3 .et_full_width_page.woocommerce-page ul.products li.product{width:20.875%;margin-right:5.5%;margin-bottom:5.5%}.et_pb_gutters3.et_left_sidebar.woocommerce-page #main-content ul.products li.product,.et_pb_gutters3.et_right_sidebar.woocommerce-page #main-content ul.products li.product{width:28.353%;margin-right:7.47%}.et_pb_gutters3.et_left_sidebar.woocommerce-page #main-content ul.products.columns-1 li.product,.et_pb_gutters3.et_right_sidebar.woocommerce-page #main-content ul.products.columns-1 li.product{width:100%;margin-right:0}.et_pb_gutters3.et_left_sidebar.woocommerce-page #main-content ul.products.columns-2 li.product,.et_pb_gutters3.et_right_sidebar.woocommerce-page #main-content ul.products.columns-2 li.product{width:48%;margin-right:4%}.et_pb_gutters3.et_left_sidebar.woocommerce-page #main-content ul.products.columns-2 li:nth-child(2n+2),.et_pb_gutters3.et_right_sidebar.woocommerce-page #main-content ul.products.columns-2 li:nth-child(2n+2){margin-right:0}.et_pb_gutters3.et_left_sidebar.woocommerce-page #main-content ul.products.columns-2 li:nth-child(3n+1),.et_pb_gutters3.et_right_sidebar.woocommerce-page #main-content ul.products.columns-2 li:nth-child(3n+1){clear:none}} #et-secondary-menu li,#top-menu li{word-wrap:break-word}.nav li ul,.et_mobile_menu{border-color:#2EA3F2}.mobile_menu_bar:before,.mobile_menu_bar:after,#top-menu li.current-menu-ancestor>a,#top-menu li.current-menu-item>a{color:#2EA3F2}#main-header{-webkit-transition:background-color 0.4s, color 0.4s, opacity 0.4s ease-in-out, -webkit-transform 0.4s;transition:background-color 0.4s, color 0.4s, opacity 0.4s ease-in-out, -webkit-transform 0.4s;transition:background-color 0.4s, color 0.4s, transform 0.4s, opacity 0.4s ease-in-out;transition:background-color 0.4s, color 0.4s, transform 0.4s, opacity 0.4s ease-in-out, -webkit-transform 0.4s}#main-header.et-disabled-animations *{-webkit-transition-duration:0s !important;transition-duration:0s !important}.container{text-align:left;position:relative}.et_fixed_nav.et_show_nav #page-container{padding-top:80px}.et_fixed_nav.et_show_nav.et-tb #page-container,.et_fixed_nav.et_show_nav.et-tb-has-header #page-container{padding-top:0 !important}.et_fixed_nav.et_show_nav.et_secondary_nav_enabled #page-container{padding-top:111px}.et_fixed_nav.et_show_nav.et_secondary_nav_enabled.et_header_style_centered #page-container{padding-top:177px}.et_fixed_nav.et_show_nav.et_header_style_centered #page-container{padding-top:147px}.et_fixed_nav #main-header{position:fixed}.et-cloud-item-editor #page-container{padding-top:0 !important}.et_header_style_left #et-top-navigation{padding-top:33px}.et_header_style_left #et-top-navigation nav>ul>li>a{padding-bottom:33px}.et_header_style_left .logo_container{position:absolute;height:100%;width:100%}.et_header_style_left #et-top-navigation .mobile_menu_bar{padding-bottom:24px}.et_hide_search_icon #et_top_search{display:none !important}#logo{width:auto;-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out;margin-bottom:0;max-height:54%;display:inline-block;float:none;vertical-align:middle;-webkit-transform:translate3d(0, 0, 0)}.et_pb_svg_logo #logo{height:54%}.logo_container{-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}span.logo_helper{display:inline-block;height:100%;vertical-align:middle;width:0}.safari .centered-inline-logo-wrap{-webkit-transform:translate3d(0, 0, 0);-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}#et-define-logo-wrap img{width:100%}.gecko #et-define-logo-wrap.svg-logo{position:relative !important}#top-menu-nav,#top-menu{line-height:0}#et-top-navigation{font-weight:600}.et_fixed_nav #et-top-navigation{-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}.et-cart-info span:before{content:"\e07a";margin-right:10px;position:relative}nav#top-menu-nav,#top-menu,nav.et-menu-nav,.et-menu{float:left}#top-menu li{display:inline-block;font-size:14px;padding-right:22px}#top-menu>li:last-child{padding-right:0}.et_fullwidth_nav.et_non_fixed_nav.et_header_style_left #top-menu>li:last-child>ul.sub-menu{right:0}#top-menu a{color:rgba(0,0,0,0.6);text-decoration:none;display:block;position:relative;-webkit-transition:opacity 0.4s ease-in-out, background-color 0.4s ease-in-out;transition:opacity 0.4s ease-in-out, background-color 0.4s ease-in-out}#top-menu-nav>ul>li>a:hover{opacity:0.7;-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}#et_search_icon:before{content:"\55";font-size:17px;left:0;position:absolute;top:-3px}#et_search_icon:hover{cursor:pointer}#et_top_search{float:right;margin:3px 0 0 22px;position:relative;display:block;width:18px}#et_top_search.et_search_opened{position:absolute;width:100%}.et-search-form{top:0;bottom:0;right:0;position:absolute;z-index:1000;width:100%}.et-search-form input{width:90%;border:none;color:#333;position:absolute;top:0;bottom:0;right:30px;margin:auto;background:transparent}.et-search-form .et-search-field::-ms-clear{width:0;height:0;display:none}.et_search_form_container{-webkit-animation:none;animation:none;-o-animation:none}.container.et_search_form_container{position:relative;opacity:0;height:1px}.container.et_search_form_container.et_pb_search_visible{z-index:999;-webkit-animation:fadeInTop 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeInTop 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}.et_pb_search_visible.et_pb_no_animation{opacity:1}.et_pb_search_form_hidden{-webkit-animation:fadeOutTop 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeOutTop 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}span.et_close_search_field{display:block;width:30px;height:30px;z-index:99999;position:absolute;right:0;cursor:pointer;top:0;bottom:0;margin:auto}span.et_close_search_field:after{font-family:'ETmodules';content:'\4d';speak:none;font-weight:normal;font-variant:normal;text-transform:none;line-height:1;-webkit-font-smoothing:antialiased;font-size:32px;display:inline-block;-webkit-box-sizing:border-box;box-sizing:border-box}.container.et_menu_container{z-index:99}.container.et_search_form_container.et_pb_search_form_hidden{z-index:1 !important}.et_search_outer{width:100%;overflow:hidden;position:absolute;top:0}.container.et_pb_menu_hidden{z-index:-1}form.et-search-form{background:rgba(0,0,0,0) !important}input[type="search"]::-webkit-search-cancel-button{-webkit-appearance:none}.et-cart-info{color:inherit}#et-top-navigation .et-cart-info{float:left;margin:-2px 0 0 22px;font-size:16px}#et-top-navigation{float:right}#top-menu li li{padding:0 20px;margin:0}#top-menu li li a{padding:6px 20px;width:200px}.nav li.et-touch-hover>ul{opacity:1;visibility:visible}#top-menu .menu-item-has-children>a:first-child:after,#et-secondary-nav .menu-item-has-children>a:first-child:after{font-family:'ETmodules';content:"3";font-size:16px;position:absolute;right:0;top:0;font-weight:800}#top-menu .menu-item-has-children>a:first-child,#et-secondary-nav .menu-item-has-children>a:first-child{padding-right:20px}#top-menu li .menu-item-has-children>a:first-child{padding-right:40px}#top-menu li .menu-item-has-children>a:first-child:after{right:20px;top:6px}#top-menu li.mega-menu{position:inherit}#top-menu li.mega-menu>ul{padding:30px 20px;position:absolute !important;width:100%;left:0 !important}#top-menu li.mega-menu ul li{margin:0;float:left !important;display:block !important;padding:0 !important}#top-menu li.mega-menu>ul>li:nth-of-type(4n){clear:right}#top-menu li.mega-menu>ul>li:nth-of-type(4n+1){clear:left}#top-menu li.mega-menu ul li li{width:100%}#top-menu li.mega-menu li>ul{-webkit-animation:none !important;animation:none !important;padding:0px;border:none;left:auto;top:auto;width:90% !important;position:relative;-webkit-box-shadow:none;box-shadow:none}#top-menu li.mega-menu li ul{visibility:visible;opacity:1;display:none}#top-menu li.mega-menu.et-hover li ul{display:block}#top-menu li.mega-menu.et-hover>ul{opacity:1 !important;visibility:visible !important}#top-menu li.mega-menu>ul>li>a{width:90%;padding:0 20px 10px}#top-menu li.mega-menu>ul>li>a:first-child{padding-top:0 !important;font-weight:bold;border-bottom:1px solid rgba(0,0,0,0.03)}#top-menu li.mega-menu>ul>li>a:first-child:hover{background-color:transparent !important}#top-menu li.mega-menu li>a{width:100%}#top-menu li.mega-menu.mega-menu-parent li li,#top-menu li.mega-menu.mega-menu-parent li>a{width:100% !important}#top-menu li.mega-menu.mega-menu-parent li>.sub-menu{float:left;width:100% !important}#top-menu li.mega-menu>ul>li{width:25%;margin:0}#top-menu li.mega-menu.mega-menu-parent-3>ul>li{width:33.33%}#top-menu li.mega-menu.mega-menu-parent-2>ul>li{width:50%}#top-menu li.mega-menu.mega-menu-parent-1>ul>li{width:100%}#top-menu li.mega-menu .menu-item-has-children>a:first-child:after{display:none}#top-menu li.mega-menu>ul>li>ul>li{width:100%;margin:0}#et_mobile_nav_menu{float:right;display:none}.mobile_menu_bar{position:relative;display:block;line-height:0}.mobile_menu_bar:before,.et_toggle_slide_menu:after{content:"\61";font-size:32px;left:0;position:relative;top:0;cursor:pointer}.mobile_nav .select_page{display:none}.et_pb_menu_hidden #top-menu,.et_pb_menu_hidden #et_search_icon:before,.et_pb_menu_hidden .et-cart-info{opacity:0;-webkit-animation:fadeOutBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeOutBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}.et_pb_menu_visible #top-menu,.et_pb_menu_visible #et_search_icon:before,.et_pb_menu_visible .et-cart-info{z-index:99;opacity:1;-webkit-animation:fadeInBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeInBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}.et_pb_menu_hidden #top-menu,.et_pb_menu_hidden #et_search_icon:before,.et_pb_menu_hidden .mobile_menu_bar{opacity:0;-webkit-animation:fadeOutBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeOutBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}.et_pb_menu_visible #top-menu,.et_pb_menu_visible #et_search_icon:before,.et_pb_menu_visible .mobile_menu_bar{z-index:99;opacity:1;-webkit-animation:fadeInBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeInBottom 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}.et_pb_no_animation #top-menu,.et_pb_no_animation #et_search_icon:before,.et_pb_no_animation .mobile_menu_bar,.et_pb_no_animation.et_search_form_container{animation:none !important;-o-animation:none !important;-webkit-animation:none !important;-moz-animation:none !important}body.admin-bar.et_fixed_nav #main-header{top:32px}body.et-wp-pre-3_8.admin-bar.et_fixed_nav #main-header{top:28px}body.et_fixed_nav.et_secondary_nav_enabled #main-header{top:30px}body.admin-bar.et_fixed_nav.et_secondary_nav_enabled #main-header{top:63px}@media all and (min-width: 981px){.et_hide_primary_logo #main-header:not(.et-fixed-header) .logo_container,.et_hide_fixed_logo #main-header.et-fixed-header .logo_container{height:0;opacity:0;-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}.et_hide_primary_logo #main-header:not(.et-fixed-header) .centered-inline-logo-wrap,.et_hide_fixed_logo #main-header.et-fixed-header .centered-inline-logo-wrap{height:0;opacity:0;padding:0}.et-animated-content#page-container{-webkit-transition:margin-top 0.4s ease-in-out;transition:margin-top 0.4s ease-in-out}.et_hide_nav #page-container{-webkit-transition:none;transition:none}.et_fullwidth_nav .et-search-form,.et_fullwidth_nav .et_close_search_field{right:30px}#main-header.et-fixed-header{-webkit-box-shadow:0 0 7px rgba(0,0,0,0.1) !important;box-shadow:0 0 7px rgba(0,0,0,0.1) !important}.et_header_style_left .et-fixed-header #et-top-navigation{padding-top:20px}.et_header_style_left .et-fixed-header #et-top-navigation nav>ul>li>a{padding-bottom:20px}.et_hide_nav.et_fixed_nav #main-header{opacity:0}.et_hide_nav.et_fixed_nav .et-fixed-header#main-header{-webkit-transform:translateY(0px) !important;transform:translateY(0px) !important;opacity:1}.et_hide_nav .centered-inline-logo-wrap,.et_hide_nav.et_fixed_nav #main-header,.et_hide_nav.et_fixed_nav #main-header,.et_hide_nav .centered-inline-logo-wrap{-webkit-transition-duration:.7s;transition-duration:.7s}.et_hide_nav #page-container{padding-top:0 !important}.et_primary_nav_dropdown_animation_fade #et-top-navigation ul li:hover>ul,.et_secondary_nav_dropdown_animation_fade #et-secondary-nav li:hover>ul{-webkit-transition:all .2s ease-in-out;transition:all .2s ease-in-out}.et_primary_nav_dropdown_animation_slide #et-top-navigation ul li:hover>ul,.et_secondary_nav_dropdown_animation_slide #et-secondary-nav li:hover>ul{-webkit-animation:fadeLeft .4s ease-in-out;animation:fadeLeft .4s ease-in-out}.et_primary_nav_dropdown_animation_expand #et-top-navigation ul li:hover>ul,.et_secondary_nav_dropdown_animation_expand #et-secondary-nav li:hover>ul{-webkit-transform-origin:0 0;transform-origin:0 0;-webkit-animation:Grow .4s ease-in-out;animation:Grow .4s ease-in-out;-webkit-backface-visibility:visible !important;backface-visibility:visible !important}.et_primary_nav_dropdown_animation_flip #et-top-navigation ul li ul li:hover>ul,.et_secondary_nav_dropdown_animation_flip #et-secondary-nav ul li:hover>ul{-webkit-animation:flipInX .6s ease-in-out;animation:flipInX .6s ease-in-out;-webkit-backface-visibility:visible !important;backface-visibility:visible !important}.et_primary_nav_dropdown_animation_flip #et-top-navigation ul li:hover>ul,.et_secondary_nav_dropdown_animation_flip #et-secondary-nav li:hover>ul{-webkit-animation:flipInY .6s ease-in-out;animation:flipInY .6s ease-in-out;-webkit-backface-visibility:visible !important;backface-visibility:visible !important}.et_fullwidth_nav #main-header .container{width:100%;max-width:100%;padding-right:32px;padding-left:30px}.et_non_fixed_nav.et_fullwidth_nav.et_header_style_left #main-header .container{padding-left:0}.et_non_fixed_nav.et_fullwidth_nav.et_header_style_left .logo_container{padding-left:30px}}@media all and (max-width: 980px){.et_fixed_nav.et_show_nav.et_secondary_nav_enabled #page-container,.et_fixed_nav.et_show_nav #page-container{padding-top:80px}.et_fixed_nav.et_show_nav.et-tb #page-container,.et_fixed_nav.et_show_nav.et-tb-has-header #page-container{padding-top:0 !important}.et_non_fixed_nav #page-container{padding-top:0}.et_fixed_nav.et_secondary_nav_only_menu.admin-bar #main-header{top:32px !important}.et_hide_mobile_logo #main-header .logo_container{display:none;opacity:0;-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}#top-menu{display:none}.et_hide_nav.et_fixed_nav #main-header{-webkit-transform:translateY(0px) !important;transform:translateY(0px) !important;opacity:1}#et-top-navigation{margin-right:0;-webkit-transition:none;transition:none}.et_fixed_nav #main-header{position:absolute}.et_header_style_left .et-fixed-header #et-top-navigation,.et_header_style_left #et-top-navigation{padding-top:24px;display:block}.et_fixed_nav #main-header{-webkit-transition:none;transition:none}.et_fixed_nav_temp #main-header{top:0 !important}#logo,.logo_container,#main-header,.container{-webkit-transition:none;transition:none}.et_header_style_left #logo{max-width:50%}#et_top_search{margin:0 35px 0 0;float:left}#et_search_icon:before{top:7px}.et_header_style_left .et-search-form{width:50% !important;max-width:50% !important}#et_mobile_nav_menu{display:block}#et-top-navigation .et-cart-info{margin-top:5px}}@media screen and (max-width: 782px){body.admin-bar.et_fixed_nav #main-header{top:46px}}@media all and (max-width: 767px){#et-top-navigation{margin-right:0}body.admin-bar.et_fixed_nav #main-header{top:46px}}@media all and (max-width: 479px){#et-top-navigation{margin-right:0}}@media print{#top-header,#main-header{position:relative !important;top:auto !important;right:auto !important;bottom:auto !important;left:auto !important}} @-webkit-keyframes fadeOutTop{0%{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}to{opacity:0;-webkit-transform:translatey(-60%);transform:translatey(-60%)}}@keyframes fadeOutTop{0%{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}to{opacity:0;-webkit-transform:translatey(-60%);transform:translatey(-60%)}}@-webkit-keyframes fadeInTop{0%{opacity:0;-webkit-transform:translatey(-60%);transform:translatey(-60%)}to{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}}@keyframes fadeInTop{0%{opacity:0;-webkit-transform:translatey(-60%);transform:translatey(-60%)}to{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}}@-webkit-keyframes fadeInBottom{0%{opacity:0;-webkit-transform:translatey(60%);transform:translatey(60%)}to{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}}@keyframes fadeInBottom{0%{opacity:0;-webkit-transform:translatey(60%);transform:translatey(60%)}to{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}}@-webkit-keyframes fadeOutBottom{0%{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}to{opacity:0;-webkit-transform:translatey(60%);transform:translatey(60%)}}@keyframes fadeOutBottom{0%{opacity:1;-webkit-transform:translatey(0);transform:translatey(0)}to{opacity:0;-webkit-transform:translatey(60%);transform:translatey(60%)}}@-webkit-keyframes Grow{0%{opacity:0;-webkit-transform:scaleY(.5);transform:scaleY(.5)}to{opacity:1;-webkit-transform:scale(1);transform:scale(1)}}@keyframes Grow{0%{opacity:0;-webkit-transform:scaleY(.5);transform:scaleY(.5)}to{opacity:1;-webkit-transform:scale(1);transform:scale(1)}}/*! * Animate.css - http://daneden.me/animate * Licensed under the MIT license - http://opensource.org/licenses/MIT * Copyright (c) 2015 Daniel Eden */@-webkit-keyframes flipInX{0%{-webkit-transform:perspective(400px) rotateX(90deg);transform:perspective(400px) rotateX(90deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in;opacity:0}40%{-webkit-transform:perspective(400px) rotateX(-20deg);transform:perspective(400px) rotateX(-20deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in}60%{-webkit-transform:perspective(400px) rotateX(10deg);transform:perspective(400px) rotateX(10deg);opacity:1}80%{-webkit-transform:perspective(400px) rotateX(-5deg);transform:perspective(400px) rotateX(-5deg)}to{-webkit-transform:perspective(400px);transform:perspective(400px)}}@keyframes flipInX{0%{-webkit-transform:perspective(400px) rotateX(90deg);transform:perspective(400px) rotateX(90deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in;opacity:0}40%{-webkit-transform:perspective(400px) rotateX(-20deg);transform:perspective(400px) rotateX(-20deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in}60%{-webkit-transform:perspective(400px) rotateX(10deg);transform:perspective(400px) rotateX(10deg);opacity:1}80%{-webkit-transform:perspective(400px) rotateX(-5deg);transform:perspective(400px) rotateX(-5deg)}to{-webkit-transform:perspective(400px);transform:perspective(400px)}}@-webkit-keyframes flipInY{0%{-webkit-transform:perspective(400px) rotateY(90deg);transform:perspective(400px) rotateY(90deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in;opacity:0}40%{-webkit-transform:perspective(400px) rotateY(-20deg);transform:perspective(400px) rotateY(-20deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in}60%{-webkit-transform:perspective(400px) rotateY(10deg);transform:perspective(400px) rotateY(10deg);opacity:1}80%{-webkit-transform:perspective(400px) rotateY(-5deg);transform:perspective(400px) rotateY(-5deg)}to{-webkit-transform:perspective(400px);transform:perspective(400px)}}@keyframes flipInY{0%{-webkit-transform:perspective(400px) rotateY(90deg);transform:perspective(400px) rotateY(90deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in;opacity:0}40%{-webkit-transform:perspective(400px) rotateY(-20deg);transform:perspective(400px) rotateY(-20deg);-webkit-animation-timing-function:ease-in;animation-timing-function:ease-in}60%{-webkit-transform:perspective(400px) rotateY(10deg);transform:perspective(400px) rotateY(10deg);opacity:1}80%{-webkit-transform:perspective(400px) rotateY(-5deg);transform:perspective(400px) rotateY(-5deg)}to{-webkit-transform:perspective(400px);transform:perspective(400px)}} #main-header{line-height:23px;font-weight:500;top:0;background-color:#fff;width:100%;-webkit-box-shadow:0 1px 0 rgba(0,0,0,.1);box-shadow:0 1px 0 rgba(0,0,0,.1);position:relative;z-index:99999}.nav li li{padding:0 20px;margin:0}.et-menu li li a{padding:6px 20px;width:200px}.nav li{position:relative;line-height:1em}.nav li li{position:relative;line-height:2em}.nav li ul{position:absolute;padding:20px 0;z-index:9999;width:240px;background:#fff;visibility:hidden;opacity:0;border-top:3px solid #2ea3f2;box-shadow:0 2px 5px rgba(0,0,0,.1);-moz-box-shadow:0 2px 5px rgba(0,0,0,.1);-webkit-box-shadow:0 2px 5px rgba(0,0,0,.1);-webkit-transform:translateZ(0);text-align:left}.nav li.et-hover>ul{visibility:visible}.nav li.et-touch-hover>ul,.nav li:hover>ul{opacity:1;visibility:visible}.nav li li ul{z-index:1000;top:-23px;left:240px}.nav li.et-reverse-direction-nav li ul{left:auto;right:240px}.nav li:hover{visibility:inherit}.et_mobile_menu li a,.nav li li a{font-size:14px;-webkit-transition:opacity .2s ease-in-out,background-color .2s ease-in-out;transition:opacity .2s ease-in-out,background-color .2s ease-in-out}.et_mobile_menu li a:hover,.nav ul li a:hover{background-color:rgba(0,0,0,.03);opacity:.7}.et-dropdown-removing>ul{display:none}.mega-menu .et-dropdown-removing>ul{display:block}.et-menu .menu-item-has-children>a:first-child:after{font-family:ETmodules;content:"3";font-size:16px;position:absolute;right:0;top:0;font-weight:800}.et-menu .menu-item-has-children>a:first-child{padding-right:20px}.et-menu li li.menu-item-has-children>a:first-child:after{right:20px;top:6px}.et-menu-nav li.mega-menu{position:inherit}.et-menu-nav li.mega-menu>ul{padding:30px 20px;position:absolute!important;width:100%;left:0!important}.et-menu-nav li.mega-menu ul li{margin:0;float:left!important;display:block!important;padding:0!important}.et-menu-nav li.mega-menu li>ul{-webkit-animation:none!important;animation:none!important;padding:0;border:none;left:auto;top:auto;width:240px!important;position:relative;box-shadow:none;-webkit-box-shadow:none}.et-menu-nav li.mega-menu li ul{visibility:visible;opacity:1;display:none}.et-menu-nav li.mega-menu.et-hover li ul,.et-menu-nav li.mega-menu:hover li ul{display:block}.et-menu-nav li.mega-menu:hover>ul{opacity:1!important;visibility:visible!important}.et-menu-nav li.mega-menu>ul>li>a:first-child{padding-top:0!important;font-weight:700;border-bottom:1px solid rgba(0,0,0,.03)}.et-menu-nav li.mega-menu>ul>li>a:first-child:hover{background-color:transparent!important}.et-menu-nav li.mega-menu li>a{width:200px!important}.et-menu-nav li.mega-menu.mega-menu-parent li>a,.et-menu-nav li.mega-menu.mega-menu-parent li li{width:100%!important}.et-menu-nav li.mega-menu.mega-menu-parent li>.sub-menu{float:left;width:100%!important}.et-menu-nav li.mega-menu>ul>li{width:25%;margin:0}.et-menu-nav li.mega-menu.mega-menu-parent-3>ul>li{width:33.33%}.et-menu-nav li.mega-menu.mega-menu-parent-2>ul>li{width:50%}.et-menu-nav li.mega-menu.mega-menu-parent-1>ul>li{width:100%}.et_pb_fullwidth_menu li.mega-menu .menu-item-has-children>a:first-child:after,.et_pb_menu li.mega-menu .menu-item-has-children>a:first-child:after{display:none}.et_fullwidth_nav #top-menu li.mega-menu>ul{width:auto;left:30px!important;right:30px!important}.et_mobile_menu{position:absolute;left:0;padding:5%;background:#fff;width:100%;visibility:visible;opacity:1;display:none;z-index:9999;border-top:3px solid #2ea3f2;box-shadow:0 2px 5px rgba(0,0,0,.1);-moz-box-shadow:0 2px 5px rgba(0,0,0,.1);-webkit-box-shadow:0 2px 5px rgba(0,0,0,.1)}#main-header .et_mobile_menu li ul,.et_pb_fullwidth_menu .et_mobile_menu li ul,.et_pb_menu .et_mobile_menu li ul{visibility:visible!important;display:block!important;padding-left:10px}.et_mobile_menu li li{padding-left:5%}.et_mobile_menu li a{border-bottom:1px solid rgba(0,0,0,.03);color:#666;padding:10px 5%;display:block}.et_mobile_menu .menu-item-has-children>a{font-weight:700;background-color:rgba(0,0,0,.03)}.et_mobile_menu li .menu-item-has-children>a{background-color:transparent}.et_mobile_nav_menu{float:right;display:none}.mobile_menu_bar{position:relative;display:block;line-height:0}.mobile_menu_bar:before{content:"a";font-size:32px;position:relative;left:0;top:0;cursor:pointer}.et_pb_module .mobile_menu_bar:before{top:2px}.mobile_nav .select_page{display:none} .et_header_style_centered #main-header .container{text-align:center;height:inherit}.et_header_style_centered #main-header div#et-top-navigation{bottom:0;position:relative;width:100%}.et_header_style_centered #logo,.et_header_style_centered #et-top-navigation,.et_header_style_centered nav#top-menu-nav,.et_header_style_centered #top-menu{float:none}.et_header_style_centered #logo{max-height:64%}.et_header_style_centered #main-header .logo_container{height:100px;padding:0}.et_header_style_centered header#main-header.et-fixed-header .logo_container{height:70px}.et_header_style_centered #et_top_search{float:none;display:inline-block !important}.et_header_style_centered #et_search_icon:before{left:3px;top:-13px}.et_header_style_centered nav#top-menu-nav{display:inline-block}.et_header_style_centered #top-menu>li>a{padding-bottom:2em}.et_header_style_centered #et-top-navigation .et-cart-info{float:none}.et_header_style_centered .et-search-form input,.et_header_style_centered span.et_close_search_field{top:60%}@media all and (min-width: 981px){.et_header_style_centered.et_hide_primary_logo #main-header:not(.et-fixed-header) .logo_container,.et_header_style_centered.et_hide_fixed_logo #main-header.et-fixed-header .logo_container{height:0;opacity:0;padding:0}.et_header_style_centered .et-fixed-header .et-search-form{top:21px}.et_header_style_centered .et-fixed-header #et_search_icon:before{margin-top:0}}@media all and (max-width: 980px){.et_non_fixed_nav.et_transparent_nav.et_show_nav.et_secondary_nav_enabled.et_header_style_centered #page-container,.et_non_fixed_nav.et_transparent_nav.et_show_nav.et_header_style_centered #page-container,.et_fixed_nav.et_show_nav.et_secondary_nav_enabled.et_header_style_centered #page-container,.et_fixed_nav.et_show_nav.et_header_style_centered #page-container{padding-top:136px}.et_header_style_centered #main-header{padding:20px 0}.et_header_style_centered nav#top-menu-nav{display:none}.et_header_style_centered #logo{max-height:60px}.et_header_style_centered header#main-header .logo_container{height:auto;max-height:100px;padding:0}.et_header_style_centered #et_top_search{display:none !important}.et_header_style_centered .et_search_outer{display:none}.et_header_style_centered .et_menu_container .mobile_menu_bar{opacity:1}.et_header_style_centered #et_mobile_nav_menu{float:none;position:relative;margin-top:20px}.et_header_style_centered #main-header .mobile_nav{display:block;text-align:left;background-color:rgba(0,0,0,0.05);border-radius:5px;padding:5px 10px}.et_header_style_centered .mobile_nav .select_page{display:inline-block;color:#666;font-size:14px}.et_header_style_centered .et_menu_container .mobile_menu_bar{position:absolute;right:5px;top:2px}.et_header_style_centered .et_mobile_menu{top:53px}.et_header_style_centered #et-top-navigation .et-cart-info{display:none}} .footer-widget h4,#main-footer .widget_block h1,#main-footer .widget_block h2,#main-footer .widget_block h3,#main-footer .widget_block h4,#main-footer .widget_block h5,#main-footer .widget_block h6{color:#2EA3F2}.footer-widget li:before{border-color:#2EA3F2}.bottom-nav li.current-menu-item>a{color:#2EA3F2}#main-footer{background-color:#222222}#footer-widgets{padding:6% 0 0}.footer-widget{float:left;color:#fff}.last{margin-right:0}.footer-widget .fwidget:last-child{margin-bottom:0 !important}#footer-widgets .footer-widget li{padding-left:14px;position:relative}#footer-widgets .footer-widget li:before{border-radius:3px;border-style:solid;border-width:3px;content:"";left:0;position:absolute;top:9px}#footer-widgets .footer-widget a{color:#fff}#footer-widgets .footer-widget li a{color:#fff;text-decoration:none}#footer-widgets .footer-widget li a:hover{color:rgba(255,255,255,0.7)}.footer-widget .widget_adsensewidget ins{min-width:160px}#footer-bottom{background-color:#1f1f1f;background-color:rgba(0,0,0,0.32);padding:15px 0 5px}#footer-bottom a{-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}#footer-info{text-align:left;color:#666;padding-bottom:10px;float:left}#footer-info a{font-weight:700;color:#666}#footer-info a:hover{opacity:.7}#et-footer-nav{background-color:rgba(255,255,255,0.05)}.bottom-nav{padding:15px 0}.bottom-nav li{font-weight:600;display:inline-block;font-size:14px;padding-right:22px}.bottom-nav a{color:#bbb;-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}.bottom-nav a:hover{opacity:.7}@media all and (max-width: 980px){.footer-widget:nth-child(n){width:46.25% !important;margin:0 7.5% 7.5% 0 !important}.et_pb_footer_columns1 .footer-widget{width:100% !important;margin:0 7.5% 7.5% 0 !important}#footer-widgets .footer-widget .fwidget{margin-bottom:16.21%}.et_pb_gutters1 .footer-widget:nth-child(n){width:50% !important;margin:0 !important}.et_pb_gutters1 #footer-widgets .footer-widget .fwidget{margin-bottom:0}#footer-widgets{padding:8% 0}#footer-widgets .footer-widget:nth-child(2n){margin-right:0 !important}#footer-widgets .footer-widget:nth-last-child(-n+2){margin-bottom:0 !important}.bottom-nav{text-align:center}#footer-info{float:none;text-align:center}}@media all and (max-width: 767px){#footer-widgets .footer-widget,.et_pb_gutters1 #footer-widgets .footer-widget{width:100% !important;margin-right:0 !important}#footer-widgets .footer-widget:nth-child(n),#footer-widgets .footer-widget .fwidget{margin-bottom:9.5% !important}.et_pb_gutters1 #footer-widgets .footer-widget:nth-child(n),.et_pb_gutters1 #footer-widgets .footer-widget .fwidget{margin-bottom:0 !important}#footer-widgets{padding:10% 0}#footer-widgets .footer-widget .fwidget:last-child{margin-bottom:0 !important}#footer-widgets .footer-widget:last-child{margin-bottom:0 !important}}@media all and (max-width: 479px){#footer-widgets .footer-widget:nth-child(n),.footer-widget .fwidget{margin-bottom:11.5% !important}#footer-widgets .footer-widget.last{margin-bottom:0 !important}.et_pb_gutters1 #footer-widgets .footer-widget:nth-child(n),.et_pb_gutters1 #footer-widgets .footer-widget .fwidget{margin-bottom:0 !important}#footer-widgets{padding:12% 0}} @media all and (min-width: 981px){.et_pb_gutters3 .footer-widget{margin-right:5.5%;margin-bottom:5.5%}.et_pb_gutters3 .footer-widget:last-child{margin-right:0}.et_pb_gutters3.et_pb_footer_columns6 .footer-widget{width:12.083%}.et_pb_gutters3.et_pb_footer_columns6 .footer-widget .fwidget{margin-bottom:45.517%}.et_pb_gutters3.et_pb_footer_columns5 .footer-widget{width:15.6%}.et_pb_gutters3.et_pb_footer_columns5 .footer-widget .fwidget{margin-bottom:35.256%}.et_pb_gutters3.et_pb_footer_columns4 .footer-widget{width:20.875%}.et_pb_gutters3.et_pb_footer_columns4 .footer-widget .fwidget{margin-bottom:26.347%}.et_pb_gutters3.et_pb_footer_columns3 .footer-widget{width:29.667%}.et_pb_gutters3.et_pb_footer_columns3 .footer-widget .fwidget{margin-bottom:18.539%}.et_pb_gutters3.et_pb_footer_columns2 .footer-widget{width:47.25%}.et_pb_gutters3.et_pb_footer_columns2 .footer-widget .fwidget{margin-bottom:11.64%}.et_pb_gutters3.et_pb_footer_columns1 .footer-widget{width:100%}.et_pb_gutters3.et_pb_footer_columns1 .footer-widget .fwidget{margin-bottom:5.5%}.et_pb_gutters3.et_pb_footer_columns_3_4__1_4 .footer-widget:nth-child(1){width:73.625%;clear:both}.et_pb_gutters3.et_pb_footer_columns_3_4__1_4 .footer-widget:nth-child(1) .fwidget{margin-bottom:7.47%}.et_pb_gutters3.et_pb_footer_columns_3_4__1_4 .footer-widget:nth-child(2){width:20.875%}.et_pb_gutters3.et_pb_footer_columns_3_4__1_4 .footer-widget:nth-child(2) .fwidget{margin-bottom:26.347%}.et_pb_gutters3.et_pb_footer_columns_1_4__3_4 .footer-widget:nth-child(1){width:20.875%;clear:both}.et_pb_gutters3.et_pb_footer_columns_1_4__3_4 .footer-widget:nth-child(1) .fwidget{margin-bottom:26.347%}.et_pb_gutters3.et_pb_footer_columns_1_4__3_4 .footer-widget:nth-child(2){width:73.625%}.et_pb_gutters3.et_pb_footer_columns_1_4__3_4 .footer-widget:nth-child(2) .fwidget{margin-bottom:7.47%}.et_pb_gutters3.et_pb_footer_columns_2_3__1_3 .footer-widget:nth-child(1){width:64.833%}.et_pb_gutters3.et_pb_footer_columns_2_3__1_3 .footer-widget:nth-child(1) .fwidget{margin-bottom:8.483%}.et_pb_gutters3.et_pb_footer_columns_2_3__1_3 .footer-widget:nth-child(2){width:29.667%}.et_pb_gutters3.et_pb_footer_columns_2_3__1_3 .footer-widget:nth-child(2) .fwidget{margin-bottom:18.539%}.et_pb_gutters3.et_pb_footer_columns_1_3__2_3 .footer-widget:nth-child(1){width:29.667%}.et_pb_gutters3.et_pb_footer_columns_1_3__2_3 .footer-widget:nth-child(1) .fwidget{margin-bottom:18.539%}.et_pb_gutters3.et_pb_footer_columns_1_3__2_3 .footer-widget:nth-child(2){width:64.833%}.et_pb_gutters3.et_pb_footer_columns_1_3__2_3 .footer-widget:nth-child(2) .fwidget{margin-bottom:8.483%}.et_pb_gutters3.et_pb_footer_columns_1_4__1_2 .footer-widget:nth-child(-n+2){width:20.875%}.et_pb_gutters3.et_pb_footer_columns_1_4__1_2 .footer-widget:nth-child(-n+2) .fwidget{margin-bottom:26.347%}.et_pb_gutters3.et_pb_footer_columns_1_4__1_2 .footer-widget:nth-child(3){width:47.25%}.et_pb_gutters3.et_pb_footer_columns_1_4__1_2 .footer-widget:nth-child(3) .fwidget{margin-bottom:11.64%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_4 .footer-widget:first-child{width:47.25%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_4 .footer-widget:first-child .fwidget{margin-bottom:11.64%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_4 .footer-widget:nth-child(-n+3):not(:nth-child(1)){width:20.875%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_4 .footer-widget:nth-child(-n+3):not(:nth-child(1)) .fwidget{margin-bottom:26.347%}.et_pb_gutters3.et_pb_footer_columns_1_5__3_5 .footer-widget:nth-child(-n+2){width:15.6%}.et_pb_gutters3.et_pb_footer_columns_1_5__3_5 .footer-widget:nth-child(-n+2) .fwidget{margin-bottom:35.256%}.et_pb_gutters3.et_pb_footer_columns_1_5__3_5 .footer-widget:nth-child(3){width:57.8%}.et_pb_gutters3.et_pb_footer_columns_1_5__3_5 .footer-widget:nth-child(3) .fwidget{margin-bottom:9.516%}.et_pb_gutters3.et_pb_footer_columns_3_5__1_5 .footer-widget:first-child{width:57.8%}.et_pb_gutters3.et_pb_footer_columns_3_5__1_5 .footer-widget:first-child .fwidget{margin-bottom:9.516%}.et_pb_gutters3.et_pb_footer_columns_3_5__1_5 .footer-widget:nth-child(-n+3):not(:nth-child(1)){width:15.6%}.et_pb_gutters3.et_pb_footer_columns_3_5__1_5 .footer-widget:nth-child(-n+3):not(:nth-child(1)) .fwidget{margin-bottom:35.256%}.et_pb_gutters3.et_pb_footer_columns_3_5__2_5 .footer-widget:nth-child(1){width:57.8%}.et_pb_gutters3.et_pb_footer_columns_3_5__2_5 .footer-widget:nth-child(1) .fwidget{margin-bottom:9.516%}.et_pb_gutters3.et_pb_footer_columns_3_5__2_5 .footer-widget:nth-child(2){width:36.7%}.et_pb_gutters3.et_pb_footer_columns_3_5__2_5 .footer-widget:nth-child(2) .fwidget{margin-bottom:14.986%}.et_pb_gutters3.et_pb_footer_columns_2_5__3_5 .footer-widget:nth-child(1){width:36.7%}.et_pb_gutters3.et_pb_footer_columns_2_5__3_5 .footer-widget:nth-child(1) .fwidget{margin-bottom:14.986%}.et_pb_gutters3.et_pb_footer_columns_2_5__3_5 .footer-widget:nth-child(2){width:57.8%}.et_pb_gutters3.et_pb_footer_columns_2_5__3_5 .footer-widget:nth-child(2) .fwidget{margin-bottom:9.516%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_6 .footer-widget:first-child{width:47.25%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_6 .footer-widget:first-child .fwidget{margin-bottom:11.64%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_6 .footer-widget:nth-child(-n+4):not(:nth-child(1)){width:12.083%}.et_pb_gutters3.et_pb_footer_columns_1_2__1_6 .footer-widget:nth-child(-n+4):not(:nth-child(1)) .fwidget{margin-bottom:45.517%}.et_pb_gutters3.et_pb_footer_columns_1_6__1_2 .footer-widget:nth-child(-n+3){width:12.083%}.et_pb_gutters3.et_pb_footer_columns_1_6__1_2 .footer-widget:nth-child(-n+3) .fwidget{margin-bottom:45.517%}.et_pb_gutters3.et_pb_footer_columns_1_6__1_2 .footer-widget:nth-child(4){width:47.25%}.et_pb_gutters3.et_pb_footer_columns_1_6__1_2 .footer-widget:nth-child(4) .fwidget{margin-bottom:11.64%}.et_pb_gutters3.et_pb_footer_columns_1_4_1_2_1_4 .footer-widget:nth-child(-n+3):not(:nth-child(2)){width:20.875%}.et_pb_gutters3.et_pb_footer_columns_1_4_1_2_1_4 .footer-widget:nth-child(-n+3):not(:nth-child(2)) .fwidget{margin-bottom:26.347%}.et_pb_gutters3.et_pb_footer_columns_1_4_1_2_1_4 .footer-widget:nth-child(2){width:47.25%}.et_pb_gutters3.et_pb_footer_columns_1_4_1_2_1_4 .footer-widget:nth-child(2) .fwidget{margin-bottom:11.64%}.et_pb_gutters3.et_pb_footer_columns_1_5_3_5_1_5 .footer-widget:nth-child(-n+3):not(:nth-child(2)){width:15.6%}.et_pb_gutters3.et_pb_footer_columns_1_5_3_5_1_5 .footer-widget:nth-child(-n+3):not(:nth-child(2)) .fwidget{margin-bottom:35.256%}.et_pb_gutters3.et_pb_footer_columns_1_5_3_5_1_5 .footer-widget:nth-child(2){width:57.8%}.et_pb_gutters3.et_pb_footer_columns_1_5_3_5_1_5 .footer-widget:nth-child(2) .fwidget{margin-bottom:9.516%}} .et-social-icons{float:right}.et-social-icons li{display:inline-block;margin-left:20px}.et-social-icon a{display:inline-block;font-size:24px;position:relative;text-align:center;-webkit-transition:color 300ms ease 0s;transition:color 300ms ease 0s;color:#666;text-decoration:none}.et-social-icons a:hover{opacity:0.7;-webkit-transition:all 0.4s ease-in-out;transition:all 0.4s ease-in-out}.et-social-icon span{display:none}.et_duplicate_social_icons{display:none}@media all and (max-width: 980px){.et-social-icons{float:none;text-align:center}}@media all and (max-width: 980px){.et-social-icons{margin:0 0 5px}} #sidebar{padding-bottom:28px}#sidebar .et_pb_widget{margin-bottom:30px;width:100%;float:none}.et_right_sidebar #main-content .et_pb_column_2_3 .et_pb_countdown_timer .section p.value,.et_right_sidebar #main-content .et_pb_column_2_3 .et_pb_countdown_timer .section.sep,.et_left_sidebar #main-content .et_pb_column_2_3 .et_pb_countdown_timer .section p.value,.et_left_sidebar #main-content .et_pb_column_2_3 .et_pb_countdown_timer .section.sep{font-size:44px;line-height:44px}.et_right_sidebar #main-content .et_pb_column_1_2 .et_pb_countdown_timer .section p.value,.et_right_sidebar #main-content .et_pb_column_1_2 .et_pb_countdown_timer .section.sep,.et_left_sidebar #main-content .et_pb_column_1_2 .et_pb_countdown_timer .section p.value,.et_left_sidebar #main-content .et_pb_column_1_2 .et_pb_countdown_timer .section.sep{font-size:32px;line-height:32px}.et_right_sidebar #main-content .et_pb_column_3_8 .et_pb_countdown_timer .section p.value,.et_right_sidebar #main-content .et_pb_column_3_8 .et_pb_countdown_timer .section.sep,.et_left_sidebar #main-content .et_pb_column_3_8 .et_pb_countdown_timer .section p.value,.et_left_sidebar #main-content .et_pb_column_3_8 .et_pb_countdown_timer .section.sep{font-size:24px;line-height:24px}.et_right_sidebar #main-content .et_pb_column_1_3 .et_pb_countdown_timer .section p.value,.et_right_sidebar #main-content .et_pb_column_1_3 .et_pb_countdown_timer .section.sep,.et_left_sidebar #main-content .et_pb_column_1_3 .et_pb_countdown_timer .section p.value,.et_left_sidebar #main-content .et_pb_column_1_3 .et_pb_countdown_timer .section.sep{font-size:20px;line-height:20px}.et_right_sidebar #main-content .et_pb_column_1_4 .et_pb_countdown_timer .section p.value,.et_right_sidebar #main-content .et_pb_column_1_4 .et_pb_countdown_timer .section.sep,.et_left_sidebar #main-content .et_pb_column_1_4 .et_pb_countdown_timer .section p.value,.et_left_sidebar #main-content .et_pb_column_1_4 .et_pb_countdown_timer .section.sep{font-size:16px;line-height:16px}@media all and (min-width: 981px) and (max-width: 1100px){#sidebar .et_pb_widget{margin-left:0}.et_left_sidebar #sidebar .et_pb_widget{margin-right:0}}@media all and (min-width: 981px){#sidebar{float:left;width:20.875%}.et_right_sidebar #left-area{float:left;padding-right:5.5%}.et_right_sidebar #sidebar{padding-left:30px}.et_right_sidebar #main-content .container:before{right:20.875% !important}.et_left_sidebar #left-area{float:right;padding-left:5.5%}.et_left_sidebar #sidebar{padding-right:30px}.et_left_sidebar #main-content .container:before{left:20.875% !important}}@media all and (max-width: 980px){.et_right_sidebar #left-area,.et_right_sidebar #sidebar,.et_left_sidebar #left-area,.et_left_sidebar #sidebar{width:auto;float:none;padding-right:0;padding-left:0}.et_right_sidebar #left-area{margin-right:0}.et_right_sidebar #sidebar{margin-left:0;border-left:none}.et_left_sidebar #left-area{margin-left:0}.et_left_sidebar #sidebar{margin-right:0;border-right:none}} .widget_search .screen-reader-text,.et_pb_widget .wp-block-search__label{display:none}.widget_search input#s,.widget_search input#searchsubmit,.et_pb_widget .wp-block-search__input,.et_pb_widget .wp-block-search__button{padding:.7em;height:40px !important;margin:0;font-size:14px;line-height:normal !important;border:1px solid #ddd;color:#666}.widget_search #s,.et_pb_widget .wp-block-search__input{width:100%;border-radius:3px}.widget_search #searchform,.et_pb_widget .wp-block-search{position:relative}.widget_search #searchsubmit,.et_pb_widget .wp-block-search__button{background-color:#ddd;-webkit-border-top-right-radius:3px;-webkit-border-bottom-right-radius:3px;-moz-border-radius-topright:3px;-moz-border-radius-bottomright:3px;border-top-right-radius:3px;border-bottom-right-radius:3px;position:absolute;right:0;top:0}#searchsubmit,.et_pb_widget .wp-block-search__button{cursor:pointer} .et_pb_scroll_top.et-pb-icon{text-align:center;background:rgba(0,0,0,0.4);text-decoration:none;position:fixed;z-index:99999;bottom:125px;right:0px;-webkit-border-top-left-radius:5px;-webkit-border-bottom-left-radius:5px;-moz-border-radius-topleft:5px;-moz-border-radius-bottomleft:5px;border-top-left-radius:5px;border-bottom-left-radius:5px;display:none;cursor:pointer;font-size:30px;padding:5px;color:#fff}.et_pb_scroll_top:before{content:'2'}.et_pb_scroll_top.et-visible{opacity:1;-webkit-animation:fadeInRight 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeInRight 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}.et_pb_scroll_top.et-hidden{opacity:0;-webkit-animation:fadeOutRight 1s 1 cubic-bezier(0.77, 0, 0.175, 1);animation:fadeOutRight 1s 1 cubic-bezier(0.77, 0, 0.175, 1)}@-webkit-keyframes fadeOutRight{0%{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}100%{opacity:0;-webkit-transform:translateX(100%);transform:translateX(100%)}}@keyframes fadeOutRight{0%{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}100%{opacity:0;-webkit-transform:translateX(100%);transform:translateX(100%)}}@-webkit-keyframes fadeInRight{0%{opacity:0;-webkit-transform:translateX(100%);transform:translateX(100%)}100%{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}}@keyframes fadeInRight{0%{opacity:0;-webkit-transform:translateX(100%);transform:translateX(100%)}100%{opacity:1;-webkit-transform:translateX(0);transform:translateX(0)}} </style> <style id='jetpack-global-styles-frontend-style-inline-css'> :root { --font-headings: unset; --font-base: unset; --font-headings-default: -apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif; --font-base-default: -apple-system,BlinkMacSystemFont,"Segoe UI",Roboto,Oxygen-Sans,Ubuntu,Cantarell,"Helvetica Neue",sans-serif;} </style> <script type="text/javascript" id="jetpack-mu-wpcom-settings-js-before"> /* <![CDATA[ */ var JETPACK_MU_WPCOM_SETTINGS = {"assetsUrl":"https:\/\/vaccinenation.org\/wp-content\/mu-plugins\/wpcomsh\/vendor\/automattic\/jetpack-mu-wpcom\/src\/build\/"}; /* ]]> */ </script>   <script type="text/javascript" src="https://www.googletagmanager.com/gtag/js?id=G-9ZMDZV1D2Q" id="google_gtagjs-js" async></script> <script type="text/javascript" id="google_gtagjs-js-after"> /* <![CDATA[ */ window.dataLayer = window.dataLayer || [];function gtag(){dataLayer.push(arguments);} gtag("set","linker",{"domains":["vaccinenation.org"]}); gtag("js", new Date()); gtag("set", "developer_id.dZTNiMT", true); gtag("config", "G-9ZMDZV1D2Q"); /* ]]> */ </script>  <link rel="https://api.w.org/" href="https://vaccinenation.org/wp-json/" /><link rel="alternate" title="JSON" type="application/json" href="https://vaccinenation.org/wp-json/wp/v2/users/188655379" /><link rel="EditURI" type="application/rsd+xml" title="RSD" href="https://vaccinenation.org/xmlrpc.php?rsd" />   <style type="text/css" media="screen"> .g { margin:0px; padding:0px; overflow:hidden; line-height:1; zoom:1; } .g img { height:auto; } .g-col { position:relative; float:left; } .g-col:first-child { margin-left: 0; } .g-col:last-child { margin-right: 0; } @media only screen and (max-width: 480px) { .g-col, .g-dyn, .g-single { width:100%; margin-left:0; margin-right:0; } } </style>  <meta name="generator" content="Site Kit by Google 1.140.0" /> <script> jQuery(window).on('elementor/frontend/init', function () { var previewIframe = jQuery('#elementor-preview-iframe').get(0); // Attach a load event listener to the preview iframe jQuery(previewIframe).on('load', function () { var tpg_selector = tpg_str_rev("nottub-tropmi-gpttr nottub-aera-noitces-dda-rotnemele"); var logo = "https://vaccinenation.org/wp-content/plugins/the-post-grid"; var log_path = "/assets/images/icon-40x40.svg"; //tpg_str_rev("gvs.04x04-noci/segami/stessa/"); jQuery('<div class="' + tpg_selector + '" style="vertical-align: bottom;margin-left: 5px;"><img src="' + logo + log_path + '" alt="TPG"/></div>').insertBefore(".elementor-add-section-drag-title"); }); }); </script> <style> :root { --tpg-primary-color: #0d6efd; --tpg-secondary-color: #0654c4; --tpg-primary-light: #c4d0ff } </style> <style>img#wpstats{display:none}</style> <script> document.documentElement.className = document.documentElement.className.replace('no-js', 'js'); </script> <style> .no-js img.lazyload { display: none; } figure.wp-block-image img.lazyloading { min-width: 150px; } .lazyload, .lazyloading { opacity: 0; } .lazyloaded { opacity: 1; transition: opacity 400ms; transition-delay: 0ms; } </style> <style> </style> <meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0, user-scalable=0" />  <script type="text/javascript"> /* <![CDATA[ */ ( function( w, d, s, l, i ) { w[l] = w[l] || []; w[l].push( {'gtm.start': new Date().getTime(), event: 'gtm.js'} ); var f = d.getElementsByTagName( s )[0], j = d.createElement( s ), dl = l != 'dataLayer' ? '&l=' + l : ''; j.async = true; j.src = 'https://www.googletagmanager.com/gtm.js?id=' + i + dl; f.parentNode.insertBefore( j, f ); } )( window, document, 'script', 'dataLayer', 'GTM-KCPC4B3' ); /* ]]> */ </script>   <script src="https://cdn-ukwest.onetrust.com/scripttemplates/otSDKStub.js" type="text/javascript" charset="UTF-8" data-domain-script="018f51c2-7a96-7733-82fa-c85ce4d47aed" ></script> <script type="text/javascript"> function OptanonWrapper() { } </script> <link rel="icon" href="https://vaccinenation.org/wp-content/uploads/2022/07/cropped-VN1-32x32.png" sizes="32x32" /> <link rel="icon" href="https://vaccinenation.org/wp-content/uploads/2022/07/cropped-VN1-192x192.png" sizes="192x192" /> <link rel="apple-touch-icon" href="https://vaccinenation.org/wp-content/uploads/2022/07/cropped-VN1-180x180.png" /> <meta name="msapplication-TileImage" content="https://vaccinenation.org/wp-content/uploads/2022/07/cropped-VN1-270x270.png" /> <link rel="stylesheet" id="et-divi-customizer-global-cached-inline-styles" href="https://vaccinenation.org/wp-content/et-cache/global/et-divi-customizer-global.min.css?ver=1732171484" /></head> <body class="archive author author-charlotte-kilpatrick author-188655379 rttpg rttpg-7.7.15 radius-frontend rttpg-body-wrap rttpg-flaticon et_button_no_icon et_pb_button_helper_class et_fixed_nav et_show_nav et_primary_nav_dropdown_animation_slide et_secondary_nav_dropdown_animation_fade et_header_style_centered et_pb_footer_columns4 et_cover_background et_pb_gutter windows et_pb_gutters3 et_smooth_scroll et_right_sidebar et_divi_theme et-db">  <noscript> <iframe src="https://www.googletagmanager.com/ns.html?id=GTM-KCPC4B3" height="0" width="0" style="display:none;visibility:hidden"></iframe> </noscript>  <div id="page-container"> <header id="main-header" data-height-onload="66"> <div class="container clearfix et_menu_container"> <div class="logo_container"> <span class="logo_helper"></span> <a href="https://vaccinenation.org/"> <img src="https://vaccinenation.org/wp-content/uploads/2022/07/vaccine-nation-logo.png" width="2488" height="443" alt="VaccineNation" id="logo" data-height-percentage="60" /> </a> </div> <div id="et-top-navigation" data-height="66" data-fixed-height="40"> <nav id="top-menu-nav"> <ul id="top-menu" class="nav et_disable_top_tier"><li id="menu-item-113" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-113"><a href="https://vaccinenation.org/therapeutic/">Therapeutic</a></li> <li id="menu-item-112" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-112"><a href="https://vaccinenation.org/technology/">Technology</a></li> <li id="menu-item-111" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-111"><a href="https://vaccinenation.org/infection/">Infection</a></li> <li id="menu-item-110" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-110"><a href="https://vaccinenation.org/global-health/">Global Health</a></li> <li id="menu-item-109" class="menu-item menu-item-type-post_type menu-item-object-page menu-item-109"><a href="https://vaccinenation.org/events/">Events</a></li> <li id="menu-item-114" class="subs menu-item menu-item-type-custom menu-item-object-custom menu-item-114"><a href="/subscribe">>> Get Our Newsletters</a></li> </ul> </nav> <div id="et_top_search"> <span id="et_search_icon"></span> </div> <div id="et_mobile_nav_menu"> <div class="mobile_nav closed"> <span class="select_page">Select Page</span> <span class="mobile_menu_bar mobile_menu_bar_toggle"></span> </div> </div> </div>  </div>  <div class="et_search_outer"> <div class="container et_search_form_container"> <form role="search" method="get" class="et-search-form" action="https://vaccinenation.org/"> <input type="search" class="et-search-field" placeholder="Search …" value="" name="s" title="Search for:" /> </form> <span class="et_close_search_field"></span> </div> </div> </header>  <div id="et-main-area"> <div id="main-content"> <div class="container"> <div id="content-area" class="clearfix"> <div id="left-area"> <article id="post-8780" class="et_pb_post post-8780 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-access tag-development tag-funding tag-gates tag-grant tag-innovation tag-microarray tag-microneedle tag-needle-free tag-patch tag-research tag-technology tag-uptake tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/microneedle-technology-wins-gates-grants-of-6-6-million/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-1080x675.png?crop=1" alt="Microneedle technology wins Gates grants of $6.6 million" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-1080x675.png?crop=1" alt="Microneedle technology wins Gates grants of $6.6 million" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T110140.503-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/microneedle-technology-wins-gates-grants-of-6-6-million/">Microneedle technology wins Gates grants of $6.6 million</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 24, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/microneedle-technology-wins-gates-grants-of-6-6-million/#respond">0 comments</a></span></p><p><span data-contrast="auto">The University of Connecticut (UConn) <a href="https://today.uconn.edu/2024/10/gates-foundation-bolsters-thanh-nguyens-vaccine-research/" target="_blank" rel="noopener">announced</a> in October 2024 that associate Professor Thanh Nguyen’s research has received “significant” backing from The Bill and Melinda Gates Foundation. The Gates Foundation has awarded a series of grants totalling $6.6 million, following support from the National Institutes of Health (NIH) and the US Department of Agriculture (USDA). The funding will contribute to research and innovation for a microneedle array patch that can deliver multiple human vaccines at once. The Foundation initially awarded $2 million, which has increased after early success. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Microneedle array patch technology</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Dr Thanh Nguyen works in the College of Engineering’s School of Mechanical, Aerospace, and Manufacturing Engineering. His microneedle method is “<a href="https://today.uconn.edu/2023/11/nguyen-lab-explores-benefits-of-using-microneedle-arrays-for-vaccine-delivery/" target="_blank" rel="noopener">far less painful</a>” than traditional syringe delivery and offers access and uptake benefits. </span></p> <blockquote> <h6><span data-contrast="auto">“What if we were able to mail people vaccines that don’t need refrigeration, and they could apply to their own skin like a bandage?”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">The technology delivers highly concentrated vaccines in powder from over months, through a “nearly painless” 1-centimetre-square biodegradable patch. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The primary argument is that getting vaccines and boosters is a pain. You have to go back two or three times to get these shots. With the microneedle platform, you put it on once, and it’s done.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <h5><span data-contrast="auto">Funding increases</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">After the initial award of $2 million, the project made good progress and received additional funding to support the development of a scale-up manufacturing technology to produce patches on an industrial scale. In late September, the Gates Foundation awarded $4 million to take the patch “a step farther” as a pentavalent and Polio vaccine targeting diphtheria, tetanus, pertussis, HIV, Hepatitis B, and Polio. With this funding, the team can “build up productivity”. They are partnering with LTS to scale up production and are expanding the size of laboratory. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The award also marks a fundraising milestone for Dr Nguyen, who has earned more than $25 million in research awards, which he reflects “doesn’t come naturally”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“It comes from the recognition of the high impact of the research and the lab’s success in publishing articles. It is a testament to the importance of what we are doing.” </span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">For the latest vaccine development and technology updates, don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8775" class="et_pb_post post-8775 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-cepi tag-development tag-epidemic tag-finance tag-funding tag-gavi tag-global-health tag-pandemic tag-preparedness tag-resilience tag-response tag-strategy tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/iffim-1-billion-to-support-global-vaccine-programmes/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-1080x675.png?crop=1" alt="IFFIm: $1 billion to support global vaccine programmes" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-1080x675.png?crop=1" alt="IFFIm: $1 billion to support global vaccine programmes" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-24T102848.746-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/iffim-1-billion-to-support-global-vaccine-programmes/">IFFIm: $1 billion to support global vaccine programmes</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 24, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/iffim-1-billion-to-support-global-vaccine-programmes/#respond">0 comments</a></span></p><p><span data-contrast="auto">In October 2024 the International Finance Facility for Immunisation (IFFIm) priced a US$1 billion, 3-year fixed-rate bond to fund “<a href="https://iffim.org/press-releases/iffim-returns-market-us-1-billion-3-year-bond-support-global-vaccine-programs" target="_blank" rel="noopener">critical vaccine research and immunisation programmes</a>”. This is IFFIm’s largest single benchmark transaction in the primary market since its inaugural benchmark in 2006, with proceeds supporting Gavi and CEPI. The bond will mature on 29</span><span data-contrast="auto">th</span><span data-contrast="auto"> October 2027 and carries a semi-annual coupon of 4.125% and a semi-annual re-offer yield of 4.222%.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The success of this bond highlights the ongoing strength of IFFIm’s model, which leverages sovereign support and strong financial structuring to offer investment opportunities that make a positive impact on children’s health.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">The order book was IFFIm’s largest to date, exceeding US$4 billion. The bond drew interest from a diverse group of investors with geographic spread.</span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Support for vaccine programmes</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">IFFIm is an “important flexible tool” for organisations like Gavi; since 2006 it has provided Gavi with US$5.8 billion in financing, one sixth of its overall budget. It has been “critical” in enabling Gavi’s recent emergency responses as well as routine immunisation and health system resilience efforts. Dr Sania Nishtar, CEO of Gavi, reflected that IFFIm has been a “groundbreaking and indispensable tool”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Today’s bond issue provides us with vital flexibility in our mission to protect millions of children from preventable diseases and to protect our world from the threat of future pandemics.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">As Gavi nears the end of the 2021-2025 strategic period and prepares for the next phase, IFFIm states that the bond issue will play a “pivotal role” in supporting life-saving programmes.</span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">IFFIm has also provided approximately US$272 million in past financing to CEPI in support of the research and development of new vaccines. Dr Richard Hatchett, CEO of CEPI, acknowledged the “serious threat to global health security” presented by epidemics and pandemics. He commented that these can be “mitigated through investment in vaccine R&D and manufacturing”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The IFFIm financing mechanism enables CEPI to access the critical funding it needs to accelerate the development of vaccines against emerging infectious disease threats, for the benefit of all.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <h5><span data-contrast="auto">Offering opportunities</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">IFFIm Board Chair Ken Lay believes that the latest issue “highlights IFFIm’s unparalleled strengths”; it is “backed by sovereign donors, driven by a vital global mission, and structured to maximise impact”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“IFFIm’s bonds continue to offer investors compelling opportunities to earn competitive returns with good secondary market liquidity and assured use of proceeds.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Jorge Familiar, Vice President and Treasurer, World Bank commented that capital markets are a “powerful tool for connecting private investment with global public goods”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“As IFFIm’s Treasury Manager, the World Bank is pleased to support IFFIm in accessing capital markets to provide a long-term and flexible funding source to Gavi to accelerate access to vaccines and vaccine development.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Head of SSA and EMEA IG Syndicate, BofA Securities Adrien de Naurois congratulated the IFFIm team on a successful return to the USD market. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Today’s transaction, the first USD benchmark in two years, is a clear demonstration of IFFIm’s loyal and diverse investor base, attracted by the importance of its mission to deliver immunisation programmes to those most vulnerable via the ongoing work of Gavi.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">For the latest vaccine news, don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8770" class="et_pb_post post-8770 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-access tag-childhood tag-children tag-cost tag-effectiveness tag-efficacy tag-endemic tag-global-health tag-infectious-disease tag-infrastructure tag-model tag-mpox tag-outbreak tag-pheic tag-research tag-strategy tag-study tag-vaccination tag-vaccine tag-virus"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/study-vaccinating-children-against-mpox-most-efficient/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-1080x675.png?crop=1" alt="Study: vaccinating children against mpox “most efficient”" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-1080x675.png?crop=1" alt="Study: vaccinating children against mpox “most efficient”" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T121805.785-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/study-vaccinating-children-against-mpox-most-efficient/">Study: vaccinating children against mpox “most efficient”</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 23, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/study-vaccinating-children-against-mpox-most-efficient/#respond">0 comments</a></span></p><p><span data-contrast="auto">A study in </span><a href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00384-X/fulltext" target="_blank" rel="noopener"><i><span data-contrast="auto">The Lancet Global Health </span></i></a><span data-contrast="auto">sought to provide counterfactual scenarios to evaluate the short-term effects of different vaccination strategies on mpox cases and deaths in the Democratic Republic of the Congo (DRC). The researchers used a dynamic transmission model to simulate mpox transmission, stratified by age and province; this was used to assess potential vaccination strategies and their effects on deaths and cases in an epidemic year. The results indicate that vaccinating children aged 15 years or younger, or younger than 5 years, in endemic regions, would be the “most efficient use of vaccines” when resources are limited. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Mpox in DRC</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Mpox was first identified in the Democratic Republic of the Congo (DRC) in 1970; it is a zoonotic infectious disease caused by the monkeypox virus (MPXV), which is endemic in “numerous regions” of west and central Africa. MPXV has two clades:</span><span data-ccp-props="{}"> </span></p> <ul> <li><span data-contrast="auto">Clade I is endemic in central Africa with an estimated case fatality rate of up to 10% and mainly affecting children. It is divided into two subclades, Ia and Ib.</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Clade II was historically found in west Africa, with an estimated case fatality rate of up to 1%-3%. It is also divided into two subclades, IIa and IIb. Clade IIb was responsible for the global mpox epidemic in 2022. </span><span data-ccp-props="{}"> </span></li> </ul> <p><span data-contrast="auto">The authors state that, until 2022, MPXV was not associated with large outbreaks; most cases were related directly to sylvatic transmission from animals to humans via hunting, wild game preparation, and consumption. Increases in human-to-human transmission were identified in 2017.</span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The researchers suggest that the low likelihood of transmission in the early decades after the virus’ discovery could be related to smallpox eradication programmes, which offered cross-immunity via vaccination against a related orthopoxvirus. Indeed, since the cessation of the smallpox vaccination programme in the DRC, there has been a “concurrent increase in mpox cases and outbreak frequency”. </span><span data-contrast="auto">There is an ongoing, “unprecedentedly large” outbreak of clade I mpox in the DRC, with more than 14,000 reported suspected cases by the end of 2023 and a 4.6% case fatality rate. Over 70% of the deaths are in children younger than 15 years. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Genetic analyses of clade Ia MPXV genomes indicate that in this outbreak, multiple, independent zoonotic introductions into the human population have occurred from one or more reservoir species. An increasing burden of clade Ib MPXV infections have been identified in eastern DRC with evidence of “sustained” human-to-human transmission and many cases in women aged 15-29 years, but clade Ia infections continue to comprise most mpox cases in the DRC. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">The study</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">Bavarian Nordic’s modified vaccinia Ankara vaccine (JYNNEOS) is protective against mpox. It was approved by the US FDA in 2019 but was not widely used against mpox until the 2022 outbreak, when it was “quickly mobilised to vaccinate people at high risk of infection in the USA and Europe”. Despite its high efficacy at two doses, it is “largely unavailable” outside the USA and Europe. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">The authors aimed to inform policy and decision makers on the “potential benefits of, and resources needed,” for mpox vaccination campaigns in the DRC. They used an approach based on models from operations research and decision science to offer a robust analysis of policy choices “even in the context of incomplete and uncertain data”. The study uses mathematical modelling to simulate the spread of mpox in the DRC during 2023. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Without vaccination, the model predicted 14,700 cases of mpox and 700 deaths from mpox in the DRC over 365 days, consistent with reported estimates. Almost 50% of the cases and deaths came from the province of Equateur. Cases were evenly split between the three age groups: 34% in children under 5 years, 32% in children aged 5-15 years, and 34% in people older than 15 years. However, deaths were “predominantly” seen in children younger than 5 years (51%). </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Vaccinating 80% of children younger than 5 years in all provinces or provinces with a history of mpox cases decreased the outbreak to 10,500 cases and 400 deaths. Vaccinating in endemic provinces increased cases to 10,700 and deaths remained the same. The numbers of vaccine doses needed for the strategies were 41.4 million (all provinces), 33.8 million (provinces with a history of mpox), and 13.2 million (endemic provinces only). </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Vaccinating 80% of children younger than 15 years in all provinces or provinces with a history of mpox cases decreased the outbreak to 6,400 cases and 200 deaths. Vaccinating in endemic provinces increased cases to 6,800 and deaths remained the same. The numbers of vaccine doses required for these strategies were 81.6 million (all provinces), 67.1 million (provinces with a history of mpox), and 26.6 million (endemic provinces only). </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Vaccinating 80% of all ages in all provinces or only non-endemic provinces with a history of cases decreased the case burden to 1,400 cases and 100 deaths, and 2,000 cases and 100 deaths when vaccinating in provinces endemic for mpox. The numbers of doses required for these strategies were 170.8 million (all provinces), 142.0 million (provinces with a history of mpox), and 56.8 million (endemic provinces only).</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">Managing resources</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">The paper finds that vaccinating all ages leads to the “largest impact on magnitude of cases and deaths”, but that vaccinating only children aged 15 years or younger provides “nearly the same effect with fewer vaccine doses required”. Although vaccinating only children younger than 5 years showed a “drop-off” in averted cases and deaths, it provides the most efficiency. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“This analysis shows the effectiveness of focussing an mpox vaccination campaign specifically in the provinces endemic for mpox in the DRC. This targeted strategy prevents nearly as many cases and deaths as broader approaches but uses fewer vaccine doses and thus would be less costly to implement.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Alexandra Savinkina, fourth year PhD student in the Yale School of Public Health (YSPH) Department of Epidemiology (Microbial Diseases), <a href="https://ysph.yale.edu/news-article/yale-study-vaccinating-young-children-for-mpox-would-significantly-reduce-deaths-in-the-drc/" target="_blank" rel="noopener">commented</a> that this study could influence vaccination policy.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“My hope is that it could help inform policy for vaccination in the country and potentially the region and move the needle forward on getting vaccines to the people who need them most in the DRC.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Savinkina hopes that “we can learn from the global mpox outbreak that we can’t ignore disease in other places”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“If the resources to help people exist, I think we should be using them, whether in the U.S. or in Africa.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Gregg Gonsalves, associate professor of epidemiology at YSPH, acknowledged barriers to access.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“We take it for granted that we can get a vaccination for COVID or a flu shot at our local CVS, but the infrastructure to deliver vaccines in DRC is far less robust.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">For more vaccine research updates, <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span></p> </article> <article id="post-8765" class="et_pb_post post-8765 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-clinical-trial tag-global-health tag-health tag-infection tag-infectious-disease tag-life-sciences tag-moderna tag-mrna tag-nhs tag-norovirus tag-response tag-technology tag-uk tag-ukhsa tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/uk-begins-phase-iii-trial-of-mrna-norovirus-vaccine/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-1080x675.png?crop=1" alt="UK begins Phase III trial of mRNA norovirus vaccine" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-1080x675.png?crop=1" alt="UK begins Phase III trial of mRNA norovirus vaccine" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-23T093047.957-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/uk-begins-phase-iii-trial-of-mrna-norovirus-vaccine/">UK begins Phase III trial of mRNA norovirus vaccine</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 23, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/uk-begins-phase-iii-trial-of-mrna-norovirus-vaccine/#respond">0 comments</a></span></p><p><span data-contrast="auto">The National Institute for Health and Care Research (NIHR) <a href="https://www.nihr.ac.uk/news/uks-first-norovirus-mrna-vaccine-trial-launched" target="_blank" rel="noopener">announced</a> in October 2024 that the first Phase III randomised trial of an investigational mRNA norovirus vaccine is opening across the UK. The trial seeks to evaluate the efficacy and safety of mRNA-1403 and is sponsored by Moderna. It will be conducted across 39 sites in the country, including 27 NHS primary and secondary care sites. Investigators hope to recruit 2,500 participants between late October and early 2025. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Norovirus</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Norovirus, or the “<a href="https://www.nhs.uk/conditions/norovirus/" target="_blank" rel="noopener">winter vomiting bug</a>”, is a viral illness; it is the “<a href="https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/norovirus" target="_blank" rel="noopener">most common cause</a>” of acute gastroenteritis globally. Symptoms include acute onset diarrhoea and vomiting, but there is evidence to suggest that norovirus infection is associated with intestinal inflammation and malnutrition and could cause long-term morbidity. WHO <a href="https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/norovirus" target="_blank" rel="noopener">estimates</a> that 685 million cases of norovirus are seen each year, including 200 million cases in children under 5. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The burden of norovirus is significant; norovirus causes an estimated 200,000 deaths per year, including 50,000 child deaths, primarily impacting low-income countries. Norovirus has been estimated to cost $60 billion globally as a result of healthcare costs and economic losses.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">There are no licensed norovirus vaccines in use.</span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">The trial</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Participants in the trial will be randomly assigned to two groups. One group will receive the investigational vaccine, and the other groups will receive a placebo. While anyone who is aged 18 or older and meets the inclusion criteria is eligible for the trial, researchers are seeking participants aged 60 and older. This age group is “generally more likely to be severely affected by norovirus”. Thus, a successful vaccine would be of greatest benefit to them. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The trial is part of the <a href="https://www.gov.uk/government/news/uk-cements-10-year-partnership-with-moderna-in-major-boost-for-vaccines-and-research" target="_blank" rel="noopener">10-year partnership</a> between Moderna and the UK Health Security Agency (UKHSA) on behalf of the UK Government. It is supported by the UK Vaccine Innovation Pathway (VIP) and the NIHR, which are working together to accelerate vaccine trials in the UK. The NIHR Research Delivery Network (RDN) is working with the devolved administrations to accelerate the roll-out of “key” vaccine studies. These efforts include the NIHR’s flagship recruitment tool: Be Part of Research.</span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto"><a href="https://bepartofresearch.nihr.ac.uk/?utm_source=nihr-website&utm_medium=referral&utm_campaign=bpor-nova" target="_blank" rel="noopener">Be Part of Research</a> is an online service that connects people to health and care research across the UK. Anyone over the age of 18 can register for an account, indicating the areas of research that they are interested in. They are then sent information about suitable studies. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Advancing healthcare</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The UK Chief Investigator, Dr Patrick, is a GP in Dorset and Research Director at the NIHR’s South West Regional Research Delivery Network. Dr Moore commented that the UK is “really pleased to be able to play an important role” in finding a vaccine for this “highly contagious disease”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Outbreaks of norovirus have huge consequences, both on our health systems and our economy. This innovative trial is crucial in helping us advance healthcare.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">NIHR Chief Executive and Chief Scientific Advisor to the Department of Health and Social Care, Professor Lucy Chappell, hopes that the vaccine could “make a difference to lives of many – especially our most vulnerable citizens”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Leveraging the UK’s expertise in vaccine development, the DHSC through the NIHR and Moderna are delivering this large-scale trial at pace, so that people across the UK and the world can benefit sooner.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Health and Social Care Secretary Wes Streeting described the trial as a “huge vote of confidence in the UK’s life sciences sector”. It could also allow a “shift” away from sickness towards prevention, which would reduce pressure on the NHS and keep people healthier in the colder months. Moderna’s Chief Development Officer Dr Melanie Ivarsson is “delighted” to bring the trial to the UK.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“By advancing our investigational mRNA norovirus vaccine into a pivotal Phase III trial, we are one step closer to potentially providing a new tool to prevent infection from this highly contagious virus, which places a significant burden on health systems globally.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Sarah Collins, Commercial Director at UKHSA, reflected that norovirus “isn’t just a nasty tummy bug – it can have serious consequences” including “disruption” to health services and education settings. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“It’s fantastic to see the first trial of its kind get underway as a result of UKHSA’s strategic 10-year partnership with Moderna, which aims to enhance investment in scientific research and vaccine development to enable a rapid response to future pandemics and other infectious diseases.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p>For the latest on vaccine research, don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>.</p> </article> <article id="post-8757" class="et_pb_post post-8757 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-diagnosis tag-global-health tag-infection tag-infectious-disease tag-malaria tag-mosquito tag-mosquito-borne tag-parasite tag-partnership tag-prevention tag-public-health tag-surveillance tag-treatment tag-vaccine tag-vector tag-who"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/who-declares-egypt-malaria-free-after-100-year-effort/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-1080x675.png?crop=1" alt="WHO declares Egypt malaria-free after 100-year effort" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-1080x675.png?crop=1" alt="WHO declares Egypt malaria-free after 100-year effort" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T150001.625-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/who-declares-egypt-malaria-free-after-100-year-effort/">WHO declares Egypt malaria-free after 100-year effort</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 21, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/who-declares-egypt-malaria-free-after-100-year-effort/#respond">0 comments</a></span></p><p><span data-contrast="auto">In October 2024 <a href="https://www.who.int/news/item/20-10-2024-egypt-is-certified-malaria-free-by-who" target="_blank" rel="noopener">WHO certified Egypt</a> as malaria-free after a “nearly 100-year effort” by the government and people to end the disease. WHO described this as a “significant public health milestone” for the country’s more than 100 million inhabitants. Egypt is the third country to receive this certification in the WHO Eastern Mediterranean Region, following the United Arab Emirates and Morocco. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Across the globe, 44 countries and 1 territory have achieved this status by proving beyond reasonable doubt that the chain of indigenous malaria transmission by </span><i><span data-contrast="auto">Anopheles </span></i><span data-contrast="auto">mosquitoes has been interrupted nationwide for at least the previous three consecutive years. A country must also demonstrate its capacity to prevent the re-establishment of transmission.</span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Malaria becomes history</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">WHO states that malaria has been traced back as far as 4000 BCE in Egypt; there is genetic evidence of the disease in Tutankhamun and other ancient Egyptian mummies. More recently, efforts to reduce human-mosquito contact began in the 1920s with the prohibition of rice cultivation and agricultural crops near homes. With much of the population living along the banks of the Nile River and malaria prevalence “as high as 40%”, malaria was designated as a notifiable disease in 1930. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">By 1942, malaria cases in Egypt exceeded 3 million due to population displacement caused by the Second World War, the disruption of medical supplies and services, and the invasion of </span><i><span data-contrast="auto">Anopheles arabiensis</span></i><span data-contrast="auto">, which is a “highly efficient mosquito vector”. Egypt responded to the outbreak by establishing 16 treatment divisions and recruiting more than 4000 health workers. The Aswan Dam, completed in 1969, brought an additional risk of malaria as standing water provides a mosquito breeding ground. Thus, Egypt worked with Sudan to launch a “rigorous” vector control and public health surveillance project. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">By 2001, malaria was “firmly under control”, encouraging the Ministry of Health and Population to work on preventing the re-establishment of local malaria transmission. Egypt “rapidly” contained a small outbreak in the Aswan Governorate in 2014. The recent certification recognises continued efforts and initiatives including the free provision of malaria diagnosis and treatment to the population, regardless of legal status, and health professionals’ training to detect and screen for malaria. The country also has “strong” cross-border partnerships with neighbours like Sudan, which have been “instrumental”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">The beginning of a new phase</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">Dr Tedros Adhanom Ghebreyesus, WHO Director-General, congratulated Egypt on its achievement.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Malaria is as old as Egyptian civilisation itself, but the disease that plagued pharaohs now belongs to its history and not its future. This certification of Egypt as malaria-free is truly historic, and a testament to the commitment of the people and government of Egypt to rid themselves of this ancient scourge.” </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Tedros hopes that this will be an “inspiration to other countries in the region”, showing “what’s possible with the right resources and the right tools”. </span><span data-contrast="auto">Deputy Prime Minister of Egypt H.E. Dr Khaled Abdel Ghaffar commented that the certification is “not the end of the journey but the beginning of a new phase”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“We must now work tirelessly and vigilantly to sustain our achievement through maintaining the highest standard for surveillance, diagnosis and treatment, integrated vector management, and sustaining our effective and rapid response to imported cases. Our continued multisectoral efforts will be critical to preserving Egypt’s malaria-free status.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Abdel Ghaffar reaffirmed that the country will “continue with determination and strong will”. WHO Regional Director for the Eastern Mediterranean Dr Hanan Balkhy emphasised that the success is “not just a victory for public health but a sign of hope for the entire world”, including other endemic countries in the region. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“This achievement is the result of sustained, robust surveillance investments in a strong, integrated health system, where community engagement and partnerships have enabled progress. Furthermore, collaboration and support to endemic countries, such as Sudan, remain a priority.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">For insights into the latest malaria vaccine development progress,<a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener"> join us at the Congress in Barcelona next week</a>. Don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </article> <article id="post-8753" class="et_pb_post post-8753 post type-post status-publish format-standard has-post-thumbnail hentry category-therapeutic tag-bacteria tag-bacterial tag-cancer tag-cancer-research tag-cancer-therapy tag-cancer-vaccine tag-colorectal tag-immunotherapy tag-neoantigen tag-personalised tag-t-cell tag-therapeutic tag-therapy tag-tumour tag-vaccine tag-vector"> <a class="entry-featured-image-url" href="https://vaccinenation.org/therapeutic/bacterial-vectors-for-precision-cancer-vaccine-development/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-1080x675.png?crop=1" alt="Bacterial vectors for precision cancer vaccine development" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-1080x675.png?crop=1" alt="Bacterial vectors for precision cancer vaccine development" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-21T112846.746-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/therapeutic/bacterial-vectors-for-precision-cancer-vaccine-development/">Bacterial vectors for precision cancer vaccine development</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 21, 2024</span> | <a href="https://vaccinenation.org/category/therapeutic/" rel="category tag">Therapeutic</a> | <span class="comments-number"><a href="https://vaccinenation.org/therapeutic/bacterial-vectors-for-precision-cancer-vaccine-development/#respond">0 comments</a></span></p><p><span data-contrast="auto">Research in </span><a href="https://www.nature.com/articles/s41586-024-08033-4#Abs1" target="_blank" rel="noopener"><i><span data-contrast="auto">Nature </span></i></a><span data-contrast="auto">in October 2024 leverages evidence that bacteria “naturally home in on tumours and modulate antitumour immunity” to explore potential vaccine applications. The authors engineered a probiotic </span><i><span data-contrast="auto">Escherichia coli </span></i><span data-contrast="auto">Nissle 1917as an antitumour vaccination platform, revealing a promising immune response. In mouse models of advanced colorectal cancer and melanoma, the vaccine triggered the immune system to suppress the growth of primary and metastatic cancers. The team hopes that this research can advance personalised cancer vaccine approaches. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Bacteria as ideal vectors</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The authors identified bacteria as “ideal vectors to augment and direct” antitumour immune responses thanks to their support of the activation of both innate and adaptive immunity. Furthermore, bacteria can be synthetically engineered with ease for “safe delivery” of immunomodulatory compounds. Although various tumour neoantigen vaccines have demonstrated “promising” clinical trial results, benefit is “limited to only a subset of patients”. Thus, programming bacteria with genetic directives to release high levels of specific tumour neoantigens offers a system for the precise instruction of neoantigen targeting in situ. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">The study</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The researchers developed an engineered bacterial system in probiotic </span><i><span data-contrast="auto">Escherichia coli </span></i><span data-contrast="auto">Nissle 1917 (EcN) to “enhance expression, delivery, and immune-targeting of arrays of tumour exonic mutation-derived epitopes”. These epitopes are “highly expressed” by tumour cells and predicted to bind major histocompatibility complex (MHC) class I and class II. The system engages several “key design elements” to enhance therapeutic use:</span><span data-ccp-props="{}"> </span></p> <ol> <li><span data-contrast="auto">Optimisation of synthetic neoantigen construct form with</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Removal of cryptic plasmids and deletion of Lon and OmpT proteases to increase neoantigen accumulation </span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Increased susceptibility to phagocytosis for enhanced uptake by antigen-presenting cells (APCs) and presentation of MHC class II-restricted antigens</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Expression of listeriolysin O (LLO) to induce cytosolic entry for presentation of recombinant encoded neoantigens by MHC class I molecules and T helper 1 cell (T</span><span data-contrast="none"> H</span><span data-contrast="auto">1)-type immunity</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Improved safety for systemic administration due to reduced survival in the blood and biofilm formation</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":720,"335559737":0,"335559738":0,"335559739":160,"335559740":279,"335559991":360}"> </span></li> </ol> <p><span data-contrast="auto">Through exome and transcriptome sequencing of subcutaneous CT26 tumours the researchers developed a repertoire of neoantigens, which were predicted from highly expressed tumour-specific mutations. They then endeavoured to create a microbial system that could “accommodate the production and delivery of diverse sets of neoantigens” to lymphoid tissue and the tumour microenvironment (TME). </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Synthetic neoantigen construct optimisation and genetic engineering achieved a microbial platform </span><span data-contrast="none">(EcNc</span><span data-contrast="none">Δ</span><i><span data-contrast="none">lon</span></i><span data-contrast="none">/Δ</span><i><span data-contrast="none">ompT</span></i><span data-contrast="none">/LLO+</span><span data-contrast="none">)</span><span data-contrast="auto"> capable of robust production across diverse sets of tumour neoantigens, which was attenuated in immune-resistance mechanisms, effectively taken up by and proficient in activating APCs, and able to drive potent activation of T cells specific for encoded recombinant antigens to support enhanced cellular immunity.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <h5><span data-contrast="auto">Vaccine applications</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">The study revealed that antigen sets encompassing predicted MHC-II and MHC-II binding neoantigens mediated antitumour efficacy. Enhanced frequencies of neoantigen-specific CD4+ and CD8+ T cells were seen. Across distinct tumour models and genetic backgrounds, the antitumour effect of vaccination was “accompanied by broad modulation of the immune compartment within the TME”. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The coordinated regulation of APCs, reduction of immunosuppressive myeloid, regulatory T and B cell populations, and activation of NK cells and CD4+ and CD8+ T cells together indicate the advantage of precisely engineered microbial platforms as next-generation antitumour vaccines that align several arms of immunity.” </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Furthermore, the “unique ability” of microbial vaccines to “directly remodel” the TME could “promote synergy” across various forms of immunotherapy. Microbial neoantigen vectors locally increase neoantigens density, recruit and activate dendritic cells and CD4+ and CD8+ T cells, and reduce immunosuppressive populations and ligands within the TME. Therefore, in combination with adoptive T cell therapy (ACT), they could “oppose these resistance mechanisms and provide synergistic benefit”. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Through extra programming of the microbial vectors and rational incorporation of other immunotherapeutics, this system may achieve reliable eradication of established solid tumours and metastases through precision cancer immunotherapy using living antitumour vaccines.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <h5><span data-contrast="auto">Getting closer</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">Jongwon Im, PhD student at Columbia University, helped lead bacterial engineering aspects of the study, and <a href="https://www.cuimc.columbia.edu/news/hacking-bacteria-attack-cancer" target="_blank" rel="noopener">commented</a> on the “net effect”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The bacterial vaccine is able to control or eliminate the growth of advanced primary or metastatic tumours and extend survival in mouse models.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">These vaccines are personal, programmed to “direct the immune system” to target “distinct genetic mutations”, said Dr Nicholas Arpaia, associate professor of microbiology and immunology at Columbia University’s Vagelos College of Physicians and Surgeons.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“As we continue to integrate additional safety optimisations through further genetic programming, we are getting closer to the point of testing this therapy in patients.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Tal Danino, associate professor of biomedical engineering at Columbia’s School of Engineering, reflected that the time to treatment will “first depend on how long it takes to sequence the tumour” for each patient.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Then we just need to make the bacterial strains, which can be quite fast. Bacteria can be simpler to manufacture than some other vaccine platforms.” </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Another benefit of bacteria is the enabled delivery of a “higher concentration of drugs that can be tolerated when these compounds are delivered systemically throughout the entire body”, suggested Dr Arpaia.</span></p> <blockquote> <h6><span data-contrast="auto">“Here, we can confine delivery directly to the tumour and locally modulate how we’re stimulating the immune system.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">For the latest insights into cancer vaccine research make sure you <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">join us at the Congress in Barcelona next week</a>, and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here. </a></span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </article> <article id="post-8748" class="et_pb_post post-8748 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-childhood tag-eradication tag-funding tag-global-health tag-government tag-infectious-disease tag-investment tag-polio tag-poliovirus tag-public-health tag-resilience tag-resources tag-sanitation tag-vaccine tag-vaccines tag-virus"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/global-polio-eradication-initiative-faces-challenges/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-1080x675.png?crop=1" alt="Global Polio Eradication Initiative faces challenges" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-1080x675.png?crop=1" alt="Global Polio Eradication Initiative faces challenges" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T145039.979-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/global-polio-eradication-initiative-faces-challenges/">Global Polio Eradication Initiative faces challenges</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 18, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/global-polio-eradication-initiative-faces-challenges/#respond">0 comments</a></span></p><p><span data-contrast="auto">The Global Polio Eradication Initiative (GPEI) <a href="https://polioeradication.org/news/gpei-announces-strategy-extension-and-revised-budget-to-protect-all-children-from-polio/" target="_blank" rel="noopener">announced</a> the “difficult decision” to extend the timelines needed to achieve polio eradication. This decision, made by the Polio Oversight Board (POB) in July 2024, was shared in October 2024 with an update to funding requirements. Although GPEI recognised the “unprecedented progress” made so far, it highlighted the danger of falling into an “unacceptable future”, demanding collaboration and support for the next stages of eradication efforts. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Progress against polio</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">GPEI commented that “for more than three and a half decades” it has been supporting governments and health workers to make “unprecedented progress toward the promise of a polio-free world”. Through this work, more than 20 million people are “walking who would otherwise have been paralysed by this dreadful disease”. “Billions” of children have benefitted from lifesaving immunisations, and five out of six WHO Regions are free from wild poliovirus. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Closing the gaps</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">With broad global success, the programme is largely now “concentrated in some of the most complicated and fragile settings in which to deliver basic healthcare”. It faces “serious”, from “persistent violence to climate emergencies”. Indeed, the transmission of polio in conflict-affected areas in Gaza, Sudan, and Yemen, provides a “stark reminder” that “where conflict debilitates health and sanitation systems, polio will inevitably appear” unless eradication of all forms of the virus can be achieved. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Extended timelines </span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">In recognition of the continued challenges, the GPEI’s POB decided to extend the timelines needed to achieve polio eradication to the end of 2027 (wild poliovirus) and the end of 2029 (type 2 variant poliovirus). The decision, made in July 2024, was informed by “critical analysis and expert consultations”. The consequence of this extension is a need for further financial resources. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">In October 2024, the POB determined that the total funding needs of the extended 2022-2029 strategic period are US$6.9 billion; this is an increase from the US$4.8 billion projected for the 2022-2026 strategic period. Donors have already committed an “incredible” US$4.5 billion, leaving US$2.4 billion “urgently needed”. The funds will enable the programme to make “tactical shifts”, allowing GPEI to:</span><span data-ccp-props="{}"> </span></p> <ul> <li><span data-contrast="auto">Reach more children with polio vaccines by working with polio-affected country leaders to strengthen programme implementation</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Deploy innovative tools like novel vaccines and surveillance methods to further strengthen outbreak response</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Improve accountability at all levels, from global leadership to field managers</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Work with routine immunisation programmes by integrating polio services where possible</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Deepen relationships by strengthening community engagement</span><span data-ccp-props="{}"> </span></li> </ul> <p><span data-contrast="auto">These “shifts” are driven by partners’ expertise and a “programme-wide commitment to double down on the toughest but most critical challenges”. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">GPEI warns that shortcomings in funding or executing these efforts would have “serious consequences”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Without dedicated eradication efforts, within a decade, many thousands of children around the world could once again be paralysed or die from polio each year. This is an unacceptable future.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">The importance of donor and polio-affected country governments supported is highlighted as central in reaching all children with lifesaving vaccines and strengthening health systems in the process.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“With strengthened support and collaboration, together we can deliver a world where all children, families, and communities are forever free from polio.”</span></h6> </blockquote> <p>For the latest vaccine and global health updates, don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>.</p> </article> <article id="post-8744" class="et_pb_post post-8744 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-amr tag-animal-health tag-cattle tag-farm tag-funding tag-global-health tag-grant tag-infectious-disease tag-investment tag-one-health tag-research tag-technology tag-vaccine tag-viral-vector"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/the-vaccine-group-and-apha-secure-animal-vaccine-grant/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-1080x675.png?crop=1" alt="The Vaccine Group and APHA secure animal vaccine grant" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-1080x675.png?crop=1" alt="The Vaccine Group and APHA secure animal vaccine grant" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-18T140704.886-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/the-vaccine-group-and-apha-secure-animal-vaccine-grant/">The Vaccine Group and APHA secure animal vaccine grant</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 18, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/the-vaccine-group-and-apha-secure-animal-vaccine-grant/#respond">0 comments</a></span></p><p><span data-contrast="auto">In October 2024 the Animal and Plant Health Agency (APHA) and The Vaccine Group (TVG) <a href="https://thevaccinegroup.com/innovate-uk-smart-grant-awarded-to-the-vaccine-group-apha-for-cattle-vaccine-platform-development/" target="_blank" rel="noopener">announced</a> that Innovate UK has awarded them a Smart grant in excess of £400,000 to advance a novel viral vector platform. In a project lasting 19 months, the two organisations will use technology developed by TVG scientists in candidate vaccines for two “important diseases in cattle”: bovine respiratory syncytial virus (BRSV) and lumpy skin disease (LSD). The project will continue previous research, which identified potential vaccine candidates; it is supported by the World Reference Laboratory for Non-Vesicular Diseases at The Pirbright Institute, determining how the candidates can produce an adequate serological response in animals and protect cattle.</span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">BRSV and LSD</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Bovine respiratory syncytial virus (BRSV) is the leading viral cause of respiratory illness in young calves in the UK. It affects around 1.9 million calves each year, costing approximately £54 million. It is “prevalent worldwide” and poses a “substantial economic burden” on beef and dairy producers. In the past 10 years, lumpy skin disease (LSD) has spread “dramatically” beyond former natural enzootic geographies in Africa and the Middle East to cause “severe disease” in other regions. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Both diseases have “broad global prevalence”, and BRSV particularly affects intensively reared cattle. Currently available commercial vaccines for BRSV do not prevent shedding and are restricted from use in young calves by maternal immunity. There are no DIVA (differentiating infected from vaccinated animals) vaccines available for LSD, so use is limited to areas where serosurveillance and eradication programmes are in place. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">TVG’s vaccine solutions</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The Vaccine Group (TVG) hope to address these challenges. With “key opinion leaders” for the two diseases in the UK and Canada, TVG has inserted transgenes for protective antigens from each virus into two separate constructs through genetic manipulation. Both vaccine candidates have been shown to be genetically stable and have demonstrated “stable and prolonged” protein expression in tissue culture over multiple passages. The technology works by introducing a benign virus to cattle, which stimulates the expression of proteins to induce an immune response. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Chief Executive Officer at TVG, Dr Jeremy Salt, reflected that infectious diseases are a “major cause for concern” for cattle farmers around the world, leading to “significant losses – both in terms of animal health and welfare, and in financial terms”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Our goal in developing a viral vector platform for use in cattle effective vaccines is to overcome some of the deficiencies that affect the current commercialised vaccines. By doing so, we can better protect the farmers, their animals, and their livelihoods.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Salt also hopes to “make beef and milk production more efficient, humane, and sustainable”, whilst “helping the sector address the global challenges of antibiotic resistance and carbon emissions”. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">We look forward to hearing from Dr Salt at the Congress in Barcelona in just a few weeks; <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">get your tickets to join us there</a> and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>.</span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8739" class="et_pb_post post-8739 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-bacteria tag-collaboration tag-fast-track tag-fda tag-global-health tag-infectious-disease tag-lmic tag-manufacturing tag-multivalent tag-production tag-regulatory tag-shigellosis tag-technology tag-unmet-need tag-vaccine tag-valneva"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/valneva-and-limmatech-secure-shigella-vaccine-fast-track/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-1080x675.png?crop=1" alt="Valneva and LimmaTech secure Shigella vaccine fast track" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-1080x675.png?crop=1" alt="Valneva and LimmaTech secure Shigella vaccine fast track" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T154354.070-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/valneva-and-limmatech-secure-shigella-vaccine-fast-track/">Valneva and LimmaTech secure Shigella vaccine fast track</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 17, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/valneva-and-limmatech-secure-shigella-vaccine-fast-track/#respond">0 comments</a></span></p><p><span data-contrast="auto">Valneva and LimmaTech Biologics <a href="https://valneva.com/press-release/valneva-and-limmatech-awarded-fda-fast-track-designation-for-tetravalent-shigella-vaccine-candidate-s4v/" target="_blank" rel="noopener">announced</a> in October 2024 that they have been granted Fast Track designation by the United States FDA for Shigella4V (S4V). S4V is “the world’s most clinically advanced” tetravalent bioconjugate shigellosis vaccine candidate. In August 2024 the two organisations <a href="https://vaccinenation.org/technology/valneva-and-limmatech-partner-on-shigella-vaccine/" target="_blank" rel="noopener">announced</a> a strategic partnership and exclusive licensing agreement to develop, manufacture, and commercialise S4V. The FDA designation is granted to products in development that have the potential to treat serious conditions and fill an unmet medical need, with the goal of facilitating clinical development and expediting review. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Addressing a global health threat</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">An estimated 165 million cases of disease and 600,000 deaths are attributed to Shigella every year; the greatest burden is among children in low- and middle-income countries (LMICs). Shigellosis also affects international travellers from high-income countries and deployed military personnel in endemic regions. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Thomas Lingelbach, Chief Executive Officer of Valneva, stated that shigellosis is the “second leading cause of fatal diarrhoeal disease worldwide” with no approved Shigella vaccine. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The development of Shigella vaccines has been identified as a priority by the World Health Organisation (WHO). Fast Track designation allows us to work closely with the FDA to accelerate our efforts to deliver a preventative solution against this deadly disease.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Franz-Werner Haas, Chief Executive Officer of LimmaTech, is “highly encouraged” by the designation, which “reinforces our efforts”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“[It] underscores the significant potential of the S4V Shigella vaccine candidate to address a serious global health threat.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <h5><span data-contrast="auto">The way forward</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">After <a href="https://vaccinenation.org/technology/limmatech-announces-positive-interim-data-for-shigella4v/" target="_blank" rel="noopener">positive Phase I/II results earlier</a> in the year, LimmaTech will conduct a Phase II Controlled Human Infection Model study (CHIM) in the United States and a Phase II paediatric study in LMICs. These are expected to begin before the end of 2024. Valneva will assume all further development, including chemistry, manufacturing, and controls (CMC) and regulatory activities. It will also be responsible for global commercialisation if the vaccine is approved. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8734" class="et_pb_post post-8734 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-100-days-mission tag-access tag-cepi tag-covid-19 tag-development tag-economic tag-equity tag-global-health tag-health tag-investment tag-lmic tag-manufacturing tag-model tag-pandemic tag-preparedness tag-research tag-resilience tag-study tag-technology tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/modelling-study-100-days-mission-demands-vaccine-equity/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-1080x675.png?crop=1" alt="Modelling study: 100 Days Mission demands vaccine equity" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-1080x675.png?crop=1" alt="Modelling study: 100 Days Mission demands vaccine equity" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-17T115800.553-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/modelling-study-100-days-mission-demands-vaccine-equity/">Modelling study: 100 Days Mission demands vaccine equity</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 17, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/modelling-study-100-days-mission-demands-vaccine-equity/#respond">0 comments</a></span></p><p><span data-contrast="auto">A study in </span><a href="https://www.thelancet.com/journals/langlo/article/PIIS2214-109X(24)00286-9/fulltext" target="_blank" rel="noopener"><i><span data-contrast="auto">The Lancet Global Health </span></i></a><span data-contrast="auto">estimates the impact that the 100 Days Mission could have had on the COVID-19 pandemic. The authors find that the implementation of non-pharmaceutical interventions (NPIs) within the 100 Days Mission could have averted around 8.33 million deaths, corresponding to a monetary saving of US$14.35 trillion. Investment in manufacturing and health systems contribute an increase to 11.01 million deaths averted. The researchers comment on the value of the 100 Days Mission but emphasise the importance of “prioritising a more equitable global vaccine distribution”. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">In search of greater vaccine benefits </span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Although COVID-19 vaccines are estimated to have prevented almost 20 million deaths, the authors demand a better understanding of the “further health and economic benefits that could have been achieved” through shorter development times and “improved global equity in pandemic preparedness”. <a href="https://cepi.net/cepi-20-and-100-days-mission" target="_blank" rel="noopener">CEPI’s 100 Days Mission</a> was proposed in 2021, establishing the ambition of cutting vaccine development time for new pathogens to 100 days. This about a third of the time taken to deliver the first COVID-19 vaccine. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The availability of COVID-19 vaccines within 100 days would have substantially changed the pandemic; however, these benefits would be finite without enabling equitable access to vaccine products through system equity.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Various efforts to encourage global vaccine distribution were “hampered” by inequities, and it is recognised that manufacturing capacity should be “expanded but also diversified” to “promote self-sufficiency and regional resilience”. Furthermore, supply chains and infrastructure must be scaled to enable the delivery of vaccines that rely on cold-chain infrastructure. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">The study</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The searchers hoped to quantify the potential impact of the 100 Days Mission by retrospectively estimating the effect it would have had on the COVID-19 pandemic, thus offering evidence to support decision making around future investments in research and development capabilities. They also aimed to quantify the impact of “additional investments”. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The analyses use an extended version of a previously published compartmental susceptible-exposed-infectious-recovered transmission model of COVID-19 vaccination with an explicit healthcare pathway. The vaccination pathway was expanded to include booster vaccination alongside waning efficacy, capturing the “restoration of immunity” through booster doses. The new vaccination pathway was parameterised to match platform-specific vaccine efficacy data and the duration of protection. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The authors modelled the impact of the 100 Days Mission by simulating a counterfactual scenario where the global vaccination campaign began on 20th April 2020, 100 days after the publication of the full SARS-CoV-2 genome. This scenario assumes that vaccinations in each country took the same roll-out process, but 232 days earlier. Two additional scenarios reflected “increased investment” in research and delivery infrastructure. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">The Manufacturing scenario removed supply constraints, enabling the rollout of vaccination on 20</span><span data-contrast="auto">th</span><span data-contrast="auto"> April 2020 in every country, without stockouts. The infrastructure-equity scenario enhanced both national health systems and global distribution networks so that all countries achieved 40% vaccine coverage in the first year and 40% booster coverage in the second year. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">To account for the relaxing of non-pharmaceutical interventions (NPIs), the authors simulated three scenarios for NPI relaxation speeds as vaccination coverage improved. The History scenario assumed no changes, whereas the Target and Economic scenarios assumed earlier relaxing; the Target scenario lifted all restrictions over two months after reaching more than 80% adult coverage in high-income countries or more than 80% coverage in those older than 60 in other countries. The Economic scenario lifted NPIs more gradually after reaching the over-60 target, prioritising the reopening of schools. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">Study findings</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">The results suggest that the 100 Days Mission could have averted an additional 8.33 million deaths due to COVID-19 by the end of 2021 when combined with the History NPI lifting scenario. In this scenario, an estimated 26.72 million severe cases of COVID-19 requiring hospitalisation and 1/44 billion infections would have been averted. Most of these averted deaths, hospitalisations, and infections would have occurred in low- and middle-income countries (LMICs). </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">The estimated VSLs (value of a statistical life) that could have been saved by the 100 Days Mission through the History scenario is US$22.61 trillion globally. As VSLs are “significantly higher” in HICs, 57% of the global value of statistical life averted occurred in HICs, even though most deaths would have been averted in LMICs. To estimate the monetary values associated with lives saved the authors multiplied the number of lives saved by the country-specific monetary VSL and by the value of a statistical life-year (VSLY). </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Increased investment in both global manufacturing and health systems infrastructure further increases the number of deaths that could be averted and the associated health-economic savings.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">In the 100 Days Mission with both manufacturing and health systems investments, an estimated 11.01 million deaths could have been averted and a value of $31.29 trillion in statistical lives saved. However, the authors describe this scenario as “unlikely”. In all scenarios involving the relaxing of NPIs thanks to earlier availability of vaccines, additional lives would have been saved. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">In the Target NPI lifting scenario, an estimated 5.76 million deaths (100 Days Mission alone) to 9.20 million deaths (100 Days Mission with both manufacturing and infrastructure investments) could have been averted. In these scenarios, 12,600 and 23,900 fewer days of NPIs would have been implemented globally: 70 days and 133 days on average per country. Under the Economic scenario there were “similar trade-offs between public health and economic gains”. The public health and health economic outcomes would be greater than under the Target scenario, but still lower than the History scenarios. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">Substantial benefits</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <blockquote> <h6><span data-contrast="auto">“Earlier access to COVID-19 vaccines could have had substantial benefits.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Most of the estimated averted deaths would have been concentrated in LMICs, but this demands investments in vaccine research, supported by “improvements to manufacturing and health system infrastructures”. With these investments, the authors estimate that 11 million deaths could have been prevented globally. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Although NPIs were effective at reducing transmission they incurred “significant economic and societal costs”, including consequences for education. Therefore, a major benefit of earlier access to vaccination is the reduction in school closures; in the Economic scenario, prioritising school opening could have averted 1,120 weeks of full school closures and 2,490 of partial school closures. This represents an average of 6 weeks of fully open schools and 14 weeks of partly open schools per country. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Reopening schools and relaxing NPIs safely will crucially require scaling up both vaccine delivery infrastructure and manufacturing. Without addressing both aspects, advancements in vaccine development speed might not translate into equitable benefits globally.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">The results emphasise the importance of investments in support of the 100 Days Mission in controlling a future potential pandemic, with benefits for both health and economy. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The 100 Days Mission is ambitious, requiring global innovation through creating vaccine libraries, clinical trial networks, accelerated immune response marker identification, rapid vaccine manufacturing, and strengthened global disease surveillance.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">CEO of CEPI, Dr Richard Hatchett, <a href="https://cepi.net/100-days-save-eight-million-lives" target="_blank" rel="noopener">hopes</a> that this research will encourage global commitment to the 100 Days Mission.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“This work shows in the starkest terms why the world needs to be prepared to move faster and more equitably when novel pandemic disease threats emerge. Investing in preparedness now to make the 100 Days Mission possible for future incipient pandemics will save millions upon millions of lives and protect the global economy against catastrophic losses.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto"><a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">Join us at the Congress in Barcelona this month</a> to explore how lessons from the COVID-19 pandemic can inform better global preparedness for pandemic and epidemic pressures, and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here.</a> </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </article> <article id="post-8728" class="et_pb_post post-8728 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-access tag-agreement tag-collaboration tag-countermeasures tag-diagnostics tag-equity tag-global-health tag-government tag-outbreak tag-pandemic tag-pandemic-preparedness tag-policy tag-preparedness tag-public-health tag-resilience tag-resources tag-response tag-vaccine tag-vaccines tag-who"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/parliamentarians-support-pandemic-agreement-efforts/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-1080x675.png?crop=1" alt="Parliamentarians support Pandemic Agreement efforts" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-1080x675.png?crop=1" alt="Parliamentarians support Pandemic Agreement efforts" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T142632.006-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/parliamentarians-support-pandemic-agreement-efforts/">Parliamentarians support Pandemic Agreement efforts</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 16, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/parliamentarians-support-pandemic-agreement-efforts/#respond">0 comments</a></span></p><p><span data-contrast="auto">In October 2024, parliamentarians from across the world met at the <a href="https://www.unitenetwork.org/the-unite-global-summit/" target="_blank" rel="noopener">UNITE Global Summit</a> in Berlin to sign a statement in support of the WHO Pandemic Agreement. The statement was <a href="https://www.who.int/news/item/16-10-2024-parliamentarians-unite-in-berlin-to-sign-global-statement-supporting-the-who-pandemic-agreement" target="_blank" rel="noopener">described by WHO</a> as a “significant commitment” to “strengthen pandemic preparedness, response, and equitable access to health”. The Summit was held in collaboration with the World Health Summit (WHS), drawing global parliamentarians, civil society leaders, and health experts to “translate discussions into actionable policy priorities”.</span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Building trust for a healthier world</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto"><a href="https://www.worldhealthsummit.org/" target="_blank" rel="noopener">The World Health Summit 2024</a> was held under the theme “building trust for a healthier world”, focussing on inspiring “innovative solutions for better health and well-being for all”. The UNITE Global Summit agenda reflected key topics highlighted during WHS, divided into four pillars:</span><span data-ccp-props="{}"> </span></p> <ol> <li><span data-contrast="auto">Human rights and equitable access to health</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Global health architecture and security</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Strengthening of healthcare systems</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Sustainable financing for health</span><span data-ccp-props="{}"> </span></li> </ol> <h5><span data-contrast="auto">Support for the Pandemic Agreement</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The Pandemic Agreement is <a href="https://vaccinenation.org/global-health/who-progress-on-pandemic-agreement-negotiations/" target="_blank" rel="noopener">under negotiation</a> by WHO Member States as an attempt to address the “gaps” exposed by the COVID-19 pandemic and the threats presented by mpox and other disease outbreaks. It also seeks to “strengthen global collaboration pandemic prevention, preparedness, and response”. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">A critical moment during the summit was the signing of the Global Parliamentary Statement in Support of the Pandemic Agreement, which demonstrated the importance of parliamentarians in “ensuring global health security and safeguarding populations against future pandemics”. The statement emphasised their commitment to ensuring that “all countries, regardless of resources, have access to the tools, capacities, resources, and healthcare required” during a pandemic. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Dr Ricardo Baptista Leite, President of UNITE, commented that parliamentarians are the “voice of the people” and carry a “crucial responsibility in safeguarding public health”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The WHO Pandemic Agreement represents a historic opportunity to prevent pandemics and strengthen our global preparedness and response capabilities. By signing this statement, we are not only showing our support for the agreement but also pledging to ensure that its principles of equity, solidarity, and global cooperation are fully realised in every nation.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">WHO Director-General Dr Tedros Adhanom Ghebreyesus welcomed the support for the “once-in-a-generation opportunity to build a stronger, fairer, and more prepared global health system”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“By signing this statement, parliamentarians from around the world are showing their commitment to protecting lives from future pandemics and ensuring equitable access to vaccines, treatments, diagnostics, and other health tools for every country, particularly those with fewer resources.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <h5><span data-contrast="auto">Key commitments</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The Global Parliamentary Statement emphasises four “key commitments”:</span><span data-ccp-props="{}"> </span></p> <ol> <li><span data-contrast="auto">Equity at the core – ensuring equitable access to pandemic-related health tools based on public health need for everyone, especially countries with fewer resources</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Global solidarity – strengthening international cooperation to build resilient health systems that can prevent and respond to pandemics</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Legislative action – advocating for the ratification and implementation of the Pandemic Agreement within national legislatures, as appropriate</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Combating misinformation – providing communities with evidence-based health information to counter the spread of harmful misinformation</span><span data-ccp-props="{}"> </span></li> </ol> <p><span data-contrast="auto">Dr Baptista Leite reflected that “the challenges we face today demand a global response”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“No single country can prevent or combat pandemics alone. The WHO Pandemic Agreement is an essential step forward in ensuring that every nation has the tools, resources, and capabilities to respond to future health threats.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <h5><span data-contrast="auto">More work to be done</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">WHO states that the Pandemic Agreement “needs to continue to garner broad international support”. Within the latest commitment, parliamentarians are to work with WHO and other international organisations to ensure the Pandemic Agreement is implemented in a way that “benefits all countries”, particularly those with “limited resources”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The statement signed in Berlin is expected to act as a catalyst for global parliamentary action, fostering collaboration and solidarity among nations.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto"><a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">Join us at the Congress in Barcelona this month</a> for a keynote discussion on “strengthening global preparedness and building resilient health systems” with experts from the field, and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>.</span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8723" class="et_pb_post post-8723 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-100-days-mission tag-access tag-antigen tag-cepi tag-collaboration tag-development tag-funding tag-global-health tag-lmic tag-manufacture tag-manufacturing tag-production tag-protein tag-scale tag-speed tag-technology tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/cepi-and-nrc-work-on-safe-protein-antigens-faster/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-1080x675.png?crop=1" alt="CEPI and NRC work on safe protein antigens, faster" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-1080x675.png?crop=1" alt="CEPI and NRC work on safe protein antigens, faster" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T114751.682-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/cepi-and-nrc-work-on-safe-protein-antigens-faster/">CEPI and NRC work on safe protein antigens, faster</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 16, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/cepi-and-nrc-work-on-safe-protein-antigens-faster/#respond">0 comments</a></span></p><p><span data-contrast="auto">CEPI <a href="https://cepi.net/canadian-scientists-optimise-vaccine-process-faster-outbreak-response-0" target="_blank" rel="noopener">announced</a> in October 2024 that it is working with experts at the National Research Council of Canada (NRC) to bioengineer a “commonly used approach” to safely make protein antigens in “as little as two weeks”. This would be between eight and twelve times faster than the current timeline of antigen production for protein-based vaccines. CEPI is contributing up to CAD $850,000 and the NRC is providing up to CAD $308,000 (in kind) to establish proof-of-technology. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Low cost and high speed</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">CEPI notes the importance of manufacturers being able to make “sufficient quantities” of vaccine components at low cost to enable mass production. Although mammalian cell lines are a common choice for vaccine processes, boasting ease of culture and a high production yield, they can take four to six months to develop and optimise for antigen production. This is a “major challenge” to efforts to develop vaccines quickly in response to fast-spreading viral outbreaks. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">An optimised approach</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Scientists at the NRC have developed a mammalian cell line that could be optimised for rapid antigen production. The research is expected to “majorly accelerate” the time needed for infectious disease vaccine development, says CEPI’s Executive Director of Manufacturing and Supply Chain (Acting), Ingrid Kromann. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“If successful, this optimised cell line could help vaccine doses be more rapidly available for clinical trials and initial emergency use during future outbreaks, supporting CEPI’s goal – embraced by Canada, and other G7 and G20 nations – to respond to a novel virus with a new vaccine in just 100 days after its discovery.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Importantly, the technology is going to be suitable for transfer to low- and middle-income countries, enabling “local and rapid” vaccine production closer to the source of a future outbreak and improving accessibility. Dr Lakshmi Krishnan, Vice President of Life Sciences at the NRC, looks forward to working with CEPI to take the platform technologies forward to “accessible tools that could help accelerate vaccine production around the world”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Recognising the critical need for rapid vaccine production during a health emergency, this research and development project in our labs will advance innovative technologies to improve biomanufacturing processes and increase the efficiency of large-scale manufacturing of vaccines and other biologics.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">For the latest in vaccine technology for improved accessibility, <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">join us at the Congress in Barcelona this month</a>, and don’t forget to<a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener"> subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8718" class="et_pb_post post-8718 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-algorithm tag-cancer tag-cancer-research tag-cancer-vaccine tag-machine-learning tag-neoantigen tag-personalised tag-research tag-study tag-technology tag-therapeutic tag-therapy tag-tumour tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/neodisc-pipeline-enables-personalised-cancer-immunotherapy/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-1080x675.png?crop=1" alt="NeoDisc pipeline enables personalised cancer immunotherapy" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-1080x675.png?crop=1" alt="NeoDisc pipeline enables personalised cancer immunotherapy" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-16T105100.900-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/neodisc-pipeline-enables-personalised-cancer-immunotherapy/">NeoDisc pipeline enables personalised cancer immunotherapy</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 16, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/neodisc-pipeline-enables-personalised-cancer-immunotherapy/#respond">0 comments</a></span></p><p><span data-contrast="auto">A paper in </span><a href="https://www.nature.com/articles/s41587-024-02420-y#Abs1" target="_blank" rel="noopener"><i><span data-contrast="auto">Nature Biotechnology </span></i></a><span data-contrast="auto">in October 2024 presents an “end-to-end clinical proteogenomic pipeline” to address the challenges associated with identification and prioritisation of antigenic peptides. NeoDisc combines “state-of-the-art publicly available and in-house software” with in silico tools to identify, predict, and prioritise tumour-specific and immunogenic antigens from multiple sources. The authors demonstrate the pipeline’s superiority over recent prioritisation pipelines and showcase the features that enable “both rule-based and machine-learning approaches”. They also reveal how NeoDisc’s multiomics integration identifies “defects in the cellular antigen presentation machinery”. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Antigen discovery</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The researchers comment on the importance of personalised antigen discovery for the development of cancer vaccines. Common approaches for translational research and clinical trials include whole-genome sequencing (WGS) or whole-exome sequencing (WED) and RNA sequencing (RNAseq). However, the recent application of mass spectrometry (MS) to identify HLA-bound peptides and the use of proteogenomics have “facilitated the exploration of novel targets from a variety of antigens naturally processed and presented in cancer”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Their identification is laborious and current clinical pipelines do not support immunopeptidomics and are restricted to predicted neoantigens.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Although immunotherapies are “remarkably effective” against some indications, “robust immune pressure” can force immune editing. Therefore, it is “essential” to understand the heterogenous antigenic landscape and the tumour’s capacity to present antigens. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">The study</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">In the study, the authors introduce an “end-to-end” clinical antigen discovery proteogenomic pipeline: NeoDisc. It compiles publicly available and in-house software for the identification of immunogenic tumour-specific HLA-I and HLA-II antigens from genomics and transcriptomics and MS-based immunopeptidomics and enables their prediction and prioritisation with rule-based and machine-learning (ML) tools. It allows assessment of tumour heterogeneity and the functionality of the antigen processing and presentation machinery (APPM). The study compares NeoDisc’s performance with other tools, demonstrating its application for personalised antigen discovery and clinical implementation. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">NeoDisc is a “dedicated computational framework” combining genomic, transcriptomic, and immunopeptidomic data and integrating curated public databases of known immunogenic TSAs, TAAs, oncoviral elements, and noncanonical transcripts. It uses matched tumour and germline genomic data for sample-specific variant characterisation, tumour content estimation, and copy number variation (CNV) and somatic mutation (SM) identification. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Four variant-calling algorithms are applied to WES and WGS data; variants that are detected by two or more callers are considered to have “high identification confidence”. Although highly mutated tumours usually respond better to immunotherapy, the selection of immunogenic neoantigens among “numerous possibilities” is “challenging”. Recent screening of large datasets of neoantigens in tumours from 112 participants has allowed the training of ML for prioritisation. ML classifiers trained on a fraction of this dataset have been integrated into NeoDisc to ensure “effective prioritisation”. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">When NeoDisc’s rule-based and ML ranking approaches were compared with existing tools, the ML prioritisation algorithm “surpassed all the evaluated tools”. The researchers demonstrated NeoDisc’s “efficient prioritisation” on a cervical adenocarcinoma (CESC-1) characterised by an “exceptionally high mutational burden” (25 SMs per Mb). </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Of the 393 identified actionable mutations, representing a pool of 19,051 peptides with a predicted binding rank </span><span data-contrast="none">≤</span><span data-contrast="auto">2%, 66 HLA-I neoantigenic short peptides (minimal epitopes) were selected through rule-based prioritisation for T cell screening of autologous tumour-infiltrating lymphocytes (TILs) by </span><span data-contrast="none">IFNγ ELISpot. </span><span data-contrast="auto">11 of the 66 peptides were immunogenic, including two that “ranked among the top ten candidates”. The NeoDisc ML model reordered the tested neoantigens, resulting in an “impressive” ranking of six immunogenic peptides in the top ten. NeoDisc also successfully identified two confirmed immunogenic neoantigens in the CESC-1 tumour MS immunopeptidomic data. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Personalised vaccines</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">While the default NeoDisc settings “exhibit good performance”, biopsies with low tumour content and low mutation burden could result in the detection of an “insufficient number of actionable high-confidence expressed mutations”. This would lead to a “suboptimal vaccine”. Thus, NeoDisc offers two additional modes:</span><span data-ccp-props="{}"> </span></p> <ol> <li><span data-contrast="auto">“Sensitive mode” considers the union of mutations called by all four variant-calling tools, to be used when an insufficient number of mutations are detected.</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">“Panel mode” uses mutations listed in the available diagnostic clinical gene panel (GP) as input, allowing the design of vaccines for persons lacking dedicated biopsies. Note that GPs “often provide insufficient number of mutations leading to suboptimal lists of neoantigens or potentially none”. </span><span data-ccp-props="{}"> </span></li> </ol> <p><span data-contrast="auto">The paper states that, in cancer vaccines, long sequences are favoured over minimal short peptides, motivated by the “efficient uptake and processing by APCs”. The NeoDisc ML tool ranks mutations according to their potential immunogenicity. Long sequences are “optimally” designed through maximised coverage of high-quality predicted HLA-I and HLA-II neoantigens.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">In use in the field</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">NeoDisc is already being used in Phase I clinical trials for personalised cancer vaccines and adoptive T cell therapies in Switzerland; the authors hope that these demonstrate its “practical utility and potential for clinical translation”. Dr Michal Bassani-Sternberg of the Lausanne Branch of the Ludwig Institute for Cancer Research <a href="https://www.ludwigcancerresearch.org/news-releases/an-ai-powered-pipeline-for-personalized-cancer-vaccines/" target="_blank" rel="noopener">comments</a> that NeoDisc provides “invaluable” insights into the immunobiology of tumours and the “mechanisms by which they evade targeting by cytotoxic T cells”. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Notably, NeoDisc can also detect potential defects in the machinery of antigen presentation, alerting vaccine designers and clinicians to a key mechanism of immune evasion in tumours that can compromise the efficacy of immunotherapy. This can help them select patients for clinical studies who are likely to benefit from personalised immunotherapy, a capability that is also of great importance to optimising patient care.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Florian Huber, first author, also reflected on the significance of this research.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“NeoDisc can detect all these distinct types of tumour-specific antigens along with neoantigens, apply machine learning and rule-based algorithms to prioritise those most likely to elicit a T cell response, and then use that information to design a personalised cancer vaccine for the relevant patient.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto"><a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">Join us at the Congress in Barcelona this month</a> to hear from experts in the Cancer and Therapeutic Vaccines track on their approaches to personalised vaccine development, and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </article> <article id="post-8710" class="et_pb_post post-8710 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-clinical-trial tag-clinical-trials tag-collaboration tag-diversity tag-equity tag-network tag-patient tag-research tag-study tag-technology tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/panthera-joins-parexels-site-alliance-vaccine-network/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-1080x675.png?crop=1" alt="Panthera joins Parexel’s Site Alliance Vaccine Network" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-1080x675.png?crop=1" alt="Panthera joins Parexel’s Site Alliance Vaccine Network" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T140525.767-1-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/panthera-joins-parexels-site-alliance-vaccine-network/">Panthera joins Parexel’s Site Alliance Vaccine Network</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 15, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/panthera-joins-parexels-site-alliance-vaccine-network/#respond">0 comments</a></span></p><p><span data-contrast="auto">In October 2024, Panthera Biopartners <a href="https://www.panthera-bio.com/panthera-to-join-parexel-site-alliance-vaccine-network/" target="_blank" rel="noopener">announced</a> that Parexel has confirmed its inclusion in the Parexel Site Alliance Vaccine Network. Panthera becomes the first UK public or commercial clinical trial organisation to join the global network of high performing clinical trial sites. Parexel’s Site Alliance Vaccine Network “fosters long-term collaborative relationships” with research organisations across the globe to “deliver efficiencies”. Panthera was chosen to join the Network because of “exceptional performance in recruiting patients” across “numerous” studies and an existing “strong working relationship” with Parexel. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">Patient recruitment</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">As the “UK’s largest recruiter and runner of commercial clinical trials across its UK sites”, Panthera has recently been the top recruiter globally in four studies, the top recruiter in the UK in six studies, and achieved first patient in globally or in the UK in nine studies. The company statement acknowledges that “less than 10%” of physicians and patients participate in clinical research. Among patients who do participate, “minority groups are significantly underrepresented”. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Research activities are often concentrated in academic institutions and investigator sites, so patients and their providers are often unaware of the work, and even if they’re interested, many lack the time and resources required to join studies.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Site Management Organisations (SMOs) like Panthera are focussed “entirely” on recruiting patients and running clinical trials, collaborating with local GP practices and using targeted advertising and social media campaigns to ensure that “all sections of the community” can participate. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">Delivering efficiencies</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto"><a href="https://www.parexel.com/solutions/early-development-and-innovation/site-alliance-network-and-kol-engagement" target="_blank" rel="noopener">The Parexel Site Alliance Network</a> engages more than 340 sites and 16,000 investigators in “long-term collaborative relationships”. It is intended to “deliver efficiencies” to patients, sites, and customers. Members partner with Parexel to improve research and patient experiences. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Chris Dodd, Chief Commercial Officer at Panthera, described the company’s selection as a “testament to the effort we have put in to ensure we meet or exceed our patient recruitment targets”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“We are delighted to be working in partnership with such a successful organisation with such great site communications and stakeholder management. We look forward to working together to bring even more clinical research to the UK.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto"><a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">Join us at the Congress in Barcelona</a> to explore ways in which the whole vaccine value chain can contribute to greater diversity in research and improved participant experiences. Don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>.</span></p> </article> <article id="post-8705" class="et_pb_post post-8705 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-adverse-events tag-authorisation tag-covid-19 tag-global-health tag-infection tag-mrna tag-pandemic tag-research tag-risk tag-safety tag-study tag-vaccination tag-vaccine tag-viral-vector"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/study-highlights-facial-palsy-link-to-covid-19-vaccines/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-1080x675.png?crop=1" alt="Study highlights facial palsy link to COVID-19 vaccines" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-1080x675.png?crop=1" alt="Study highlights facial palsy link to COVID-19 vaccines" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-15T113122.637-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/study-highlights-facial-palsy-link-to-covid-19-vaccines/">Study highlights facial palsy link to COVID-19 vaccines</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 15, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/study-highlights-facial-palsy-link-to-covid-19-vaccines/#respond">0 comments</a></span></p><p><span data-contrast="auto">A study in </span><a href="https://wwwnc.cdc.gov/eid/article/30/11/24-0610_article" target="_blank" rel="noopener"><i><span data-contrast="auto">Emerging Infectious Diseases </span></i></a><span data-contrast="auto">explores the association between COVID-19 vaccination and facial palsy (FP) in South Korea. The authors use an immunisation registry linked to the national health information database to compare FP incidence in a risk window with a control window. They found an increased FP risk within 28 postvaccination, primarily after first and second doses of both mRNA and viral vaccines. They encourage clinicians to “carefully assess” the FP risk-benefit profile associated with COVID-19 vaccines and monitor neurologic signs after vaccination. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Risk of facial palsy</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Although no severe safety concerns were observed during the clinical trials of COVID-19 vaccines, an “imbalance” in facial palsy (FP) incidence after vaccination was identified in vaccinated persons compared to the general population. The aetiology of FP “remains elusive”, but autoimmune mechanisms or vaccination are “considered potential contributors to its development”. FP is included in the priority list of adverse events of special interest generated by the Safety Platform for Emergency vACcines (SPEAC) because of its “sudden and acute symptom onset”. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Despite multiple studies on the association of FP with COVID-19, we lack a “clear consensus”. As these studies have produced “controversial and inconclusive results”, the authors identified a need to generate an “in-depth body of evidence and a clear consensus” on the subject. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">The study</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">The study uses two large, linked databases in South Korea to conduct a self-controlled case series analysis. It is intended to provide evidence on the safety of COVID-19 vaccines for immunisation under the COVID-19 Vaccine Safety Research Committee (CoVaSC) in South Korea. Several vaccines were available during the study period in South Korea:</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <ul> <li><span data-contrast="auto">BNT162b2 (Pfizer-BioNTech)</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></li> <li><span data-contrast="auto">mRNA-1273 (Moderna)</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></li> <li><span data-contrast="auto">ChAdOx1 nCoV-19 (AstraZeneca)</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></li> <li><span data-contrast="auto">Ad.26.COV2.S (Janssen)</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></li> <li><span data-contrast="auto">NVX-CoV2373 (Novavax)</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></li> </ul> <p><span data-contrast="auto">The researchers identified persons aged 18 and older who received an initial COVID-19 vaccine dose between 26</span><span data-contrast="auto">th</span><span data-contrast="auto"> February 2021 and 1</span><span data-contrast="auto">st</span><span data-contrast="auto"> March 2022. Among this population, they identified and included patients with a primary FP diagnosis accompanied by a prescription for corticosteroids between 26</span><span data-contrast="auto">th</span><span data-contrast="auto"> February 2021 and 31</span><span data-contrast="auto">st</span><span data-contrast="auto"> October 2022; patients who had received a COVID-19 vaccination and had incident FP diagnosed within a prespecified observation period were also included. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Exclusion criteria included foreign born residents, participants in clinical trials, persons vaccinated abroad, and persons deviating from vaccination guidelines to account for potential exposure misclassification. Persons with a history of FP in the year preceding the observation period and those whose FP cases occurred after the end of the observation period were excluded.</span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">44,564,345 persons in South Korea were administered 129,956,027 COVID-19 vaccines doses between 26</span><span data-contrast="auto">th</span><span data-contrast="auto"> February 2021 and 1</span><span data-contrast="auto">st</span><span data-contrast="auto"> March 2022. During the study period, 15,472 FP cases with corticosteroid prescriptions were identified. Among these, 5,211 occurred up to 28 days postvaccination: 4.0 GP cases/1 million doses. Among the FP study population, the mean age at first COVID-19 vaccination was 53.1 years. 54.7% were male and 45.3% were female. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">The study showed FP risk increased within 1-28 days after any COVID-19 vaccine dose. Increased FP risks were observed with the second dose and combined first and second doses, but no association was found for the third dose. The increased FP risk was identified across vaccine types. The incidence rate ratios (IRR) were “generally consistent” across age groups and, after application of the Benjamini-Hochberg adjustment, “generally remained consistent” across sex. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Implications</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The findings of this study add to growing evidence of a positive association between FP and COVID-19 vaccination. The exact biological mechanism for the development of FP after vaccination remains unknown. However, “plausible links” between FP and mRNA and viral vector vaccines have been proposed. The study revealed increased FP risk in persons homologously vaccinated with mRNA vaccines, especially for BNT162b2 and in those with at least a single dose of mRNA vaccine. Furthermore, it revealed elevated risks among patients who received homologous dosing of viral vector vaccines.</span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">An important consideration is the suggested link between COVID-19 infection itself and FP onset. In South Korea, the annual incidence of Bell’s palsy increased from 23.0 to 30.8 cases per 100,000 persons from 2008 and 2018. It reached 32.5 cases per 100,000 persons during 2021-2022, which suggests an increasing trend during the pandemic. Additionally, a study in South Korea indicated that COVID-19 infection is associated with a higher risk for Bell’s palsy for both COVID-19 vaccine recipients and nonrecipients. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“In conclusion, our study revealed a transient risk for FP after any dose of COVID-19 vaccine.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">The authors note that, although the risk for FP “appears elevated”, the absolute number of cases was “small”. Risk for FP should therefore not discourage patients from receiving COVID-19 vaccinations.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Because FP is generally mild and manageable, physicians should monitor neurologic signs after COVID-19 vaccination and provide patients with a comprehensive evaluation of the risk-benefit profile associated with COVID-19 vaccines.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto"><a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">Join us at the Congress in Barcelona this month</a> to explore the processes by which vaccine safety is evaluated and monitored after rollout, and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8700" class="et_pb_post post-8700 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-africa tag-africa-cdc tag-animal tag-cepi tag-climate-change tag-endemic tag-funding tag-global-health tag-human tag-infection tag-infectious-disease tag-livestock tag-lmic tag-mosquito tag-mosquito-borne tag-one-health tag-outbreak tag-oxford tag-partnership tag-research tag-rift-valley-fever tag-trial tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/promising-rift-valley-vaccine-enters-phase-ii-in-kenya/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-1080x675.png?crop=1" alt="“Promising” Rift Valley vaccine enters Phase II in Kenya" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-1080x675.png?crop=1" alt="“Promising” Rift Valley vaccine enters Phase II in Kenya" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T155321.416-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/promising-rift-valley-vaccine-enters-phase-ii-in-kenya/">“Promising” Rift Valley vaccine enters Phase II in Kenya</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 14, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/promising-rift-valley-vaccine-enters-phase-ii-in-kenya/#respond">0 comments</a></span></p><p><span data-contrast="auto">Phase II trials of a “promising” human vaccine candidate against Rift Valley fever are beginning in Kenya with CEPI support. CEPI <a href="https://cepi.net/promising-human-rift-valley-fever-vaccine-enter-phase-ii-clinical-trials-kenya" target="_blank" rel="noopener">reported</a> in October 2024 that this is the “most advanced stage of testing” for a human Rift Valley fever vaccine in an “outbreak-prone area”. Scientists at the University of Oxford and the Kenya Medical Research Institute (KEMRI)-Wellcome Trust Research Programme are leading the trial with $3.7 million funding from CEPI. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">Rift Valley fever</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">First identified in Kenya’s Rift Valley, Rift Valley fever is usually found in people after direct contact with infected animals or bites from infected mosquitoes. Most infected people experience “mild disease”, but a small proportion develop the “severe haemorrhagic form”, with a risk of blindness, convulsions, encephalitis, and bleeding. In these cases, mortality rates can reach 50%. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Rift Valley fever has been detected across “much of Africa” and in the Middle East. It is mosquito-borne, which makes it “climate sensitive”. There is therefore a risk of outbreaks spreading to new areas or increasing in frequency or size. There are Rift Valley fever vaccines for animals, but no currently available or licensed vaccines for human use; the disease is a priority disease for R&D for WHO and CEPI. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <h5><span data-contrast="auto">ChAdOx1 RVF in trial</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">The vaccine, known as ChAdOx1 RVF, is based on the University of Oxford’s ChAdOx1 vaccine platform. It has <a href="https://vaccinenation.org/infection/chadox1-vaccine-for-rift-valley-fever-shows-promise-in-trial/" target="_blank" rel="noopener">shown positive results in healthy adults in the UK</a>, meeting “many of the optimal product characteristics” of a WHO target product profile. It is one of three Rift Valley fever candidates in CEPI’s portfolio. 240 healthy adults will participate in the research, following local trial approvals. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Funding for the trial comes under CEPI’s <a href="https://vaccinenation.org/technology/cepi-partners-with-oxford-funding-vaccines-for-disease-x/" target="_blank" rel="noopener">strategic partnership</a> with the University to accelerate the development of globally accessible vaccines against outbreak pathogens. Both organisations are “committed to enabling access to any vaccine outputs developed through this partnership”, including developing a target product profile suitable for low- and middle-income countries (LMICs), assessing the need for technology transfer, and priority supply to LMICs at an affordable price. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto">Professor George Warimwe, Principal Investigator of the trail and Deputy Executive Director of the KEMRI-Wellcome Trust Research programme, reflected that “nearly 100 years” after the disease was identified, there are “still no approved vaccines or treatments”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“This vaccine trial brings us closer to addressing the rising frequency of outbreaks.”</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Richard Hatchett, CEO of CEPI, commented that Rift Valley fever “disproportionately affects the lives and livelihoods of vulnerable pastoral communities”, causing human fatalities and livestock losses. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Investing in the promising human ChAdOx1 RVF vaccine diversifies CEPI’s portfolio and gives us a greater chance at protecting vulnerable populations against this worrisome threat that may become more prevalent with climate change.” </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Director General of Africa CDC, H.E. Dr Jean Kaseya, agreed that the disease “leads to livestock losses and human fatalities, thus impoverishing communities who largely depend on livestock for their livelihood”.</span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The launch of a Phase II clinical trial of a Rift Valley fever vaccine candidate in an endemic country is a crucial milestone in our efforts to control this disease. Africa CDC is proud to support this initiative that not only prioritises the health of our people but also demonstrates the continent’s growing leadership in advancing clinical research.” </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Kaseya stated that the ChAdOx1 RVF vaccine “offers hope to vulnerable populations” who are “disproportionately affected by the growing impact of climate change”. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> <p><span data-contrast="auto"><a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">Join us at the Congress in Barcelona later this month</a> to explore efforts to address the growing challenges of climate change and infectious disease with vaccine development and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></p> </article> <article id="post-8695" class="et_pb_post post-8695 post type-post status-publish format-standard has-post-thumbnail hentry category-therapeutic tag-antigen tag-cancer tag-cervical tag-cervical-cancer tag-combination tag-efficacy tag-hpv tag-research tag-results tag-strategy tag-study tag-technology tag-therapeutic tag-therapy tag-vaccine"> <a class="entry-featured-image-url" href="https://vaccinenation.org/therapeutic/transgene-shares-disappointing-tg4001-study-update/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-1080x675.png?crop=1" alt="Transgene shares “disappointing” TG4001 study update" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-1080x675.png?crop=1" alt="Transgene shares “disappointing” TG4001 study update" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T150035.745-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/therapeutic/transgene-shares-disappointing-tg4001-study-update/">Transgene shares “disappointing” TG4001 study update</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 14, 2024</span> | <a href="https://vaccinenation.org/category/therapeutic/" rel="category tag">Therapeutic</a> | <span class="comments-number"><a href="https://vaccinenation.org/therapeutic/transgene-shares-disappointing-tg4001-study-update/#respond">0 comments</a></span></p><p><span data-contrast="auto">Transgene <a href="https://www.transgene.fr/en/press-releases/" target="_blank" rel="noopener">announced</a> in October 2024 that the primary objective of its randomised Phase II study of TG4001 has not been met. The study was evaluating TG4001 in combination with avelumab versus avelumab alone in patients with recurrent or metastatic HPV16-positive cervical and anogenital tumours. The primary objective was improvement in progression-free survival. Although this failure is “disappointing” to the company, Transgene states that it is evaluating the full results to “determine the best way forward”.</span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">TG4001</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Transgene’s <a href="https://www.transgene.fr/en/tg4001/" target="_blank" rel="noopener">TG4001</a> is an “innovative therapy capable of combating papillomavirus-induced cancers”. It teaches the immune system to identify and destroy the cancer cells expressing HPV-16 antigens, specifically E6 and E7. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Results and implications </span><span data-ccp-props="{"134233117":false,"134233118":false,"201341983":0,"335551550":1,"335551620":1,"335559685":0,"335559737":0,"335559738":0,"335559739":160,"335559740":279}"> </span></h5> <p><span data-contrast="auto">The pre-planned subgroup analysis showed a positive efficacy trend in favour of the TG4001-containing regiment in cervical cancer patients. However, this requires further confirmation through additional analyses. These patients account for around half of the total patients enrolled in the study. Treatment was well tolerated, with adverse events “consistent” with previous observations. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Transgene is currently evaluating the full study results in detail to determine the best way forward for this programme and will communicate further once this is completed.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Alessandro Riva, Chair and CEO of Transgene, acknowledged that “failure to meet the primary objective in our Phase II study with TG4001 is disappointing”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Nevertheless, we are encouraged by the positive efficacy trend in favour of the combination regiment in cervical cancer patients. We plan to complete a full and rigorous analysis of the data before deciding on any path forward for this asset.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Riva thanked patients and caregivers for their “important contribution” to the study.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“With a diversified portfolio of novel immunotherapies targeting solid tumours, our strategy remains focussed on advancing our lead asset, TG4050, an individualised cancer vaccine for head and neck cancers for use following surgery and adjuvant therapy.” </span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">For the latest cancer vaccine research updates don’t forget to <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">get your ticket to the Congress in Barcelona this month</a> and <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8690" class="et_pb_post post-8690 post type-post status-publish format-standard has-post-thumbnail hentry category-global-health tag-access tag-africa tag-development tag-equity tag-europe tag-finance tag-funding tag-global-health tag-health tag-infectious-disease tag-public-health tag-resilience tag-technology tag-vaccine tag-vaccine-development"> <a class="entry-featured-image-url" href="https://vaccinenation.org/global-health/eib-global-supports-akagera-medicines-with-e2-million/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-1080x675.png?crop=1" alt="EIB Global supports Akagera Medicines with €2 million" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-1080x675.png?crop=1" alt="EIB Global supports Akagera Medicines with €2 million" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T120236.729-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/global-health/eib-global-supports-akagera-medicines-with-e2-million/">EIB Global supports Akagera Medicines with €2 million</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 14, 2024</span> | <a href="https://vaccinenation.org/category/global-health/" rel="category tag">Global Health</a> | <span class="comments-number"><a href="https://vaccinenation.org/global-health/eib-global-supports-akagera-medicines-with-e2-million/#respond">0 comments</a></span></p><p><span data-contrast="auto">In October 2024 the European Investment Bank (EIB Global) <a href="https://www.eib.org/en/press/all/2024-372-eib-global-backs-akagera-vaccine-development-in-rwanda" target="_blank" rel="noopener">announced</a> €2 million financing for early-stage vaccine development in Rwanda by Akagera Medicines Africa Limited. The support is intended to accelerate research, development, and manufacturing of new vaccines against infectious diseases like tuberculosis, HIV, Lassa fever, and Ebola. It will also be used to “strengthen technical skills and expertise” to support “home-grown discovery, manufacturing, and development of vaccine delivery systems” in Rwanda. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Global Gateway</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">This financing is part of the<a href="https://commission.europa.eu/strategy-and-policy/priorities-2019-2024/stronger-europe-world/global-gateway_en" target="_blank" rel="noopener"> EU Global Gateway</a> initiative, a strategy to “boost smart, clean, and secure links in digital, energy, and transport sectors and to strengthen health, education, and research systems”. Team Europe is mobilising up to €300 million between 2021 and 2027 to “allow EU’s partners to develop their societies and economies” whilst creating opportunities for EU Member States to “invest and remain competitive”. EIB Global supports “high impact investment” to enhance healthcare and pharmaceutical manufacturing, encourage greater “health resilience”, and support equitable access to healthcare. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">Continent-based solutions</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">EIB Global states that Africa bears the highest disease burden globally, demanding “more home-grown or continent-based solutions”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Vaccination is a critical activity to ensure and guide investments in universal health and has a crucial role to play in achieving 14 of the 17 United Nations Sustainable Development Goals.” </span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto"><a href="https://www.akageramedicines.com/" target="_blank" rel="noopener">Akagera Medicines</a> was founded in 2018 and registered a 100%-owned subsidiary in Kigali in 2022. Its <a href="https://www.akageramedicines.com/" target="_blank" rel="noopener">mission</a> is “targeting tuberculosis and other infectious diseases with liposomal nanotherapeutics”. Commenting on the financing announcement at the World Health Summit in Berlin, Chief Executive Officer Michael Fairbanks recognised the “significant support” of the European Investment Bank.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“We are now a clinical company and moving faster to build human capacity and specialised infrastructure in Africa to support vaccine development.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">CEO of the Rwanda Social Security Board (RSSB) Regis Rugemanshuro stated that the financial support is an “important contribution to the realisation of Rwanda’s vision to become a biotech hub” and the wider vision of “Africa becoming self-reliant in vaccine and medicine manufacturing”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“RSSB is looking forward to deepening partnerships with EIB and other international institutions to build resilient healthcare ecosystems in Rwanda and in Africa.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Vice President of EIB Thomas Ostros identified the Bank’s “close cooperation with public and private partners” to “accelerate development of innovative solutions”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The EIB is committed to further strengthening our partnership with local and international players, to scale up investment and support innovative technology together.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Belen Calvo Uyarra, EU Ambassador to Rwanda, agreed that the investment was another “important milestone”.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Through Global Gateway, the EU is focussed on advancing equitable access to health products and local manufacturing in Africa.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">For more from key players in efforts to establish local manufacturing capacities in Africa and champions of equitable access to health products, <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">join us at the Congress in Barcelona later this month</a>. Don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8685" class="et_pb_post post-8685 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-access tag-agreement tag-biotech tag-conjugate tag-funding tag-global-health tag-investment tag-partnership tag-protein tag-service tag-solution tag-technology tag-vaccine tag-vaccine-development tag-vaccine-technology"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/sk-bioscience-announces-3-million-investment-in-finabio/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-1080x675.png?crop=1" alt="SK bioscience announces $3 million investment in FinaBio" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-1080x675.png?crop=1" alt="SK bioscience announces $3 million investment in FinaBio" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-14T092150.567-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/sk-bioscience-announces-3-million-investment-in-finabio/">SK bioscience announces $3 million investment in FinaBio</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 14, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/sk-bioscience-announces-3-million-investment-in-finabio/#respond">0 comments</a></span></p><p><span data-contrast="auto">SK bioscience <a href="https://www.skbioscience.com/en/news/news_01_01?mode=view&id=276&" target="_blank" rel="noopener">announced</a> in October 2024 that it has signed an agreement to acquire a stake in Fina Biosolutions (FinaBio) with a $3 million investment. SK bioscience becomes FinaBio’s first and sole strategic investor with a goal of improving the immunogenicity and productivity of conjugate vaccines. This announcement is another example of SK bioscience’s investment in global companies to “create synergies in business” after <a href="https://vaccinenation.org/technology/sk-bioscience-completes-idt-biologika-acquisition/" target="_blank" rel="noopener">recently completing the acquisition of a controlling stake in IDT Biologika</a>. The company states that it is securing its “competitiveness” through strategic investments in “promising companies with exceptional technology” and M&As to “lay the foundation for a great leap forward into a leading global company”. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">FinaBio’s technology</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">Founded in 2006, FinaBio <a href="https://finabio.net/about-us/" target="_blank" rel="noopener">seeks</a> to “help emerging market vaccine manufacturers learn to make affordable protein polysaccharide conjugates for vaccines”. It is now a “premier provider” of laboratory and consulting services, specialising in the research and development of conjugate vaccines for pneumoniae, meningococcal, typhoid, and other diseases. One of FinaBio’s key assets is FinaXpress, a proprietary E. coli expression system, that can produce proteins not previously made in the bacteria, like the carrier protein CRM197. FinaBio has expanded access to this protein, marketed as <a href="https://finabio.net/crm197-2/" target="_blank" rel="noopener">EcoCRM</a>. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">FinaBio is also developing a next-generation conjugation technology that is site-specific and targets the desired location for antigen binding. This is intended to boost immunogenicity and productivity. Supplying conjugation technology and carrier proteins to various global biotech companies and institutions, FinaBio continues to expand its business units. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">A conjugate collaboration</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">SK bioscience will use FinaBio’s CRM197 technology in its efforts to “secure the high effectiveness of diverse conjugate vaccines while increasing profitability through high-yield processes”. CEO and President of SK bioscience Jaeyong Ahn is “delighted to continue developing partnerships with global firms that have next-generation vaccine technology”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Through our mid- to long-term collaboration with FinaBio, we will advance the vaccines we are developing to the next level and strengthen our competitiveness for global market expansion.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Andrew Lees, Founder and CEO of FinaBio, apprecitaes SK’s “confidence” in the organisation and support of accelerated global commercialisation of EcoCRM.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Combined with our efficient conjugation technology, this will enable the development of the next generation conjugate vaccines. It will also allow us to continue our mission of promoting affordable vaccines.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">We look forward to welcoming FinaBio back to the exhibition floor at the Congress in Barcelona later this month; <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">get your tickets to connect with their team there</a> and don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <article id="post-8681" class="et_pb_post post-8681 post type-post status-publish format-standard has-post-thumbnail hentry category-technology tag-broad tag-cepi tag-coronavirus tag-covid-19 tag-development tag-epidemic tag-funding tag-global-health tag-immunology tag-infectious-disease tag-mers tag-pandemic tag-policy tag-research tag-roadmap tag-sars tag-science tag-technology tag-vaccine tag-vaccine-development tag-virus"> <a class="entry-featured-image-url" href="https://vaccinenation.org/technology/cepi-and-cidrap-advance-coronavirus-vaccine-rd-roadmap/"> <img data-src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-1080x675.png?crop=1" alt="CEPI and CIDRAP advance coronavirus vaccine R&D roadmap" width="1080" height="675" data-srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-480x320.png 480w" data-sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" src="data:image/gif;base64,R0lGODlhAQABAAAAACH5BAEKAAEALAAAAAABAAEAAAICTAEAOw==" class="lazyload" style="--smush-placeholder-width: 1080px; --smush-placeholder-aspect-ratio: 1080/675;" /><noscript><img src="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-1080x675.png?crop=1" alt="CEPI and CIDRAP advance coronavirus vaccine R&D roadmap" class="" width="1080" height="675" srcset="https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-1080x675.png?crop=1 1080w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-980x653.png 980w, https://vaccinenation.org/wp-content/uploads/2024/10/Heading-2024-10-11T165907.112-480x320.png 480w" sizes="(min-width: 0px) and (max-width: 480px) 480px, (min-width: 481px) and (max-width: 980px) 980px, (min-width: 981px) 1080px, 100vw" /></noscript> </a> <h2 class="entry-title"><a href="https://vaccinenation.org/technology/cepi-and-cidrap-advance-coronavirus-vaccine-rd-roadmap/">CEPI and CIDRAP advance coronavirus vaccine R&D roadmap</a></h2> <p class="post-meta"> by <span class="author vcard"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/" title="Posts by Charlotte Kilpatrick" rel="author">Charlotte Kilpatrick</a></span> | <span class="published">Oct 11, 2024</span> | <a href="https://vaccinenation.org/category/technology/" rel="category tag">Technology</a> | <span class="comments-number"><a href="https://vaccinenation.org/technology/cepi-and-cidrap-advance-coronavirus-vaccine-rd-roadmap/#respond">0 comments</a></span></p><p><span data-contrast="auto">CEPI <a href="https://cepi.net/world-leading-coronavirus-vaccine-rd-roadmap-receive-fresh-updates" target="_blank" rel="noopener">announced</a> in October 2024 that the Centre for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota is to receive US$3.2 million to advance its open access <a href="https://cvr.cidrap.umn.edu/" target="_blank" rel="noopener">Coronavirus Vaccines Research and Development (R&D) Roadmap</a>. This is an “important tool created to guide the development of vaccines” against multiple coronaviruses. CIDRAP will monitor and evaluate R&D progress and “catalyse efforts” to develop broadly protective vaccines. The investment from CEPI will monitor progress towards the roadmap goals and milestones and enable the creation of an online database of current literature and reports on coronavirus vaccine research. </span><span data-ccp-props="{}"> </span></p> <h5><span data-contrast="auto">The CIDRAP roadmap </span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">CIDRAP’s roadmap is developed with guidance from over 50 scientific leaders and financial support from The Rockefeller and Gates Foundations. It aims to respond to the threat of coronaviruses, highlighted in the experience of three new coronavirus epidemics (SARS, MERS, COVID-19) in just 20 years. Coronaviruses are a “<a href="https://cvr.cidrap.umn.edu/executive-summary" target="_blank" rel="noopener">real and present threat</a>” that demand a “large, comprehensive, and coordinated” initiative. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“The ultimate goal of developing broadly protective coronavirus vaccines is therefore multi-faceted: to create more efficacious and durable COVID-19 vaccines, mitigate the potential threat of future coronaviruses that have not yet emerged, and, ideally, prevent infections and transmission.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">The roadmap covers five topic areas each with “key barriers and knowledge gaps” and corresponding “technical milestones for measuring success”:</span><span data-ccp-props="{}"> </span></p> <ul> <li><span data-contrast="auto">Virology applicable to vaccine R&D</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Immunology and immune correlates of protection</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Vaccinology</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Animal and human infection models for coronavirus vaccine research</span><span data-ccp-props="{}"> </span></li> <li><span data-contrast="auto">Policy and financing</span><span data-ccp-props="{}"> </span></li> </ul> <h5><span data-contrast="auto">CEPI’s support</span><span data-ccp-props="{}"> </span></h5> <p><span data-contrast="auto">The funding contributes to monitoring progress on these goals and milestones and supports an open access online research database as well as an open access online summary of all broadly protective coronavirus vaccines in preclinical and clinical development and a dashboard tracking funding and investment. </span><span data-ccp-props="{}"> </span></p> <p><span data-contrast="auto">Dr Michael Osterholm, Regents Professor and Director of CIDRAP recognised CEPI’s contribution to coronavirus vaccine research and development.</span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“CEPI’s support and collaboration with CIDRAP will fast forward our efforts at creating broadly protective coronavirus vaccines.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">Dr Kent Kester, Executive Director of Vaccine R&D, CEPI, commented that COVID-19 was the “third new coronavirus to strike in the past 20 years, portending the emergence of further novel coronaviruses”. </span><span data-ccp-props="{}"> </span></p> <blockquote> <h6><span data-contrast="auto">“Having the latest information on vaccine research and progress within coronavirus vaccine R&D readily and openly available in CIDRAP’s roadmap will enhance the approach being pursued by CEPI and other scientific investigators around the world to develop vaccines that could confer protection against multiple coronaviruses at the same time.”</span><span data-ccp-props="{}"> </span></h6> </blockquote> <p><span data-contrast="auto">For the latest coronavirus vaccine research updates, including insights into the challenges of universal vaccine development, <a href="https://secure.terrapinn.com/V5/step1.aspx?E=10840" target="_blank" rel="noopener">join us at the Congress in Barcelona this month</a>. Don’t forget to <a href="https://vaccinenation.org/subscribe/" target="_blank" rel="noopener">subscribe to our weekly newsletters here</a>. </span><span data-ccp-props="{}"> </span></p> </article> <div class="pagination clearfix"> <div class="alignleft"><a href="https://vaccinenation.org/author/charlotte-kilpatrick/page/2/" >« Older Entries</a></div> <div class="alignright"></div> </div> </div> </div> </div> </div> <span class="et_pb_scroll_top et-pb-icon"></span> <footer id="main-footer"> <div id="footer-bottom"> <div class="container clearfix"> <ul class="et-social-icons"> </ul><div id="footer-info">VaccineNation - Strategy & Innovation in Vaccines </div> </div> </div> </footer> </div> </div>  <script defer id="bilmur" data-customproperties="{"woo_active":"0"}" data-provider="wordpress.com" data-service="atomic" src="https://s0.wp.com/wp-content/js/bilmur.min.js?m=202447"></script> <script data-cfasync="false"> (function(w,i,s,e){window[w]=window[w]||function(){(window[w].q=window[w].q||[]).push(arguments)};window[w].l=Date.now();s=document.createElement('script');e=document.getElementsByTagName('script')[0];s.defer=1;s.src=i;e.parentNode.insertBefore(s, e)}) ('wisepops', '//wisepops.net/loader.js?v=2&h=BW3aDEEvXW'); </script><style id="et-builder-googlefonts-inline">/* Original: https://fonts.googleapis.com/css?family=Roboto:100,100italic,300,300italic,regular,italic,500,500italic,700,700italic,900,900italic&subset=cyrillic,cyrillic-ext,greek,greek-ext,latin,latin-ext,vietnamese&display=swap *//* User Agent: Mozilla/5.0 (Unknown; Linux x86_64) AppleWebKit/538.1 (KHTML, like Gecko) Safari/538.1 Daum/4.1 */@font-face {font-family: 'Roboto';font-style: italic;font-weight: 100;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOiCnqEu92Fr1Mu51QrIzc.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 300;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TjARc9.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 400;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOkCnqEu92Fr1Mu52xP.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 500;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51S7ABc9.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 700;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TzBhc9.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 900;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TLBBc9.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 100;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOkCnqEu92Fr1MmgWxP.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 300;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmSU5vAw.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 400;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOmCnqEu92Fr1Me5Q.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 500;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmEU9vAw.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 700;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmWUlvAw.ttf) format('truetype');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 900;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmYUtvAw.ttf) format('truetype');}/* User Agent: Mozilla/5.0 (Windows NT 6.1; WOW64; rv:27.0) Gecko/20100101 Firefox/27.0 */@font-face {font-family: 'Roboto';font-style: italic;font-weight: 100;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOiCnqEu92Fr1Mu51QrIzQ.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 300;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TjARc-.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 400;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOkCnqEu92Fr1Mu52xM.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 500;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51S7ABc-.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 700;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TzBhc-.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 900;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TLBBc-.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 100;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOkCnqEu92Fr1MmgWxM.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 300;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmSU5vAA.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 400;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOmCnqEu92Fr1Me5g.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 500;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmEU9vAA.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 700;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmWUlvAA.woff) format('woff');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 900;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmYUtvAA.woff) format('woff');}/* User Agent: Mozilla/5.0 (Windows NT 6.3; rv:39.0) Gecko/20100101 Firefox/39.0 */@font-face {font-family: 'Roboto';font-style: italic;font-weight: 100;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOiCnqEu92Fr1Mu51QrIzI.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 300;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TjARc4.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 400;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOkCnqEu92Fr1Mu52xK.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 500;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51S7ABc4.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 700;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TzBhc4.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: italic;font-weight: 900;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOjCnqEu92Fr1Mu51TLBBc4.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 100;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOkCnqEu92Fr1MmgWxK.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 300;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmSU5vBg.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 400;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOmCnqEu92Fr1Me4A.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 500;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmEU9vBg.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 700;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmWUlvBg.woff2) format('woff2');}@font-face {font-family: 'Roboto';font-style: normal;font-weight: 900;font-display: swap;src: url(https://fonts.gstatic.com/s/roboto/v32/KFOlCnqEu92Fr1MmYUtvBg.woff2) format('woff2');}</style><script type="text/javascript" src="https://vaccinenation.org/wp-includes/js/jquery/jquery.min.js?ver=3.7.1" id="jquery-core-js"></script> <script type='text/javascript' src='https://vaccinenation.org/wp-includes/js/jquery/jquery-migrate.min.js?m=1686289764'></script> <script type="text/javascript" id="jquery-js-after"> /* <![CDATA[ */ jqueryParams.length&&$.each(jqueryParams,function(e,r){if("function"==typeof r){var n=String(r);n.replace("$","jQuery");var a=new Function("return "+n)();$(document).ready(a)}}); /* ]]> */ </script> <script type="text/javascript" id="awsm-ead-public-js-extra"> /* <![CDATA[ */ var eadPublic = []; /* ]]> */ </script> <script type="text/javascript" id="adrotate-clicker-js-extra"> /* <![CDATA[ */ var click_object = {"ajax_url":"https:\/\/vaccinenation.org\/wp-admin\/admin-ajax.php"}; /* ]]> */ </script> <script type="text/javascript" id="divi-custom-script-js-extra"> /* <![CDATA[ */ var DIVI = {"item_count":"%d Item","items_count":"%d Items"}; var et_builder_utils_params = {"condition":{"diviTheme":true,"extraTheme":false},"scrollLocations":["app","top"],"builderScrollLocations":{"desktop":"app","tablet":"app","phone":"app"},"onloadScrollLocation":"app","builderType":"fe"}; var et_frontend_scripts = {"builderCssContainerPrefix":"#et-boc","builderCssLayoutPrefix":"#et-boc .et-l"}; var et_pb_custom = {"ajaxurl":"https:\/\/vaccinenation.org\/wp-admin\/admin-ajax.php","images_uri":"https:\/\/vaccinenation.org\/wp-content\/themes\/Divi\/images","builder_images_uri":"https:\/\/vaccinenation.org\/wp-content\/themes\/Divi\/includes\/builder\/images","et_frontend_nonce":"a99dc5b0ab","subscription_failed":"Please, check the fields below to make sure you entered the correct information.","et_ab_log_nonce":"6a5151c701","fill_message":"Please, fill in the following fields:","contact_error_message":"Please, fix the following errors:","invalid":"Invalid email","captcha":"Captcha","prev":"Prev","previous":"Previous","next":"Next","wrong_captcha":"You entered the wrong number in captcha.","wrong_checkbox":"Checkbox","ignore_waypoints":"no","is_divi_theme_used":"1","widget_search_selector":".widget_search","ab_tests":[],"is_ab_testing_active":"","page_id":"8780","unique_test_id":"","ab_bounce_rate":"5","is_cache_plugin_active":"yes","is_shortcode_tracking":"","tinymce_uri":"https:\/\/vaccinenation.org\/wp-content\/themes\/Divi\/includes\/builder\/frontend-builder\/assets\/vendors","accent_color":"#ec008c","waypoints_options":[]}; var et_pb_box_shadow_elements = []; /* ]]> */ </script> <script type='text/javascript' src='https://vaccinenation.org/_static/??-eJyNjksOwjAMRC9EGxUQXSE2XCQfl7rkR+y0yu1JVVYIVaws2/NmZomNDp7Bs4g2P9CTAKfANNKXxgSd3fqaSEQzBDWB5tahbyc6LP+S2zVmZVHvwNKkwJJBWFRJpiKmV4ZUWl2xJ6QvikdwQOKOM64ZpBNGph/230IXAo9VHqzdUaLXNpu6qYzWQBIDSM4JhCleOtSNJAKupbdRjT9tB+QZDVXrm7t2/enY9d350r0BRlmHPQ=='></script> <script type="text/javascript" src="https://vaccinenation.org/wp-includes/js/dist/vendor/react.min.js?ver=18.3.1" id="react-js"></script> <script type='text/javascript' src='https://vaccinenation.org/wp-includes/js/dist/hooks.min.js?m=1727673091'></script> <script type="text/javascript" src="https://vaccinenation.org/wp-includes/js/dist/i18n.min.js?ver=5e580eb46a90c2b997e6" id="wp-i18n-js"></script> <script type="text/javascript" id="wp-i18n-js-after"> /* <![CDATA[ */ wp.i18n.setLocaleData( { 'text direction\u0004ltr': [ 'ltr' ] } ); /* ]]> */ </script> <script type="text/javascript" src="https://vaccinenation.org/wp-content/plugins/jetpack/jetpack_vendor/automattic/jetpack-videopress/build/divi-editor/index.js?minify=false&ver=b98caf5d79ac1860331b" id="jetpack-videopress-divi-pkg-js"></script> <script type='text/javascript' src='https://vaccinenation.org/wp-content/themes/Divi/core/admin/js/common.js?m=1732171461'></script> <script type="text/javascript" src="https://vaccinenation.org/wp-content/plugins/wp-smushit/app/assets/js/smush-lazy-load.min.js?ver=3.16.6" id="smush-lazy-load-js"></script> <script type="text/javascript" id="smush-lazy-load-js-after"> /* <![CDATA[ */ function rw() { Waypoint.refreshAll(); } window.addEventListener( 'lazybeforeunveil', rw, false); window.addEventListener( 'lazyloaded', rw, false); /* ]]> */ </script> <script type="text/javascript" src="https://stats.wp.com/e-202447.js" id="jetpack-stats-js" data-wp-strategy="defer"></script> <script type="text/javascript" id="jetpack-stats-js-after"> /* <![CDATA[ */ _stq = window._stq || []; _stq.push([ "view", JSON.parse("{\"v\":\"ext\",\"blog\":\"209026272\",\"post\":\"0\",\"tz\":\"0\",\"srv\":\"vaccinenation.org\",\"hp\":\"atomic\",\"ac\":\"2\",\"amp\":\"0\",\"j\":\"1:14.1-a.3\"}") ]); _stq.push([ "clickTrackerInit", "209026272", "0" ]); /* ]]> */ </script> </body> </html>